Welcome. Who is here? What is this?

Here's news and info about three primary blood cancers, Lymphoma, Myeloma and Leukemia with a decided patient's perspective.  I hope this helps whether you're newly diagnosed or veteran survivor.  

       Is this You?              This is me.            We're Not Alone!    

 Is this You cancer patient    Click This is me    We are not alone, cancer warriors
Check my:Link to my blog

 

Twitter Feed

Click my Social Media, good stuff

YouTube -- https://www.youtube.com/user/JackWhelanAdvocate Twitter -- https://twitter.com/JackWhelan Google+ -- http://www.google.com/+JackWhelanAdvocate Facebook -- https://www.facebook.com/jack.whelan.98031

AACR Legislative: Write your Congressmen!

LinkedIn

Professional Research Advocacy

 

American Association for Cancer Research

 

 American Society of Clinical Oncology 

 

Alliance for Clinical Research Excellence and Safety

  

National Organization for Rare Diseases 

Rare Disease Legislative Advocates  

Research Advocacy Network 

Alliance for Clinical Trials Oncology, Jack Whelan member

Patient Advocates In

Society for Participatory Medicine

Health Advocate Code of Conduct and Professional Standards

WEGO Health Speakers Bureau 

Connect With Me At ExpertFile

 

Music and audio player

As seen or quoted on these TV stations

ABC Good Morning America CBS Sunday Morning 2 News 3 News 8 10 News 12 News WIDK 10 28 News KCOY KCAU 9 KILL TV3 KLTV 7 KMPH 26 KOTA 28 News America my FOX LIVE HD 5 blip 28 News FOX-25 FOX-5 NEWS-25HD KYTX-19 NBC4i NBC29 ABC 33-40 WAND 17HD WBAY 2 WBOC 16 WECT 6 WHBQ 13 WITN WLBT 3 WMCT 5 WRCB 3 WSET 13 WTOC 11 WTVM 9 WVUE 8

Past Dates

Monday, March 27th, 2017

2nd Annual Patient Centric Clinical Research, Jack is Opening Keynote - 08:00AM
Hilton Springfield 6550 Loisdale Road
Springfield, VA 22150
USA
312.602.9683 [map]
Price: $2150.00

8:00 REGISTRATION & WELCOME COFFEE 

8:50 CHAIRPERSON’S OPENING REMARKS 

Robert Loll, Vice President, Business Development, PRAXIS 

9:00 OPENING KEYNOTE: ROAD TO PRECISION MEDICINE: BENEFITS OF PATIENT CENTRICITY IN CLINICAL TRIALS 

Patient and Research Advocate Jack Whelan, presently battling two incurable cancers by participating in eight clinical trials of conventional chemotherapy and novel targeting agents uses his keen observations and very personal, inspiring, gripping and fun story to help illustrate shortcomings and opportunities to improve the clinical trials process by embracing true patient-centric thinking and processes throughout the healthcare system. Giving a real-world patient’s perspective, he helps define many of the fundamental issues that must be squarely addressed by biopharma, healthcare, payers, policy makers and industry regulators. 

- Ride the road to Personalized Medicine still under construction with a unique Patient Centric view 

- Come away with compelling, actionable ideas to improve outcomes for patients and your organization 

- A reminder about the important work you’re doing extending and saving lives 

Jack Whelan, Patient/Research Advocate 

2nd Annual Patient Centric Clinical Research: Engagement & Innovation Conference

Defining Patient Centricity Across Patient, Industry & Stakeholder Perspectives, Integrating the Patient’s Voice into Clinical Research to Streamline Timely Trials from Initial Development to Subject Recruitment & Retention, all while Optimizing Patient’s Engagement through the use of Technology & Social Media
March 27-28, 2017 | Springfield, VA | Hilton Springfield

ABOUT THE CONFERENCE

Throughout the healthcare industry, pharmaceutical and biotech manufacturers, patient groups and policy makers alike, are continuing the mission to enhance collaborations with patients in order to align stakeholder needs and expectations in clinical research. At the very center of this phenomenon is patient centricity, evolving into an increasingly vital approach to clinical testing within pharmaceutical and biotech companies. From initial development and study design to methods to continue to keep patients engaged in trials, patient centricity is essential in order for executives to remain at the forefront of impactful and promising industry trends, all while ensuring patient wellness and satisfaction when involved in trials.

During the conference, distinguished industry leaders and attendees will uncover the future of patient centricity through progressive case studies complimented by interactive scenario-based workshops. Bringing together leading patient organizations and industry clinical executives, participants will have a unique opportunity to explore leading strategies surrounding cutting-edge topics for debate from integrating the patient voice throughout clinical research operations to utilize technology & social media to increase clinical trial engagement and retention. Furthermore, exchange group sessions involving clinical trial subjects will delve deep into challenges ranging from educating the patients to getting direct perspectives on the best methods for aligning patient needs at the center of clinical research. Case study driven presentations, high level keynote sessions as well as roundtable panel discussions complemented by multiple networking opportunities will foster a sense of collaboration, inspiring progress and give executives the tools needed to maximize patient-centric strategies.

 

Thursday, March 9th, 2017

IO-ICON Immuno-Oncology Integrated Community Oncology Network, Annual Meeting, Jack is Research Advocate
IO-ICON Immuno-Oncology Integrated Community Oncology Network, Annual Meeting, Jack is Research Advocate - 07:00 AM
Houston International Airport Marriott
Houston, TX
USA
Not published [map]
Price: By Invitation only

We are looking forward to another great meeting with a few new twists this time including our single day format for the meeting. For those who do arrive Thursday evening, we will have an informal reception/dinner to kick off the meeting. Friday will be a very busy day with the morning breakouts - CNAG, Lung RAG, Heme RAG - beginning at 7 AM. We follow that with a late morning General Session at which we will hear about Real World Data Initiatives from our HEOR Colleagues and panel as well as have a discussion on Multidisciplinary Safety Management in IO therapy.

Over lunch break we will learn about a Patient Advocacy Initiative and opportunity for IO-ICON. Afternoon breakouts - EAG, VPAG, Open Research Forum - take place from 2 -5 PM and then we wrap up with a short closing session. Get ready to learn and share your feedback as together we work to stay current on IO!

 

IO-ICON UPDATE for my Patient/Research Advocate friends:

The US Oncology Advocacy team at Bristol-Myers Squibb has created new resources for patients who are dealing with a diagnosis of lung cancer or renal cell carcinoma (RCC) and their caregivers. The cards are designed to provide information to patients faced with a diagnosis of lung or RCC and their caregivers about the services and programs of various Patient Advocacy organizations that they can reach out to for information including educational materials, counseling services, assistance navigating financial and insurance issues, locating clinical trials, and connecting with other patients.

Website and contact information for six lung cancer organizations is provided: Free to Breathe, Lung Cancer Alliance, LUNGevity, CancerCare, Cancer Support Community (CSC), and the Bonnie J. Addario Lung Cancer Foundation. In terms of RCC, information is included on that card for the following organizations: Cancer Support Community (CSC), CancerCare, Kidney Cancer Association, and National Kidney Foundation. Laminated copies of the card can be obtained from your BMS Sales Representative.

Tuesday, December 6th, 2016

Digital Healthcare Initiatives Ideation Session by SUNOVION, Jack is speaking
Digital Healthcare Initiatives, Ideation Session by SUNOVION - 8:00 AM
Google Inc. 355 Main Street 5th Floor
Cambridge, MA 02142
USA
877 312 6552 [map]
Price: By Invitation

Digital Healthcare Initiatives - Ideation Session

Driving Healthcare Innovation From Within

Inspiration | Ideation | Innovation

 

Healthcare is being redesigned globally with new technologies and approaches that promise to improve access, delivery, and patients' lives.

 

To continue to fulfill our shared mission to contribute to society through the betterment of healthcare and the fuller lives of people, we need to determine how to best approach this new era -  to be the forefront of providing solutions and partnering with stakeholders to drive innovation.

 

Driving healthcare innovation starts from within our organizations. You're invited to participate in an internal, immersive session spanning two days to identify the opportunities and challenges that will help  inform and guide the formation of our digital healthcare initiatives. A cross-functional, cross-company team will explore best practices and success factors for implementing our digital healthcare strategy.

 

 MEETING LOCATION

Google Cambridge  355 Main Street, 5th Floor  Cambridge, MA 02142

 

TRAVEL PARAMETERS

Arrivals:

Please arrive by 8:30 AM on Tuesday, December 6, 2016 as the Opening General Session begins promptly at 9:00 AM.

Departures: 

   Please depart after the meeting concludes at 2:30 PM on Wednesday, December 7, 2016.

 

Friday, November 25th, 2016

Synevo Clinical Trials Symposium 2016 - 08:00
Intercontinental Hotel, Bulevardul Nicolae Bălcescu 4
Bucharest 010051
Romania
+4 021 407 07 00, Ext. 302 [map]
Price: By Invitation

Dear colleagues and friends,

I am very pleased to announce you that we have reached this year at the 8th edition of our symposium organized in Bucharest, Romania.

We invite you all to join us for our event dedicated to professionals working in clinical research field, pharma sponsors, biotech companies and CRO’s representatives, investigators (clinicians and general practitioners, laboratory specialists (lab physicians, chemists, biologists, biochemists, etc.).

You will have the chance to listen presentations of very well known speakers, KOL in their field, into a relaxing environment where you can also build and cultivate relationships and do the networking with your peers.

The event is credited with CME credits.

Be the first to register on our website where you will find all necessary details of this professional meeting of Clinical Trials specialists. Please be aware that there is a limited number of participants.

Cristina Florescu Moraid, Md, Msc, EuSpLM
Regional Director Romania, Moldova, Bulgaria and Serbia Synevo Central Lab

 

 

 

Monday, November 7th, 2016

Digital@Clinical Summit at Pfizer - 08:00
Pfizer Headquarters
New York City, NY
USA [map]
Price: By Invitation

I believe Pfizer is one of the leading Pharmaceutical firms interested in all things Patient Centric.  It was an invitation from Pfizer in Cambridge, MA many years ago when I met with their team to explore engaging patients that got me interested in professional Advocacy as I learned Pharma and Biotech wanted to open lines of communications with Patients and Caregivers.  It is a distinct honor to be asked to be a keynote speaker at this important meeting at Pfizer's HQ in New York.

This conference is a networking and information-sharing forum to help connect the teams working with various mobile, social and HIT-related tools in clinical development at Pfizer.

Pfizer will open up the program to be available for the thousands of global colleagues at Pfizer working in development and will be featuring the active work underway with mobile and wearables.  The company's intent is to help teams appreciate how these tools are actively being used and to see pathways for them to do the same for their studies.  The event will be hosted in NY on Nov7 with a global livestream (and video archived).

The remainder of the agenda is focused on two themes – digital to improve patient experience and to enable novel data capture.  Each area will include real-world experiences of Pfizer teams using eConsent, retention aids, gamification, novel ePRO tools, and wearables, with the intent of helping others see how tools were used, their impact, and how they can do the same. 

 

 

 

Thursday, November 3rd, 2016

Alliance for Clinical Trials in Oncology Patient Advocate Committee, Lymphoma & GU - 08:00
Chicago O'Hare Lowes Hotel
Chicago, IL 60636
USA [map]
Price: By Invitation

"The Alliance for Clinical Trials in Oncology is a national clinical trials network sponsored by the National Cancer Institute (NCI) that consists of about 10,000 cancer specialists at hospitals, medical centers, and community clinics across the United States and Canada. The Alliance develops and conducts clinical trials with promising new cancer therapies, and utilizes scientific research to develop treatment and prevention strategies for cancer, as well as researching methods to alleviate side effects of cancer and cancer treatments.

The Alliance seeks to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines, committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer. The Alliance conducts trials in the following disease and modality areas: breastgastrointestinal (GI), genitourinary (GU), leukemialymphomamyeloma, neuro-oncologyrespiratory, experimental therapeutics (rare cancers), cancer control and transplant".

 

 

Tuesday, October 18th, 2016

World Companion Diagnostics CDx 2016, Boston MA Jack is speaking - 09:00AM
Boston Convention and Exhibition Center, 415 Summer St.
Boston, MA 02210
United States
888 670 8200 [map]
Price: $1399. - $2399.

 

My third year speaking at World CDx a leader in Patient Centric thinking and action.  Conference Producer Hanson Wade's goal is to accelerate progress within organisations and across industries. Our primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers.

Accelerate the Biomarker Validation, Clinical Development & Market Adoption of the Next Generation of Targeted Therapies & Diagnostics

The 7th Annual World CDx Boston Summit 2016 will once again provide the industry-defining platform for drug, diagnostic and tech developers to accelerate the progression of targeted-therapies and diagnostics from biomarker validation, through the clinic and to stratified patient populations.

Discover the latest end to end case studies demonstrating how to maximize the added value of precision medicine and tackle the cost-benefit analysis associated with embarking on a diagnostic strategy. Be part of critical discussions around the role of biomarkers and diagnostics in immuno-oncology, demonstrating clinical utility with liquid biopsies, securing evidence-based reimbursement and more.

Develop and Execute a Robust Biomarker-Diagnostic Strategy to Unlock the Added Value of Precision Medicine
At this critical time in the history of precision medicine, it is crucial for the fields key opinion leaders,most exciting new-comers and those looking to start harnessing targeted therapies and high-value diagnostics to come together to accelerate tailored treatments to patients in need.

World CDx Boston 2016 will not only focus on the leading case studies in precision medicine but also tackle the most challenging and sobering conversations around, how far have we come with targeted therapies and companion diagnostics, the impact of precision medicine on the healthcare system and is the fit of precision medicine in drug development still a square peg in a round hole?

  • Understand the impact of biomarkers in immuno-oncology drug development to underpin the future of precision medicine in the hottest area of drug development
  • Decipher the evolving reimbursement landscape for diagnostics, testing and biomarker-driven therapies to underpin your market access and adoption strategies to deliver significant return on investment
  • Uncover the role of complementary diagnostics and how they inform targeted therapy selection to add this emerging approach to your precision medicine strategy
  • Harness liquid biopsy methodologies for non-invasive diagnostic development and real time patient monitoring whilst demonstrating clinical utility with this approach
 
  • Construct patient population size vs. return on investment strategy for targeted drug development in large pharma and emerging biotech’s with discussion
  • Successfully navigate regulatory paradigms for targeted therapies, laboratory-developed tests, next generation sequencing and complementary diagnostics
  • Incorporate biomarkers and diagnostics into early and late clinical trial designs to ensure access to the right patients in preparation for regulatory approval and reimbursement success
  •  Unlock the trapped potential of the data in from your biomarker-driven therapy programs, next generation sequencing protocols and multi-omic integration studies

 

 

Monday, October 10th, 2016

Patient Centered Clinical Trials USA 2016 Philadelphia - 08:00
Sonesta Rittenhouse Square
Philadelhia, PA
USA [map]
Price: Various

A truly collaborative, patient-centered dialogue is only possible by including patients. The patient panel which ran at the 2015 conference, will be expanded in every direction for 2016. Therefore, the entire agenda has been designed and shaped with the help of thousands of patient voices through a global survey and multiple in-depth consultations with leaders in Pharma, advocacy groups, regulatory bodies and patients themselves.  

The 2016 summit will be the only place to:

  • ENGAGE PATIENT GROUPS and make your trial accessible
  • MAKE RECRUITMENT EFFECTIVE by reaching a larger customer base
  • OVERCOME RETENTION ISSUES: understand the needs of the market
  • MEET REGULATORY REQUIREMENTS: partner with patient advocates and gain their support
  • HARNESS THE BENEFITS OF ‘PATIENT CENTRICITY’ to create a sustainable health model

What You Can Expect

The conference will offer a unique mix of engaging sessions, debates, round tables, and 1-1 networking with top pharma, patient groups, site representatives and industry thought leaders. While reimagining the entire patient journey from recruitment through to the post-trial debrief, delegates will learn and debate new approaches to:

  • Develop the patient-pharma relationship in clinical research
  • Maximize trial success through improvements in current workflows and trial operations
  • Draw on patient-initiated research and (e)PRO
  • Optimize the patient experience before the study even starts
  • Address trial-fatigue through new systems and innovations
  • Close ties with principal investigators and research sites
  • Re-think Informed Consent in the digital age

5 reasons why you cannot miss Patient-Centered Clinical Trials 2016!

1

Fast-Track Knowledge: A unique combination of keynotes, executive panels, industry case studies, presentations and focus groups balances high-level strategy and actionable, operational insights. We'll zoom in on the most relevant issues, following a heavily-researched agenda. There is no better way to train your clinical teams in two days out of the office.

2

Expert Speakers: You will benefit from the exclusive insights of our faculty of senior industry speakers and renowned topic experts, the most important stakeholders in the vendor and technology space and academia.

3

Exclusive Case Studies, Best Practices: You’ll learn from pharma's experiences, novel pilots and get first-hand data on the actual implementation of patient-centered R&D. No other event offers a critical review of the latest innovations in trial management from a strategic as well as operational perspective.

4

Unrivalled Networking: You will collaborate with more than 100 of your peers - all in one room. 2 days of focused engagement with senior colleagues, advocacy groups, CROs and SMOs. You’ll be shaking hands with the sharpest minds driving patient relationships and clinical research management. Expand your business and invest in your career.

5

Benchmark with the Best: Where are the industry leaders going with non-traditional partnerships? How have they adapted internally? Shape your benchmarking strategy on innovative organizational models, business collaborations and patient alliances with the leaders in the field.

Thursday, October 6th, 2016

Partnerships in Clinical Trials US, Boston Jack is Speaking - 08:00AM
PCT Loft at Boston Convention & Exhibition Center
Boston, Massachusetts 02210
USA [map]
Price: See website

Details to follow:

 

Click:  https://lifesciences.knect365.com/partnershipsinclinicaltrials/agenda/1

 

 

 

Contact:  Brian Schiff, bschiff@iirusa.com 
+1 (646) 895-7444

Wednesday, October 5th, 2016

IQ Symposium Mission Possible: New Horizons in Drug Development Jack is speaking - 08:00AM
Lansdowne Resort and Spa
Leesburg, VA
USA
202 230 5607 [map]
Price: Invitation, see website

More to follow, please see website.  

 

Jack is speaking onOctober 5th, at 10:50AM

Friday, September 30th, 2016

2016 Immuno-Oncology Integrated Community Oncology Network (IO-ICON) Fall Meeting, Chicago, IL
2016 Immuno-Oncology Integrated Community Oncology Network (IO-ICON) Fall Meeting, Chicago, IL - 08:00
Westin Michigan Avenue 909 North Michigan Avenue
Chicago, IL 60011
USA
609 897 5068 [map]
Price: By Invitation only

IO-ICON Advisors

Bristol Myers Squibb 2016 Immuno-Oncology Integrated Community Oncology Network (IO-ICON) Fall Meeting from September 30th to October 1st, 2016 in Chicago, IL. 

 

More to follow.

Thursday, September 29th, 2016

ACCC Institute for Clinical Immuno-Oncology Summit, Philadelphia - 08:00AM
Sonesta Hotel,1800 Market Street
Philadelphia, PA
USA [map]
Price: See website

Institute for Clinical Immuno-Oncology National Conference

9.30.16 - Philadelphia, Pa

Register

The Institute for Clinical Immuno-Oncology (ICLIO) one-day conference provides a comprehensive look at the challenges and opportunities within the emerging clinical applications of cancer immunotherapy. Expert faculty will empower the multidisciplinary team members to handle the dynamic and unique intricacies of the treatment and delivery of immuno-oncology with a focus on care in the community setting. No matter where you are on the path to integrate immunotherapy into your operations, the ICLIO National Conference will help you reach your destination. ICLIO is an institute of the Association of Community Cancer Centers (ACCC).

WHAT YOU WILL LEARN

  • Real-world understanding and optimization of clinical immuno-oncology
  • Strategies for ensuring reimbursement of these new treatments
  • Tactics to operationalize immuno-oncology at your cancer program
  • Patient access and advocacy techniques
  • Education and training opportunities

Thursday, September 22nd, 2016

AACR Rally for Medical Research Hill Day, Washington DC - TBA
From the Mayflower Hotel to the Capitol, 1127 Connecticut Ave NW
Washington, DC
USA [map]
Price: no charge

Research and Legislative Advocates associated with AACR and other leading professional advocacy organizations will be meeting with members of Congress urging them to again provide rational funding for biomedical research.

See this 5-minute Video of Highlights from the 2015 “Rally for Medical Research Hill Day

Here’s the link https://youtu.be/seT4f0J_WsI which includes footage and interviews from our two special days in mid-September 2015 where patients, survivors, advocates, researchers and many others gathered in Washington, D.C. to call for robust, sustained, and predictable funding increases for the National Institutes of Health (NIH). Along with the many citizen advocates featured in the video, Senators Dick Durbin (D-Illinois), Jerry Moran (R-Kansas), Patty Murray (D-Washington), and Amy Klobuchar (D-Minnesota) as well as Representative Tom Cole (R-Oklahoma) joined the effort and spoke to Rally Hill Day participants.  

To Provide Information about the FY 2017 Budget Environment.

While the two-year budget deal that was signed into law by President Obama in November, 2015, provided an additional $25 billion for domestic spending priorities in FY 2016 (which also helped allow for the $2 billion increase that NIH received in FY 2016), the agreement does not allow for much of an increase in the overall pot for discretionary spending in the second year of the budget deal (FY 2017).  Therefore, as a result of these federal budget constraints, it’s going to be extremely important for all of us to constantly ask Members of Congress to prioritize funding for NIH in FY 2017, especially if we hope to continue the momentum from the $2 billion funding increase the NIH received in FY 2016. 

 

We are very much encouraged by recent comments from the Chairmen of the respective Appropriations Subcommittees in the Senate and House that oversee NIH and other health, education, and labor programs (the Labor-HHS-Education Appropriations Subcommittees), including last week’s remark by Senate Chairman Roy Blunt (R-MO) that he is anxious to build on the $2 billion increase provided for the NIH in FY 2016, a goal that he says he shares with his House counterpart (House Chairman Tom Cole). 

 In addition, at an event hosted by the Federation of American Societies for Experimental Biology (FASEB) on March 2, 2016, to recognize Senator Blunt’s and Representative Cole’s leadership, Chairman Cole stated, “The most important thing, as Roy has already said, is to make sure that the $2 billion increase in 2016 is not a one-hit wonder.  We want this to become a regular pattern for Congress, to make these NIH investments in a regular, manageable, and predictable way so that the scientific community knows they will continue.”

 

 

Thursday, September 15th, 2016

WORLD CDX LISBON SUMMIT - 08:00AM
Lisbon
Portugal [map]
Price: Please see website

WORLD CDX LISBON SUMMIT

SEPTEMBER 15-16, 2016 LISBON, PORTUGAL.

 

The Curtis & Wyss Group are pleased to invite you to the “Cdx Lisbon Summit” scheduled on September 15-16, 2016 in Lisbon, Portugal.

This premier B2B event will bring together experts from all levels of the value chain to ensure maximum knowledge transfer and professional exchange; elaborate on the best practices within the companion diagnostics (CDx) industry as well as academia to discuss, hear and learn about their experiences on latest trends on companion diagnostics (CDx) development, to network and enjoy excellent mix of case studies, interactive panel discussions, speed networking and workshops.

It is an honor and privilege to invite you to participate in this Summit. We look forward to welcoming you at the Summit in Lisbon upcoming October!

Key Practical Learning Points of the Summit:

  • The latest trends of companion diagnostics (CDx) development
  • Partnering strategies to achieve successful commercialization of CDx
  • Manufacture CDx at the anticipated scale
  • Pharmaceutical and Diagnostics Companies Perspectives
  • CDx development and pre-launch commercialization costs
  • Finding the appropriate business models for CDx companies
  • The laboratory developed test (LDT) & In vitro diagnostic (IVD) Models
  • Introduction of a strategy that can improve the existing models

Who should attend? VCEOs, Companion Diagnostics Vice-Presidents, Directors, Chief Medical Officers, Including:

  • Associate Director, Companion Diagnostics
  • Director, Global Diagnostic
  • Senior Director, Worldwide Regulatory Strategy
  • Leader, Companion Diagnostic Development
  • Senior Director, Biomarkers
  • Senior Director, Regulatory Affairs
  • Scientific Director, Medical Sciences
  • Leader, Companion Diagnostic Development
  • Senior Principal Scientist
  • Biomarker & Experimental Medicine Leader
  • Director Diagnostic & Experimental Pathology
  • Head, Personalized Healthcare, Corporate Development & Ventures

From Industries Including

  • Pharmaceutical, Biotechnology, Research Institutes, CD entities

Thursday, September 8th, 2016

How Will Precision Medicine Revolutionize Healthcare - 6:00PM
Microsoft Corp. Center 255 Main Street
Cambridge, MA 02142
USA
617.871.9286 [map]
Price: $40.00 at door

Join us for healthy refreshments, including freshly made SUSHI, sandwiches, and nonalcoholic drinks.

Price: $30 until September 7th at 8:00 pm; $40 after then and at the door as ticket availability permits.

FREE TICKET for full time college students through Stay in MA.

Place: 

Microsoft Corporate Center
255 Main St.
Cambridge, MA 02142
(Please note: do not go to the Microsoft NERD Center on 1 Memorial Dr. which is often confused with this location as it is right around the corner.) 

Schedule:
Networking - 6:00 pm to 6:40 pm 
Program: 6:40 pm to 8:00 pm 
Networking: 8:00 pm to 8:45 pm

Far too many diseases do not have a proven means of prevention or effective treatments. We must gain better insights into the biological, environmental, and behavioral influences on these diseases to make a difference for the millions of Americans who suffer from them. Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. While some advances in precision medicine have been made, the practice is not currently in use for most diseases.

That’s why on January 20, 2015, President Obama announced the Precision Medicine Initiative® (PMI) in his State of the Union address. Through advances in research, technology and policies that empower patients, the PMI will enable a new era of medicine in which researchers, providers and patients work together to develop individualized care.

The President called for $215 million in fiscal year 2016 to support the Initiative, which includes several components with efforts from across the federal government. Of this total proposed budget, $130 million was allocated to NIH to build a national, large-scale research participant group, called a cohort, and $70 

million was allocated to the National Cancer Institute to lead efforts in cancer genomics as part of PMI for Oncology.

THE PRECISION MEDICINE INITIATIVE FROM THE WHITE HOUSE

Jack Whelan (panelist)

Jack is a 7 yr survivor of a rare, incurable blood cancer moving from a career IT Research Analyst to Research Advocate.  Travel with Jack on an intensely personal and oft-humorous bumpy ride on the road to Personalized Medicine still under construction while he is treated for a rare, incurable blood cancer. Encounter some relapsed/refractory detours, conflicting signals and biomarkers, inhibiting regulatory roadblocks and potholes in the healthcare system.  Learn why Jack, not much of beer drinker himself hangs a bottle of Guinness on his chemo infusion rack and speaker’s podium. Using business communications and research skills from his career as a Wall Street Research Analyst in Information Technology (IT) and career Sales VP in IT, he now helps bridge the communications gap between life sciences, medical professionals and patients as a Patient Advocate, Research Advocate and Legislative Advocate.

Jack hopes all of us appreciate the value and noble work of life sciences employees and companies involved in cancer research and care.  A decided friend to BioPharma as an engaged, informed e-Patient Opinion Leader (POL) and advocate he regularly speaks to and for these companies, to open much-needed, lines of communications with patients, providers and policymakers.

He encourages all patients to explore novel targeting agents many of which are now in Clinical Trials.  Using genetic and genomic information to develop new disease-specific targeted therapeutics might be safer and more effective treatment than conventional chemotherapy.  Jack’s a frequent speaker and participant at the best industry and advocacy conferences in the Americas and Europe sharing his engaging, gripping, hopeful and fun story about survival.
Jack understands the realities of his blood cancer as he has repeatedly relapsed and has been refractory to most of the therapies received thus far; however his goal is repeated periods of progression free survival during which the promise of science and delivery of successful therapeutics will be achieved. 

 

Raju Kucherlapati, Ph.D. (panelist)

   

Raju Kucherlapati, Ph.D., is the Paul C. Cabot Professor in the Harvard Medical School Department of Genetics. He is also a professor in the Department of Medicine at Brigham and Women’s Hospital.

Dr. Kucherlapati was the first Scientific Director of the Harvard Medical School-Partners Healthcare Center for Genetics and Genomics. His research focuses on gene mapping, gene modification, and cloning disease genes. From 1989-2001, Dr. Kucherlapati was the Lola and Saul Kramer Professor of Molecular Genetics and Chairman of the Department at the Yeshiva University Albert Einstein College of Medicine. He was previously a professor in the Department of Genetics at the University of Illinois, College of Medicine. He began his research as an assistant professor in the Department of Biochemical Sciences at Princeton University.

He has chaired numerous NIH committees and served on the National Advisory Council for Human Genome Research and the NCI Mouse Models for Human Cancer Consortium. He is also a member of the Cancer Genome Atlas project of the National Institutes of Health. He is a member of the Institute of Medicine of the National Academy of Sciences and a fellow of the American Association for the Advancement of Science.

Dr. Kucherlapati received his B.S. and M.A. in Biology from universities in India, and he received his Ph.D. from the University of Illinois at Urbana, as well as conducting post-doctoral work at Yale University.

Jeffrey A. Golden, M.D. (panelist)

 

Jeffrey A. Golden is the Ramzi S. Cotran Professor of Pathology at Harvard Medical School and the Chair of Pathology at the Brigham and Women’s Hospital.  He received his BA from the University of California, San Diego and his MD from the University of Pennsylvania.  He trained in anatomic pathology and neuropathology at the Massachusetts General Hospital followed by postdoctoral training in the Department of Genetics at Harvard Medical School at which time he was an Instructor in the Department of Pathology at Brigham and Women’s Hospital.  He returned to the University of Pennsylvania School of Medicine and the Children’s Hospital of Philadelphia as an Assistant Professor of Pathology and Laboratory Medicine in 1996 rising to the rank of Professor in 2008.  In 2003 he established the division of Developmental Biology for Pediatric Disorders at the Children’s Hospital of Philadelphia and in 2008 was appointed Pathologist-in-Chief at the Children’s Hospital of Philadelphia.  In 2012 he moved back to Boston to assume the Chair of the Department of Pathology at the Brigham and Women’s Hospital.  There he is leading the development and implementation of Computational Pathology and Precision Medicine.  In addition to his local roles he is a past president of the American Association of Neuropathologists, an Associate Editor for the Journal of Neuropathology and Experimental Neurology, and a member of many editorial boards.  He has served on many international, national and local committees, has organized numerous national and international meetings, and is a regular grant reviewer for international funding agencies and the NIH, including chairing numerous study sections.  Finally, his work has been recognized with a number of awards including the Litchfield Lectureship at Oxford College, the Dorothy Russell Memorial Lectureship from the British Neuropathology Society, and twice the Weil Award from the American Association of Neuropathologists.

Candida Fratazzi, MD (panelist)

 

Dr. Fratazzi has 25 years’ experience in biomedical research. Dr Fratazzi devised the concept of a Strategic Clinical Innovation Organization (SCIO) and founded the first SCIO –Boston Biotech Clinical Research (BBCR), LLC in 2009, with the objective of actively contributing to innovation in clinical research. Dr. Candida Fratazzi is an Orphan Diseases expert: she has worked in cystic fibrosis, Fabry disease, Gaucher’s disease, and multiple sclerosis projects. As the President of BBCR, LLC, Dr. Fratazzi acts as a consultant to biotech, pharmaceutical and medical device companies of all sizes, advising her clients on optimum clinical plan development and how to design clinical trials that reduce the risk of late-stage failure. Dr Fratazzi has held senior positions at Wyeth, Shire, TKT, Vitex and Altus Pharmaceuticals. Her experience encompasses all stages of clinical research. Her most recent achievements include: Recipient of the Cambridge Award for Pharmaceutical Consultant 2013, Developed and presented workshops: BIO Conference 2011 and 2012, Invited speaker: ACRP 2012; MBC 2010 and 2011; GLG 2011 and authored several book chapters.

 

Wednesday, September 7th, 2016

Outsourcing in Clinical Trials, New Engand 2016, Boston - 08:00AM
Sheraton Boston Hotel 39 Dalton Street
Boston, MA 02199
USA [map]
Price: from Free to $2895

Discovering latest strategies for operational challenges during clinical trials including patient centricity, sites and trial design

Arena International are looking forward to returning to Boston for our flagship event, Outsourcing in Clinical Trials New England on 7th-8th September 2016. Last years’ event saw over 500 attendees from the pharmaceutical, biotech and medical device industry attend thought leadership presentations, interactive panel and roundtable discussions and networking sessions. This years’ agenda has even more innovative sessions and fascinating content including a regulatory workshop for medical devices, a patient recruitment panel from past and current patients and an interactive debate focusing on outsourcing vs. procurement.

OCT New England is catered for the pharma, biotech and medical device companies in the New England region who are working in clinical operations and partnering for clinical trials. The 2 day conference provides a unique opportunity to network with peers and meet service providers in an informal environment.

We look forward to seeing you in Boston

 

EVENT NEWS

Content for OCT New England 2016 agenda confirmed

The agenda has been finalized for this years’ OCT New England conference and there are lots of exciting new topics that will be presented.

Who should attend?

OCT New England brings together senior level professionals working in operations and outsourcing of clinical trials within and the surrounding area of Boston.

See what our 2015 attendees said...

Last years’ event was a huge success attracting 500+ professionals working on clinical trials but don’t take our word for it, see here what our 2015 delegates had to say.

Jack Whelan is speaking on September 7th at 4:45PM 

Sunday, August 14th, 2016

Encouraging and Sustaining Cancer Advocacy Programs and Efforts (ESCAPE) Tucson, AZ
Encouraging and Sustaining Cancer Advocacy Programs and Efforts (ESCAPE) - 12:00 check in
Cancer Advocacy Leadership Conference at Miraval
Tuscon, AZ 85739
USA
520 575 9602 [map]
Price: See website

ESCAPE to Thrive

The only gathering of its kind, ESCAPE to Thrive 2016 is the premier event designed by and for community cancer advocates. It combines features of a national leadership conference and a restorative retreat, with an underlying focus on the wellness of the individual advocate as well as their cancer organization. Miraval is home to ESCAPE. Dedicated to inspiring Life in Balance, it is an integral component of the conference with its mind/body recharge effect.

Is escape right for you? Are you…

  • On the front lines of cancer advocacy as a professional or volunteer survivorship advocate?
  • Affiliated with a nonprofit cancer organization?
  • A patient educator, navigator, social worker, blogger, research reviewer, community outreach/support group leader or engaged in other advocacy work?
  • Seeking to gain productive collaborations and powerful partnerships with fellow cancer advocates, industry representatives and other stakeholders?
  • Wanting to know more about how to effect change in public policy on a local, regional, and national level?
  • Looking for ways to combat compassion fatigue and prevent burnout?

Special note to ESCAPE alumni – There is no selection process as in the past! All alums are welcome to return! Need a roommate?  

What you need to know first:

  • There is no registration fee to attend the conference.
  • In lieu of a registration fee, all advocates agree to fully participate in the program on Day 1.  Learn more.
  • Advocates must stay at Miraval all three nights of the conference (or longer!) Learn More.
  • Come by yourself or bring a fellow advocate, spouse/partner, family member or friend to share your room. (All conference sessions are open to non-advocate guests.) Click for agenda. | Click here to find a roommate.
  • Space is limited (by design) and available on a first-come, first-served basis. 

Monday, July 4th, 2016

Horizon Discovery Company Meeting Cambridge England, Jack is speaker - 09:00AM
8100 Cambridge Research Park Waterbeach United Kingdom
Cambridge, England CB25 9TL
United Kingdom [map]

Horizon Diagnostics

We provide independent external controls to routinely monitor the performance of your workflows and assays  REFERENCE STANDARDS

 

Horizon Research Services

We provide precision gene-editing, isogenic cell line assays, cutting edge screening platforms and in vivo models to help solve your research and drug development challenges  RESEARCH SERVICES

Horizon Bioproduction

We provide products and services that aim to revolutionize the production of large molecule therapeutics, providing solutions for all organizations of all sizes  BIOPRODUCTION

 

Horizon Genomics

We provide genetically-defined isogenic cell lines and in vivo research models provide tools to help researchers understand complex genetic diseases  CELL LINES IN VIVO MODELS

 

 

 

Tuesday, June 28th, 2016

Rare Disease Legislative Advocacy (RDLA) NE Conference, UMass Boston, Jack is the MC
Rare Disease Legislative Advocacy (RDLA) NE Conference, UMass Boston, Jack is MC - 10:00AM - 3:00PM
University of Massachusetts, Campus Center 3rd Floor 100 Morrissey Blvd
Boston, MA 0225
USA
202 803 6047 [map]
Price: .00

We want to ensure that Members of Congress hear directly from constituents affected by rare disease about the urgent need to pass 21st Century Cures and other priorities for the rare community during the summer recess.

Please join me (I'll the the Master of Ceremonies) and the Rare Disease Legislative Advocates along with rare disease patients, caregivers, academics and other stakeholders at our Northeast Legislative Conference on Tuesday, June 28th, at the University of Massachusetts Boston from 10am to 3pm

The event is free and lunch will be provided. Space is limited so register today! 

   REGISTER   

Join us to:

  • Discover why public policy should be a top priority
  • Network with other local rare disease advocates
  • Learn how we can schedule meetings for you with your Representative and Senators in their local offices during In-District Lobby Days

In order to enable advocates from other states to attend, the EveryLife Foundation will offer ten $200 travel stipends.  Advocates from outside of Massachusetts can apply for a stipend online through June 22nd. Applicants will be notified on June 23rd and checks will be available for pick-up at the conference.

Please share this invitation with your community. The more we work together, the greater our impact!

Questions? Please email Stephanie Fischer, Senior Director, Patient Engagement and Communications, at sfischer@everylifefoundation.org

Thank you to our sponsors and advocacy partners for this event.              

 

Monday, June 27th, 2016

Festival of Genomics, Boston 2016, Jack is speaking - 09:00AM
Boston Convention and Exhibition Center
Boston, MA 02210
USA [map]
Price: $349.00

What is the Festival of Genomics?

The Festival is a 3 day celebration of genomics across the spectrum from the lab to the clinic, taking in new research, technology and advances in medicine. Essentially it’s the ultimate genomic gathering. The aim is to unite the different stakeholders of the community around a series of progress-critical topics. We’ve removed the usual boundaries and walls to create a spirit of unity distinct from anything else in the calendar.

We believe in providing an environment for creative scientists to flourish and we encourage those with the ability to make connections between diverse ideas, concepts and data to come and share with their peers. The path to progress is through originating new ideas and through challenging existing concepts and models, and the Festival is the best place to do that.

Just like other great Festivals, it’s not just about our headliners and stage acts, but the full range of activities around the site that give that ‘Festival feeling’ and make the experience memorable. Introducing some of the more unusual elements opens the door to an atmosphere of fun and informality which makes striking up a conversation with your peers and heroes effortless.


What’s going on this year?

There are a number of brand new experiences & returning features to keep you busy at this year’s event;

  • New content tracks to broaden your horizons – check out all 12!
  • In-depth workshops to tackle those trickier topics
  • Zoning on the show floor to help you network and find relevant content more easily
  • A live lab exploring a full genomics workflow
  • Extended poster zones and brand new stages around the festival to celebrate research and advances in techniques and technologies
  • Site visit to the genomics powerhouse, the Broad Institute
  • Evening session dedicated to genomics & space exploration
  • 3 new feature tracks focusing on investment, genetic counselling & drug development
  • Race the Helix will return to help raise money for Greenwood charity for genomic disease
  • Fiendishly difficult tasks in our all new ‘genomics workflow challenges’

There is plenty more to see and do on site. Download the Festival Guide to discover more.

 

Front Line Genomics is a media company dedicated to supporting the genomics community. Our mission is to help deliver the benefits of genomics to patients faster. You can read more of our story here.

In addition to the 3 Festivals, please see the magazine and web portal same thing as events in a portable format: unite the genomics community to bring the benefit of genomic medicine to patients faster.

Monday, June 20th, 2016

American Cancer Society Cancer Action Network (ACS) 9th Annual Research Breakfast, Boston MA - 7:00 AM
Revere Boston Hotel 200 Stuart Street
Boston, MA 02210
USA [map]
Price: By Invitation only

The American Cancer Society Cancer Action Network (ACS CAN) will host the 9th Annual New England Research Breakfast on Monday, June 20, 2016.
We hope you can join us!

  • Keynote Speaker - Dr. Douglas Lowy, Acting Director of the U.S. National Cancer Institute
  • Honoree - Dr. Ed Benz, President and CEO of Dana-Farber Cancer Institute
  • Honorary Chair - Boston Mayor Marty Walsh 

The ACS CAN New England Research Breakfast is a premiere event that brings together more than 250 leaders from business, education, health care, government and research communities to advance the work of ACS CAN.

The 2015 Research Breakfast speakers included Massachusetts Governor Charlie Baker, Boston Mayor Marty Walsh and Dr. Jeffrey Engelman, Director of Thoracic Cancers, Massachusetts General Hospital Cancer Center.   

THANK YOU TO THE 2016 
CORPORATE & INDIVIDUAL SPONSORS

DIAMOND PRESENTING SPONSOR 
EMD Serono

GOLD SPONSOR 
Hologic
Purdue Pharma

SILVER SPONSORS
Astellas
AstraZeneca
Bristol-Myers Squibb

Dana-Farber Cancer Institute
Momenta Pharmaceuticals
Partners HealthCare 
Takeda Oncology

BRONZE SPONSORS
ARIAD Pharmaceuticals
Beth Israel Deaconess Medical Center
Boston University
Cataldo Ambulance Service
EYP, Inc.
Infinity Pharmaceuticals, Inc. 
Lahey Health Cancer Institute
Mass General Cancer Center 
Radius Health, Inc.
Sandoz
TD Bank
TESARO


TABLE SPONSORS 
Acentech
Amgen
BOND
Boston Biomedical
Boston Children's Hospital
Blueprint Medicines
Dana-Farber/Brigham and Women's Cancer Center
EY
Firestone & Parson Inc.
Genentech
HarborOne
Idera Pharmaceuticals, Inc.
The Jackson Laboratory
ImmunoGen, Inc.
King Street Properties
Latham and Watkins LLP
Massachusetts Medical Society
Massachusetts Society of Clinical Oncologists
Novartis
Nutter McClennen & Fish
Pannone Lopes Devereaux & West LLC
Pfizer
Thermo Fisher Scientific
Ropes & Gray LLP
T3 Advisors
UMass Memorial Health Care, Inc. 
WilmerHale

CONTRIBUTORS
Abco Leasing
August Cervini
Harvard Pilgrim Health Care
MassBio
McDermott Quilty & Miller
PAREXEL
Mark Goldberg, MD
Shalini Vallabhan, PhD

 

  If you are interested in sponsorship please contact Lexa Sullivan at Lexa.Sullivan@cancer.org

Contributions or gifts to the American Cancer Society Cancer Action Network, Inc.,
are not tax deductible

 

 

Thursday, June 16th, 2016

eyeforpharma Oncology Market Access & Pricing 2016, Philadelphia, Jack is speaking - 09:00AM
Sheraton Philadelphia Downtown
Philadelphia, PA 19103
USA
215 448 2000 [map]
Price: $2995.00

Back for a 7th year, eyeforpharma Oncology Market Access & Pricing Summit brings together all stakeholders, including pharma, insurance companies, patient advocacy groups, and cancer associations to bridge the gap on the differing views of “value”.

Now in its 7th year, our conference is regarded by many as the most targeted and high-level gathering on commercialization cancer products in the US.  150+ senior executives are now confirmed to attend. Gain actionable insights from leading oncology innovators including: Lilly, Janssen, Eisai, Celgene, Takeda, ASCO Bristol Myers Squibb, and others in biotech and pharma.  

 

Why attend?

  • Value-Based Pricing Metrics Round RobinHear why payers are hungry for these models, how they may leverage them, and which metrics will make a significant impact on the market access environment
  • Determine How to Best Position Your Brand in an Evolving MarketWork cross-functionally with teams to address the challenges these metrics bring to develop a stronger market access trajectory by better demonstrating your products’ importance.
  • Prepare for Stakeholder’s DemandsAdopt new business strategies that effectively generate, manage, and apply relevant health economic and clinical data from drug development through reimbursement
  • Set Your Brand Apart in the Changing Payment Model LandscapeDecipher how potential APMs may impact your products and determine which are likely to have significant risks for the adoption of innovative drugs and biologics.

 

 

Track-Record of Proven Success:

83%  call our sessions essential

94%  said they will likely return again next year

97%  rated the program very well run

Tuesday, June 14th, 2016

mHealth for Clinical Trials 2016, Hanson Wade - 09:00AM
Westin Boston Waterfront Hotel
Boston, MA 02210
USA
+44 (0) 20 3141 8700 [map]
Price: $2699.

mHealth for Clinical Trials 2016 will address the technicalregulatory and cultural barriers in the adoption of mobile and digital technology to help you transform your clinical trials process. Driven by real world case studies, this conference will show you exactly how these technologies can be implemented to:

  • Revolutionize the way patients are enrolled, increasing engagement and adherence
  • Enable more frequent and efficient data collection
  • Significantly reduce trial cost and duration

Within the last year, the FDA themselves have been actively encouraging the use of mHealth technology to enable faster, more cost effective trials that facilitate getting better drugs to patients, sooner. Now is the time the transform your clinical trials process.

Join the leaders in both mHealth and clinical innovation, along with clinical investigators, study leaders, clinical data and IT professionals to explore in full the applications and limitations of these technologies.

The FDA has sent a number of signals in the last year that they are keen to see the use of mHealth technology in clinical trials to enable faster, more cost effective trials that facilitate getting better drugs to patients, sooner. The message has been clear – the barriers to using mobile technology to enhance clinical trials are not regulatory.

mHealth for Clinical Trials 2016 is your complete and essential guide to implementing mHealth technologies to enhance and expedite clinical development.

Driven by practical case studies and real-world examples of mobile technologies put to work in clinical studies, the agenda addresses issues that range from the accuracy of data collected with wearable sensors, to managing cultural change within an organisation.

Hear how leading companies are transforming the way they conduct trials, using technologies such as:

  • Mobile devices
  • Wearable sensors
  • Apps
  • The Internet of Things (IoT)
  • Social Media

mHealth for Clinical Trials 2016 is especially unique in bringing together all key stakeholders in the development and adoption of these technologies. Representation from Clinical Operations and study leaders to Clinical Data and Informatics – from both study sponsors and from trial sites – ensures that discussions at the event are practical, constructive, and represent all points of view.

If you want to be involved and have any questions, email info@hansonwade.com.

 

Friday, June 10th, 2016

International Waldenstrom's Macroglobulinemia Foundation IWMF Annual Rd Forum, Providence RI - 09:00 AM
Omni Providence Hotel 1 W Exchange St
Providence, RI 02903
USA
401-598-8000 [map]
Price: Registration required

The IWMF's annual Educational Forum presents a unique opportunity for patients and caregivers to learn about our disease from specialists in Waldenstrom’s macroglobulinemia (WM) who are involved in many areas of clinical practice and research. Held in a different part of the United States every year, the “Ed Forum” offers something for everyone, no matter what your experience or level of knowledge.

Presentations aimed at the layperson address symptoms and complications of the disease, current treatment options, new therapies on the horizon, and recent research findings that may someday lead to a cure. Breakout sessions permit in-depth exploration of specialized topics and opportunities for patients and caregivers to share their experiences in a safe and supportive environment.

The annual IWMF Educational Forum is your connection for education, camaraderie, and support! To see slides and videos from recent Educational Forum presentations, click here.

2016 Ed Forum Details and Registration Information

The 2016 Educational Forum will be located in the center of downtown Providence, Rhode Island, one of New England’s most historically significant cities and within walking distance of a wide variety of restaurants, specialty shops, and the city’s main college campuses.

Prior to the start of general sessions on Friday, June 10, we are offering a morning session especially for the newly diagnosed and first time attendees. To view the entire 2016 Educational Forum agenda, click here .

To register online for the 2016 Educational Forum, click here. Or print a copy of the registration form here to fill in and mail with your payment to the IWMF Business Office. You must indicate on the registration form if you plan to attend the special Newly Diagnosed/First Timers Session. Additional details regarding the registration fee and payment are on the form.

You are responsible for making your own room reservations at the Omni Providence Hotel. We have negotiated a special rate of $145/night, which is guaranteed for three days before and after the Educational Forum for a limited number of rooms. You can make online reservations here(link is external) or call 401-598-8000 or Toll-Free 800-843-6664 and mention the code “060516INTWALDEN” to obtain our special rate, which will be available until May 20. Rooms at the Omni are on track to be a sellout, especially on certain days. 

 

Friday, June 3rd, 2016

ASCO Annual Meeting, Chicago IL Jack participating in variety of panels
ASCO Annual Meeting, Chicago IL June 3 - 09:00AM
McCormick Place
Chicago, IL 60636
USA
703 449 6418 [map]
Price: $1995

The Annual Meeting brings together 30,000 oncology professionals from around the world. Educational sessions feature world-renowned faculty discussing state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Science sessions present the latest ground-breaking research in oral and poster format.

You’ll meet friends, make connections, and bring back new ideas to your practices and hospitals. Take the time to familiarize yourself with the different opportunities the Annual Meeting offers. Markkey dates on your calendar, find out about networking opportunities, and learn about the committees that develop the session content you’ll discover onsite.

Collective Wisdom: The Future of Patient-Centered Care and Research

The theme for ASCO 2016 is Collective Wisdom: The Future of Patient-Centered Care and Research. Spanning disciplines, disease sites, and treatment approaches, it is our combined knowledge that will shape the future of patient care and research. We must partner with health care professionals and specialists of diverse backgrounds to meet the evolving challenges in providing optimal care to our patients. With exciting advances in big data technology, our collective wisdom will become all the more powerful as new insights will be revealed in seconds, not years. The impact of our wisdom, however, can only be as great as our ability to strengthen the delivery of and access to high-quality cancer care. As medical professionals and as a Society, we must all continue to evolve cancer care and research with each new discovery. Fifty years from now, we can hope that future medical professionals can look back and thank us for pioneering aspects of cancer treatment that were developed in our era.

Research Advocacy Network AdvocateInstitute, 2016 Focus on Research Scholars, Friday June 3, 6:30 - 8:30PM Sheraton Grand Hotel

Open Table Discussion on Prostate Cancer, Saturday June 4th 10:00 - 11:00AM Jack participating

Welcome Luncheon Saturday June 4th 12:00 - 1:00PM Jeannne Salamone and Christy Behene ASCO Staff

CancerLinQ Patient Advocate Forum  Sunday June 5th 12:00 - 1:00PM  Jack participating as a panelist and member of CancerLinQ Patient Advocate Committee.

TAPUR Study Update, Sunday June 5th 4:00 - 4:45PM  Richard Schilsky, MD ASCO's CMO and Jane Perlmutter, PhD Patient Advocate

US FDA Update on Expanded Access, Monday June 6th 12:00 - 1:00PM Patient Liaison Program

 

Monday, May 23rd, 2016

Covance CDCS Project Leadership Meeting, Jack is a keynote speaker
COVANCE Project Leadership Meeting - 09:00AM
Crowne Plaza Princeton
Princeton, NJ
USA [map]
Price: By Invitation only

 

Patient Perspective on Clinical Trials and Personalized Medicine.

Jack is a Keynote speaker.

Friday, May 20th, 2016

19th Annual Massachusetts Prostate Cancer Symposium - 07:30 AM
Marriott Newton, MA 2345 Commonwealth Avenue
Newton, MA 02466
USA [map]
Price: .00

2016 MPCC Annual Symposium

The 19th Annual Massachusetts Prostate Cancer Symposium — leading prostate cancer specialists provide up-to-date information on the latest in prostate cancer treatment and research — in user-friendly language!.

 

 

MPCC_Symposium_2016_rev4-2

 

 

 

Tuesday, May 17th, 2016

Perspectives in Clinical Trials: Patient Insioghts, Jack is speaking on a panel, Cambridge MA
Perspectives in Clinical Trials, Cambridge, MA - 11:45
Cambridge Innovation Center
Cambridge, MA 02142
USA
802 291 0645 [map]
Price: No charge

Perspectives in Clinical Trials: Patient Insights

Tuesday May 17, 2016 11:40 Lunch and Learn

Cambridge Innovation Center, Cambridge MA 

Join colleagues for a patient panel and engaging discussion focusing on the challenges and successes of clinical trials from the patient point of view.  The three patient panelists have each had their own unique journey and will provide their valuable insights, advice and hopes for positive changes as well as answer questions from the audience.  Lunch is provided.

Jack Whelan, Corrie Painter and Alicia Staley are speakers.

Wednesday, May 4th, 2016

AAADV In-Depth Discussion Group Drug Development for Rare Tumors - 09:00 AM
Bethesda North Marriott Hotel and Conference Center
Bethesda, MD 20852
USA
(301) 822.9200 [map]
Price: $2400.

Developing therapies for rare diseases presents a variety of logistical and statistical challenges, not the least of which is designing and conducting clinical trials that are capable of generating sufficient data to support regulatory approval. This is an increasingly important topic for the development of oncologic drug products, particularly in this era of targeted therapeutics. Improved knowledge of cancer biology and advances in biotechnology have created unprecedented opportunities for developing effective treatments directed at distinct biological, molecular or genetic tumor-specific characteristics; however, these opportunities often come with challenges related to developing drugs in small subsets of patients who have tumors bearing the characteristics of interest. 

Overcoming the challenges inherent in evaluating cancer therapies aimed at treating small patient populations requires a multidisciplinary approach, stakeholder collaboration, innovative trial design and conduct methods, and regulatory flexibility. 

This in-depth discussion group will provide an overview of the challenges to the development of therapies for the treatment of rare cancers and strategies to address these challenges.

AAADV Workshop

Leaders in clinical and translational cancer research from academia, industry, government and the nonprofit advocacy sectors convene each spring in Bethesda, Maryland, for a unique forum designed to speed cancer treatments to patients. Our two and one-half day, on-site interactive AAADV Workshop offers a mix of small group lectures, moderated discussions, plenary lectures and facilitated case studies of successful drug applications. Participants gain valuable insights on negotiating the spectrum of successful drug development and hone their strategic planning skills with a focus on target validation and pathway identification. The AAADV is the only workshop held in collaboration with the U.S. Food and Drug Administration designed specifically to help, participants understand and negotiate the drug development approval process so that effective cancer treatments can reach patients more quickly.

Who Should Attend

The AAADV Workshop is designed for scientists and consumer advocates with clinical trial experience interested in developing agents for the diagnosis, treatment or prevention of cancer. Individuals with limited experience in the regulatory aspects of oncology drug development will benefit from the knowledge and networking with more-experienced investigators and advocates.

Participants Will:
  • Examine the most urgent issues and meaningful trends in anticancer agent development and
    validation.
  • Learn new approaches for diagnosing, treating and preventing cancer.
  • Benefit from a mix of small group lectures, moderated discussions, facilitated case studies of
    successful new drug applications and plenary lectures.
  • Network with researchers, regulators, patient advocates and others working on the frontlines of
    cancer research and treatment.

Tuesday, May 3rd, 2016

AAADV Fundamentals Workshop, U.S. FDA, Bethesda, MD Jack had to cancel
AAADV Fundamentals Workshop, U.S. FDA, Bethesda, MD Jack had to cancel - 09:00AM
Bethesda North Marriott Hotel and Conference Center 5701 Marinelli Road
Bethesda, MD 20852
USA
(301) 822.9200 [map]
Price: By Invitation only
AAADV Workshop

Leaders in clinical and translational cancer research from academia, industry, government and the nonprofit advocacy sectors convene each spring in Bethesda, Maryland, for a unique forum designed to speed cancer treatments to patients. Our two and one-half day, on-site interactive AAADV Workshop offers a mix of small group lectures, moderated discussions, plenary lectures and facilitated case studies of successful drug applications. Participants gain valuable insights on negotiating the spectrum of successful drug development and hone their strategic planning skills with a focus on target validation and pathway identification. The AAADV is the only workshop held in collaboration with the U.S. Food and Drug Administration designed specifically to help, participants understand and negotiate the drug development approval process so that effective cancer treatments can reach patients more quickly.

Who Should Attend

The AAADV Workshop is designed for scientists and consumer advocates with clinical trial experience interested in developing agents for the diagnosis, treatment or prevention of cancer. Individuals with limited experience in the regulatory aspects of oncology drug development will benefit from the knowledge and networking with more-experienced investigators and advocates.

Participants Will:
  • Examine the most urgent issues and meaningful trends in anticancer agent development and
    validation.
  • Learn new approaches for diagnosing, treating and preventing cancer.
  • Benefit from a mix of small group lectures, moderated discussions, facilitated case studies of
    successful new drug applications and plenary lectures.
  • Network with researchers, regulators, patient advocates and others working on the frontlines of
    cancer research and treatment.

Tuesday, May 3rd, 2016

PRO & eCOA CONGRESS Orlando, FL - 0900
Orlando World Center Marriott
Orlando, FL 32821
USA
(407) 239 4200 [map]
Price: By Invitation

Overview

Do you want to learn more about eCOA, and meet others who are leading and working in this exciting industry?

Then you should attend the PRO & eCOA Congress.

This is the only US event dedicated to providing case studies and pragmatic information on the clinical science, regulatory and innovative technologies used to collect patient data for clinical studies. Study leaders present their best practices, and caveats. Small group workshops discuss eSource, Safety Monitoring, and Biosensor integrations. You’ll see which technologies are in beta testing at the Innovation Lab (Boston).

At the end of two days, you will have met and engaged with US’ leading eCOA community; and garnered new tools and methodologies to effectively implement eCOA initiatives.

 

At the Congress, You Will Learn How to:

  • Effectively implement an ePRO Strategy within your organization
  • Become an internal leader in PRO and eCOA; and help teams expedite study set-up times and arrive at a go/no-go decision faster
  • Migrate standardized instruments to an electronic implementation

Key Congress Topics

  • Innovation: New Data Endpoint Opportunities for Clinical Trials
  • Data Management: Surveillance
  • Site Focus: Which Technologies REALLY Reduce Clinical Site Burden
  • Case Study: First time use of eCOA + Respiratory + Cardiac
  • Case Study: Complex study success
  • Regulatory: How to Prepare for an Audit
  • Clinical Operations: Best Practices for Conducting a User Site Testing (UST) as Required by FDA

Who Should Attend

  • Clinical Operations
  • Data Management
  • Regulatory Affairs
  • Outsourcing
  • eClinical Technologies
  • Health Outcomes

Sponsored by ERT

ERT is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development.

Tuesday, April 12th, 2016

2016 PRO and eCOA Congress Sitges, Spain - 0900
Joan Salvat Papasseit, 38
Barcelona – Sitges 08870
Spain [map]
Price: By Invitation

Overview

Do you want to learn more about eCOA, and meet others who are leading and working in this exciting industry?

Then you should attend the PRO & eCOA Congress.

This is the only European event dedicated to providing case studies and pragmatic information on the clinical science, regulatory and innovative technologies used to collect patient data for clinical studies. Study leaders present their best practices, and caveats. Small group workshops discuss eSource, Safety Monitoring, and Biosensor integrations. You’ll see which technologies are in beta testing at the Innovation Lab (Boston).

At the end of two days, you will have met and engaged with Europe’s leading eCOA community; and garnered new tools and methodologies to effectively implement eCOA initiatives.

Key Congress Topics

  • Innovation: New Data Endpoint Opportunities for Clinical Trials
  • Data Management: Surveillance
  • Site Focus: Which Technologies REALLY Reduce Clinical Site Burden
  • Case Study: First time use of eCOA + Respiratory + Cardiac
  • Case Study: Complex study success
  • Regulatory: How to Prepare for an Audit
  • Clinical Operations: Best Practices for Conducting a User Site Testing (UST) as Required by FDA

Who Should Attend

  • Clinical Operations
  • Data Management
  • Regulatory Affairs
  • Outsourcing
  • eClinical Technologies
  • Health Outcomes

 Sponsored by ERT

ERT is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development.

 

 

 

Monday, April 11th, 2016

Testify at Massachusetts State House Against S1048 State Panels on Drug Price Controls
Testify at Massachusetts State House Against State Panels to control drug prices, veru bad. - 11:00 AM
State House 24 Beacon Street
Boston, MA 02133
USA
617 722 2000 [map]
Price: No Charge

April 11, 2016

The Honorable James T. Welch

Senate Chair, Joint Committee on Health Care Financing

Commonwealth of Massachusetts

State House, Room 309

Boston, MA  02133

 

The Honorable Jeffrey Sanchez

House Chair, Joint Committee on Health Care Financing

State House, Room 236

Boston, MA  02133

 

Dear Co-Chairs Welch and Sanchez:

 

As a patient who has benefited greatly from advances in biopharmaceutical research, I write in opposition to S1048.

 

My life has been extended by scientific research, access to cutting edge clinical trials, and therapies that didn’t exist a few years ago.  The high cost of health care in general is an ongoing concern.  However, policies and proposals such as S1048, that threaten the search for cures, are a greater concern.

Price controls and overregulation of life science companies are counterproductive, especially when they are already heavily regulated at the federal level.  Public policy should balance industry oversight by government with providing an environment that fosters research and discovery.  The legislation before you could have a chilling effect on the continued progress of discovery and treatment.  

The value of breakthrough medications can’t be reduced to dollars and cents — as I know from personal experience.  After I was diagnosed with a rare incurable blood cancer seven years ago, I participated in clinical trials for experimental treatments that continue to extend my life.  For me and countless other Massachusetts patients, the health benefits of these medicines remain priceless.

Most concerning is that the proposed legislation would allow a state board to decide if a prescription is too expensive then set a “maximum allowable price.”

Additionally, the bill calls for disclosure of research and development spending on individual medicines as a measure of their cost.  Research spending on an individual therapy does not reflect the actual costs of drug development.  Only one in 5,000 drug therapies that pharmaceutical companies begin testing actually get approved by the U.S. Food and Drug Administration.  It’s largely because of expensive failures that pharmaceutical companies spend an average of $2.6 billion for each approved medicine, according to a recent Tufts University study.

A recent report by the National Bureau of Economic Research documents that price controls will slow the production of new cures. According to the report, “cutting prices by 40 to 50 percent in the United States will lead to between 30 and 60 percent fewer research and development projects being undertaken in the early stage of developing a new drug.”

Drug price controls are already harming the health of Americans, thanks to something called “Step Therapy” or “Fail First.”  Under this arrangement, patients are often required to change their prescription to a less expensive drug simply to save the health system money.  If the new drug is not as safe or effective as the original prescription, patients must wait for the treatment to fail.  After that, it can take another 30 days before they receive the originally prescribed medicine. 

This happened to me.  I was prescribed Lyrica, which is used to treat neuropathy — a common condition in cancer patients.  I had to fail first on Cymbalta that was less effective, but cost 2 cents less per pill.  My health was jeopardized over a few pennies.  S1048 is an even more aggressive attempt to sacrifice patient health to try to save a little money in the short-term.

Breakthrough pharmaceuticals can be expensive.  But their benefits are often invaluable.  As someone who owes his life to drug research, it’s unthinkable that policymakers could be so quick to discount the incredible value of pharmaceutical innovation. 

I respectfully urge you to oppose this legislation.

 

Thank you.

Jack Whelan

9 Deerberry Lane

Andover, MA  01810

 

Thursday, April 7th, 2016

Clinical Trials Patient Experience Summit, San Jose, CA Jack, keynote speaker cancelled
Clinical Trials Patient Experience Summit - 08:00AM
Palo Alto Sheraton
Palo Alto, CA
USA
203.253.6401 [map]
Price: TBD

FROM VOLUME TO VALUE: CONNECT WITH PATIENTS ON THEIR TERMS & ADVANCE CLINICAL RESEARCH

 

"PARTICIPATORY MEDICINE IS A MOVEMENT IN WHICH NETWORKED PATIENTS SHIFT FROM BEING MERE PASSENGERS TO RESPONSIBLE DRIVERS OF THEIR HEALTH, AND IN WHICH PROVIDERS ENCOURAGE AND VALUE THEM AS FULL PARTNERS." (PATIENTDRIVEN.ORG)

OVERVIEW

The Clinical Trials Patient Experience Forum is the first conference of its kind to focus on ways for pharma clinical trials to take advantage of new opportunities tobecome more patient-centric and leverage new strategies to connect patients; as well as how these new wearable technologies have the potential to collect, warehouse, analyze, utilize, regulate and secure patient data.

WHO?

Global experts will converge at the forefront of clinical research, patient experience, data analytics, and early detection and diagnosis for pharma clinical trials. If you’re involved with R&D, sales and marketing, healthcare IT, data management, mHealth, patient engagement or health outcomesthis is the place to be.

 

BE THERE!

Join 30+ speakers, 150+ senior-level pharma, clinical trials, technology, behavioral medicine and mHealth executives April 7-8, 2016 in Palo Alto, CAto learn, network, develop and improve the way pharma clinical trials can connect patients with the resources they need, and improve the patient experience.

 

Tuesday, April 5th, 2016

BioIT World Conference - 08:00AM
Seaport Hotel, One Seaport Lane
Boston, MA 02210
United States
877 732 7678 [map]
Price: See website

About the Event

Since its debut in 2002, the Annual Bio-IT World Conference & Expo has established itself as a premier event showcasing the myriad of IT and informatics applications and enabling technologies that drive biomedical research, drug discovery & development, and clinical and healthcare initiatives. The Bio-IT World Conference & Expo continues to be a vibrant event that unites 3,000+ life sciences, pharmaceutical, clinical, healthcare, and IT professionals from more than 30 countries.

Spanning three days, the 2016 meeting includes 13 parallel conference tracks and 16 pre-conference workshops. Compelling talks, including best practice case studies and joint partner presentations, will feature over 260 of your fellow industry and academic colleagues discussing themes of big data, smart data, cloud computing, trends in IT infrastructure, omics technologies, high-performance computing, data analytics, open source and precision medicine, from the research realm to the clinical arena.

 

 

Monday, February 1st, 2016

Had to cancel speaking engagements 02-01 thru 04-01-2016
Had to cancel speaking engagements 02-01 thru 04-01-2016 - Very expensive treatment
Home
Boston area, MA 02210
USA
617 820 5145 [map]
Price: My Life

Hi Friends and in particular Conference Producers.

I hope I have given enough notice to let you know that I will not be able to speak at most conferences during the rest of Q1 and part of Q2, 2016.

I'm starting chemotherapy treatment again for a second cancer, a metastatic prostate cancer.  But I'll be back, I promise.

For the rest of the story, please check my blog.  Thanks.

Jack

Sunday, January 10th, 2016

PCT Advisory Board Meeting, New York, Jack is Advisor for PCT Conference
Personalized Clinical Trials
Davio's
New York, NY
USA
347 461 4502 [map]

Planning Meeting, conference info to follow.

Thursday, November 19th, 2015

4th Annual Patient-Centered Oncology Care, Baltimore MD - Jack is a Keynote Speaker - 9:0 AM
Baltimore Marriott Waterfront Hotel, 700 Aliceanna Street
Baltimore, MD 21202
USA
410 385 3000 [map]
Price: $299

The American Journal of Managed Care will host its 4th Annual Patient-Centered Oncology Care® Meeting on November 19-20, 2015, in Baltimore. The event will offer unique perspectives on emerging topics in oncology care from today’s leading health experts.

AJMC’s Patient-Centered Oncology Care meeting is an important event for anyone interested in “crossing the chasm” that appears between providers and the rest of the healthcare world, including payers and hospital administrators, explained Peter P. Yu, MD, immediate past president of the American Society of Clinical Oncology, and the keynote speaker at PatientCentered Oncology Care 2014. Through the Patient-Centered Oncology Care meetings, AJMC is creating opportunities for everyone involved in cancer care to meet in the same place and have the dialogue that is so important to making care better for patients.

The event will feature sessions on genomics, the future of immuno-oncology, precision medicine, and more.

REGISTRATION FEE: $299 Registration fee includes:

• Admission to the evening networking reception on November 19

• Admission to all sessions, presentations, and discussions on November 19 and 20

• Breakfast, lunch, and snacks on November 20th

For registration assistance, please e-mail AJMCmeetings@ajmc.com or call (609) 716-7777.

Monday, November 16th, 2015

Patient Empowerment: The Impact of Patients on Clinical Development Research - 5:30PM
Tekeda Pharmaceuticals International
Cambridge, MA 01810
United States
973-575-0606 ext 3 [map]
Price: $70.00

Patient Empowerment: The Impact of Patients on Clinical Development Research

Mon, Nov 16, 2015

5:30 PM - 9:00 PM

Takeda Pharmaceuticals International, Cambridge, MA

Join a panel discussion on integrating the patient voice into clinical development research, with the goal to enhance recruitment and retention in clinical trials, to best serve patient needs.

 

Event Type: Program (Education)
Audience: General/All
Primary Competency: 1. Demonstrates integrity
Second Competency: 3. Exhibits business and industry acumen

Event description
With the emphasis on patient-focused drug development, patient advocacy groups are playing an increasingly important role and are having greater impact on the entire drug development continuum - from discovery through approval and beyond into the marketplace. Different organizations representing the patient perspective are influencing early drug discovery, preclinical and clinical studies across numerous therapeutic areas. In addition, government regulatory agencies are increasingly seeking more patient engagement. It is critical for individuals and organizations in the healthcare industry to understand different ways to partner with patient groups in planning clinical studies in order to increase the likelihood that trials address patient needs, as well as to incorporate the patient’s voice into research and development, and to design and implement trials in ways that optimize recruitment and retention.

Join the event moderator Michele Derai (Aptel Research), and representatives from across the industry, panelists Kathy Gram (Takeda), Deborah Peirce (Baxalta), Daphne Psacharopoulos (PatientsLikeMe), and Jack Whelan (Research Advocate) for a lively discussion on the role and influence of patient advocacy groups on clinical research and development.

Learning objectives
1. Assess the contribution patient groups can make on clinical development research
2. Identify the challenges of a patient-centered approach in clinical development research
3. Define the recipe for win-win partnerships between pharma and patient groups for clinical development research

Agenda
5:30 PM - 6:30 PM     Registration/networking, appetizers
6:30 PM - 6:40 PM     Welcome/opening remarks
6:40 PM - 7:00 PM     Introduction of topic and panel
7:00 PM - 8:00 PM     Panel discussion
8:00 PM - 8:15 PM     Q&A
8:15 PM - 8:25 PM     Closing remarks
8:25 PM - 9:00 PM     Networking

Event location
Takeda Auditorium
40 Landsdowne Street
Cambridge, MA 02139

Directions

Sponsors

 
 
 

Speakers
Daphne Psacharopoulos  
Sr. vice president, client services and strategic initiatives, Patients Like Me

Jack Whelan
Research advocate

Moderator
Michele Derai 
CEO, Aptel Research

Wednesday, November 11th, 2015

WorldCourier Patient Centric Approach to Clinical Trials, Webcast from London
The Patient Centric Approach to Clinical Trials - 10:00 AM (ET, New York) 3PM (London)
Webcast www.tinyurl.com/WhelanCT
London, England
United Kingdon [map]
Price: .00

How the delivery of nursing care and supplies influence the clinical trial experience for the patient

When it comes to clinical trials, one of the biggest issues for pharmaceutical companies is patient recruitment & retention. For a patient, the biggest issues are being accepted & enrolled, then whether they can withstand the demands of the trials. For some, it could be a life-threatening condition and they have exhausted other medical options. The challenges surrounding patient recruitment and retention could lead to missed treatment or patient drop-out; ultimately, this results in lost participants, lost data and for the patient, the loss of so much more. 

This webinar, chaired by Sue Lee (Technical Portfolio Manager at World Courier) will explore these challenges and provide actionable suggestions to help sponsors improve the patient's clinical trial experience.

Jack Whelan, Research Advocate, ePatient and seven-year survivor of a rare incurable blood cancer will share his experiences and identify some trial pitfalls from a patient's perspective. He will offer suggestions as to how the healthcare industry can make the trial experience better for patients and move medicine forward.

Helena Baker, Vice President of Global Nursing Services for the Medical Research Network, will address how home healthcare can encourage enrolment and aid retention by easing the patient burden.

Enroll now for this webinar, that combines real life experiences with actionable insights to improve studies and discover how companies can ensure when the drug arrives to the patient, it will be used effectively offering the best chance for success and the most benefit to the patient.

 

Presented by

Sue Lee,

Technical Portfolio Manager

Sue Lee has worked for World Courier for 25 years. During this time she has experienced a variety of customer service and operational functions, including the setting up of numerous, multi national, clinical sites for the transportation of biological samples. She has orchestrated the shipping thousands of shipments with very specific temperature requirements to a host of challenging locations, and each presenting their own obstacles and dilemmas.

Jack Whelan,

Author, Lecturer, Research Advocate, Cancer Warrior & Survivor, ePatient, Clinical Trials

Jack Whelan is a 7 yr survivor of a rare, not-yet-curable blood cancer moving from a career IT Research Analyst to Research Advocate. In Advocacy he's an active with AACR, ASCO, DIA, LLS, RDLA, NORD, NIH's NCTN, ACRES and others and frequent speaker and participant in Life Sciences conferences. 

He lives in Andover MA with his wife Jan, has three 'fabulous' daughters and sons-in-law and proud grandparents of four twin-grandchildren including twin granddaughters and twin boy and girl another granddaughter and recently a grandson. Diagnosed in early 2007 with an active Waldenstrom's Macroglobulinemia, a rare lymphoplasmacytic lymphoma for which there is no cure yet, Jack has participated in six Clinical Trials at Dana Farber Cancer Institute, (DFCI) in Boston, MA and Londonderry, NH. He is also treated at Brigham & Women's Hospital (BWH) in Boston. 

As an effective e-Patient/Research Advocate, Jack's message to patients is to explore novel targeting molecular agents available in Clinical Trials; when coupled with genetic and genomic information and diagnostics these could be a safer and more effective than conventional chemotherapy.

Helena Baker,

Vice President of Global Nursing Services

Helena Baker is the Vice President of Global Nursing Services at the MRN, where she is responsible for all aspects of the company's nursing service delivery, in addition to clinical governance, nursing strategy and managing clinical risk.

She is currently managing the development of an international nurse training and development program and plans for international expansion of the business into emerging markets across the world.

As a registered nurse, Helena has 30 years of experience in nursing and healthcare, including roles at The Royal London in Whitechapel, Ferring Pharmaceuticals Ltd, and St Bartholemew's. In 1998, Helena founded Helena Baker Associates, working as a healthcare analyst to the pharmaceutical industry, before joining Healthcare at Home and then MRN in 2007.

 

Thursday, November 5th, 2015

Alliance fr Clinical Trials in Oncology Meeting, Chicago IL - 08:00AM
Loews Chicago O'Hare Hotel
Chicago, IL 60636
USA [map]
Price: Invitation only

Alliance for Clinical Trials in Oncology 

  • Group Meetings - Group meetings are open to all Alliance members and industry representatives. These meetings, structured to foster collaboration, serve as a forum to share research accomplishments of the Alliance committees with the membership and collaborators. Educational sessions, mostly aimed at nurses and clinical research professionals, a plenary session led by the Group Chair, and a networking event are held at the Group meetings. Committee Chairs may plan closed and open sessions depending on their committee’s needs. Group meetings are held in the fall, typically November.

The Alliance for Clinical Trials in Oncology seeks to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines, committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer.

OUR MISSION

The mission of the Alliance for Clinical Trials in Oncology is to reduce the impact of cancer by:

  • Conducting high quality multidisciplinary cancer control, prevention, and treatment trials that engage a comprehensive research network
  • Furthering our understanding of the biological basis of the cancer process and its treatment, from discovery, to validation, to clinical practice
  • Providing a scientific and operational infrastructure for innovative clinical and translational research in the academic and community settings

WHAT WE DO

The Alliance for Clinical Trials in Oncology develops and conducts clinical trials with promising new cancer therapies, and utilizes the best science to develop optimal treatment and prevention strategies for cancer, as well as researches methods to alleviate side effects of cancer and cancer treatments. The Alliance has been awarded a grant by the National Cancer Institute (NCI) as a member of the NCI National Clinical Trials Network (NCTN). The Alliance has also been awarded a grant to serve as a research base for the NCI Community Research Oncology Program (NCORP). Collectively, the Alliancecomprises nearly 10,000 cancer specialists at hospitals, medical centers, and community clinics across the United States and Canada. To learn more about collaborating with the Alliance, click here.

Tuesday, October 27th, 2015

PRO & eCOA Congress, Washington DC - Jack is speaking - 7:30 AM
Hotel Palomar
Washington, DC 20037
USA
202-448-1800 [map]
Price: $395, ERT customer nvitation complimentary

Overview

Do you want to learn more about eCOA, and meet others who are leading and working in this exciting industry?

Then you should attend the PRO & eCOA Congress.

This is the only US event dedicated to providing case studies and pragmatic information on the clinical science, regulatory and innovative technologies used to collect patient data for clinical studies. Study leaders present their best practices, and caveats. Small group workshops discuss eSource, Safety Monitoring, and Biosensor integrations. You’ll see which technologies are in beta testing at the Innovation Lab (Boston).

At the end of two days, you will have met and engaged with the US’ leading eCOA community; and garnered new tools and methodologies to effectively implement eCOA initiatives.

At the Congress, You Will Learn How to:

  • Effectively implement an ePRO Strategy within your organization
  • Become an internal leader in PRO and eCOA; and help teams expedite study set-up times and arrive at a go/no-go decision faster
  • Migrate standardized instruments to an electronic implementation

Key Congress Topics

  • The Science behind Why Rater Training is Critical to Clinical Trials
  • Global Regulations for Collecting electronic source data (eSource)
  • How BYOD is used today; and where it will be in 2016
  • Innovative data streams for eCOA: biosensors, wearables, Internet of Things
  • Become a Congress Sponsor

    To take advantage of these outstanding opportunities: Please contact Carolyn Peterson,  carolyn.peterson@ert.com

    Who Should Attend

     

    • Clinical Operations
    • Data Management
    • Regulatory Affairs
    • Outsourcing
    • eClinical Technologies
    • Health Outcomes

     

Saturday, October 24th, 2015

IWMF Support Group Meeting - Hartford CT, Jack is speaking
IWMF CT WM Support Group Meeting - Hartford CT, Jack is speaking - 1:30 PM
Covenant Village of Cromwell 52 Missionary Road (Commons Building)
Cromwell, CT 06416
USA
203 820 3018 [map]
Price: Reservations required if you want dinner

Monday, October 19th, 2015

Patient-Centered Clinical Trials 2015 Philadelphia by eyeforpharma - Jack is speaking - 08:00 AM
Le Méridien
Philadelphia, PA
USA
215 422 8200 [map]
Price: $1895.

Implement a common framework: Collaborate with key stakeholders to set a master blueprint for patient engagement in clinical trials

Put the patient’s voice at the core of your study design: Hear best practices to enhance your trials’ success with higher patient engagement

Improve the patient experience in clinical trials: Revitalize recruitment, boost retention, and inform study design

Align with compliance and regulation: Hear the latest guidelines on patient partnerships in clinical trials directly from regulatory bodies and compliance experts

Disrupt the clinical enterprise with the latest patient-centered technology:
 Discover technologies that are reshaping and disrupting clinical trials through direct patient involvement 

 

Pharma/ Biotech/ CRO

You will highly benefit from attending if you are an Executive/ VP, Director or Manager with responsibilities or involvement in the following areas:

  • Patient Recruitment/Enrollment/ Retention/ Engagement/ Advocacy
  • Study Start-up, Planning & Feasibility
  • Trial Management
  • Clinical Operations
  • Clinical Innovation
  • Trial Optimization
  • Clinical Project Management
  • PRO/ePRO
  • Clinical Site Services/ Site Feasibility
  • Clinical Affairs
  • Clinical Design
  • Clinical Science & Technology
  • Data Capture & Management

Participation in this high-level conference will also be a significant benefit for clinical site monitors, Principal Investigators and Clinical Research Associates.

Research & Government

In addition to Directors from patient outreach and advocacy groups, the event will be engaging other important stakeholders from academic research institutions and Government (NIH Patient Recruitment and Public Liaison Office).

Solution providers

Consultants and technology vendors providing services to the above audience, such as:

  • Patient Recruitment firms
  • Patient Mobile App solutions
  • Patient software solutions
  • Patient payment systems
  • Point of Care Lab products for patients
  • Clinical Trial Material companies
  • EMR companies

Sunday, October 18th, 2015

IWMF New England Support Group Meeting - Boston, Jack is speaking
IWMF New England Support Group - Boston, Jack is speaking - 12:00
Dana Farber Cancer Institute 450 Brookline Avenue
Boston, MA 02215
USA
978 273 2449 [map]
Price: no charge

Jack Whelan will be speaking about his long journey as an eight year survivor of Waldenstrom's Macroglobulinemia, challenges and results of many clinical trials of targeted therapies, personal experiences that will be helpful to recently diagnosed patients and patients and caregivers managing this not-yet-curable blood cancer.  Jack will keynote a discussion about opportunities in Advocacy as a Patient Advocate, Research Advocate and Legislative Advocate.  This will be a fun, engaging presentation that includes a travelogue of global speaking engagements, a unique patient's perspective have participated in many life sciences conferences.  

Travel with Jack on an intensely personal and oft-humorous bumpy ride on the road to Personalized Medicine still under construction while he is treated for a rare, incurable blood cancer. Encounter some relapsed/refractory detours, conflicting signals and biomarkers, inhibiting regulatory roadblocks and potholes in the healthcare system.  Learn why Jack, not much of beer drinker himself hangs a bottle of Guinness on his chemo infusion rack and speaker’s podium. Using business communications and research skills from his career as a Wall Street Research Analyst in Information Technology (IT) and career Sales VP in IT, he now helps bridge the communications gap between life sciences, medical professionals and patients as a Patient Advocate, Research Advocate and Legislative Advocate.

Jack hopes all of us appreciate the value and noble work of life sciences employees and companies involved in cancer research and care.  A decided friend to BioPharma as an engaged, informed e-Patient Opinion Leader (POL) and advocate he regularly speaks to and for these companies, to open much-needed, lines of communications with patients, providers and policymakers.  

He encourages all patients to explore novel targeting agents many of which are now in Clinical Trials.  Using genetic and genomic information to develop new disease-specific targeted therapeutics might be safer and more effective treatment than conventional chemotherapy.  Jack’s a frequent speaker and participant at the best industry and advocacy conferences in the Americas and Europe sharing his engaging, gripping, hopeful and fun story about survival.

Jack understands the realities of his blood cancer as he has repeatedly relapsed and has been refractory to most of the therapies received thus far; however his goal is repeated periods of progression free survival during which the promise of science and delivery of successful therapeutics will be achieved.  His website is located at Jack-Whelan.com

 

Saturday, October 17th, 2015

IWMF Support Group Meeting - Portland Maine, Jack is speaking
IWMF Portland Maine Support Group Meeting, Jack is speaking - 12:00
To be determined
Portland, ME
USA [map]
Price: No charge

Local Support Group Meeting for the Portland Maine Group. 

Jack Whelan will be speaking about his long journey as an eight year survivor of Waldenstrom's Macroglobulinemia, challenges and results of many clinical trials of targeted therapies, personal experiences that will be helpful to recently diagnosed patients and patients and caregivers managing this not-yet-curable blood cancer.  Jack will keynote a discussion about opportunities in Advocacy as a Patient Advocate, Research Advocate and Legislative Advocate.  This will be a fun, engaging presentation that includes a travelogue of global speaking engagements, a unique patient's perspective have participated in many life sciences conferences.  

Travel with Jack on an intensely personal and oft-humorous bumpy ride on the road to Personalized Medicine still under construction while he is treated for a rare, incurable blood cancer. Encounter some relapsed/refractory detours, conflicting signals and biomarkers, inhibiting regulatory roadblocks and potholes in the healthcare system.  Learn why Jack, not much of beer drinker himself hangs a bottle of Guinness on his chemo infusion rack and speaker’s podium.      Using business communications and research skills from his career as a Wall Street Research Analyst in Information Technology (IT) and career Sales VP in IT, he now helps bridge the communications gap between life sciences, medical professionals and patients as a Patient Advocate, Research Advocate and Legislative Advocate.

Jack hopes all of us appreciate the value and noble work of life sciences employees and companies involved in cancer research and care.  A decided friend to BioPharma as an engaged, informed e-Patient Opinion Leader (POL) and advocate he regularly speaks to and for these companies, to open much-needed, lines of communications with patients, providers and policymakers.  

He encourages all patients to explore novel targeting agents many of which are now in Clinical Trials.  Using genetic and genomic information to develop new disease-specific targeted therapeutics might be safer and more effective treatment than conventional chemotherapy.  Jack’s a frequent speaker and participant at the best industry and advocacy conferences in the Americas and Europe sharing his engaging, gripping, hopeful and fun story about survival.

Jack understands the realities of his blood cancer as he has repeatedly relapsed and has been refractory to most of the therapies received thus far; however his goal is repeated periods of progression free survival during which the promise of science and delivery of successful therapeutics will be achieved.  His website is located at Jack-Whelan.com

Thursday, October 8th, 2015

Clinical Trials & IoT Forum, Boston - Jack is a speaker - 08:00AM
The Inn at Longwood Medical
Boston, MA 02115
USA
617 731 4700 [map]
Price: $1,075.00

OVERVIEW

The Clinical Trials & IoT Forum is the first conference of its kind to focus on ways for pharma clinical trials to take advantage of new opportunities to collect better data andimprove the patient experience; as well as how these new eSources collect, warehouse, analyze, utilize, regulate and secure patient data.

WHO?

Global experts will converge at the forefront of wearable technologies, data management, analytics, and early detection and diagnosis for pharma clinical trials. If you’re involved with R&D, sales and marketing, information technology, data management, patient recruitment/ engagement or health outcomes this is the place to be.

BE THERE!

Join 30+ speakers, 150+ senior-level pharma, clinical trials, technology and mHealth executives this October 7-8 in historic Boston to learn, network, develop and improve the way pharma clinical trials utilize e-Solutions, wearables, and internet of things capabilities to improve the patient experience and collect better data.

Click for list of Speakers

 

The e-Patient's Perspective on IoT to aid in Clinical Trials: A Focus on Patient Centricity

- Get a unique e-patient's perspective to dramatically improve Clinical Trials Outcomes and at lower costs using IT

- Caution don't tell patients you are "Patient Centric" if you're not doing this.

- Upside and risks of Patient Centricity

- Opportunities for BioPharma and CROs with next generation ePRO/COA, what's coming down the pike. 

Jack Whelan  e-Patient, Research Advocate

 

 

Sunday, October 4th, 2015

Health 2.0 9th Annual Fall Conference 2015, Santa Clara CA, Jack is a Speaker - 08:00
Santa Clara Convention Center 5001 Great America Parkway
Santa Clara, CA 95054
USA [map]
Price: $1995. See website

Health 2.0 9th Annual Fall Conference 2015

Health 2.0 heads back to Silicon Valley on October 4-7, 2015 to examine how another year has impacted and changed health care technology. At the 9th Annual Fall Conference you can look forward to over 200 LIVE product demos, dozens of company launches, merger announcements, engaging panel discussion with expert speakers, and 3 1/2 days of prime networking opportunity.

If you are a startup looking to attend and exhibit at Health 2.0 check out our Bootstrapped Basecamp and get great visibility in front of over 2200 health IT experts.

We have many discounted ticket options available. For more information see our ticket page.

Can’t attend the event in-person this year? Health 2.0 now offers remote attendance via webcast, and post-event archival video via an online portal or a flash drive sent to your door. More information here.

Thursday, October 1st, 2015

SYNERGY - Alliance for Clinical Research Excellence and Safety (ACRES) Boston, Jack is speaking
SYNERGY - Alliance for Clinical Research Excellence and Safety (ACRES) Boston, Jack is speaking - 11:00AM
OMNI Parker House 60 School Street
Boston, MA 02108
USA
617 227 8600 [map]
Price: $1495.00

Overview

The future of clinical research is changing. And so far, despite our best intentions, well-intended efforts at innovation and disruption have merely tweaked the current processes for clinical research with little impact. They have not gotten us out of our comfortable siloes or proposed an integrated, comprehensive approach to change. The complexity and inter-dependence of the endeavor and its many stakeholders require an integrating mechanism—a system—to connect, coordinate and streamline policies and procedures on a global scale.

The chilling reality that 70% of all clinical research sites still never do more than a single trial and that more than a third of the cost of doing a trial is spent just on monitoring illuminate the vast waste that exists throughout the enterprise. Estimates are that over 30 cents of every dollar spent on clinical research is wasted. With $20 billion at stake yearly, this situation is unsustainable. Not only does the current approach waste money, it wastes precious human resources as well. And in the end, patients are on the losing end if changes are not made.

This situation calls for action, not just talking or listening. SYNERGY is more than a conference—it is a different kind of event. SYNERGY will abandon a simple “talking-heads” content-flow model in favor of an interactive, personally engaging, solution-generating model—every attendee will be a participating thought leader.

SYNERGY will engage participants directly in the work of building a next-generation, synergistic clinical research system, by and for all stakeholders, to enhance clinical research safety, quality and efficiency worldwide for the benefit of all involved, especially patients.

On October 1-2nd, join us at the OMNI in Boston to experience and participate in the only conference dedicated exclusively to exploring the challenges, opportunities and benefits of collaboratively building an innovative, open, integrated global clinical research system, based on systems thinking and principles of Accountable Research.™

 
REGISTER NOW
Event Details
What: SYNERGY
Why: Where Clinical Research, Innovation, Collaboration and Systems Thinking Come Together!
When: October 1 - 2, 2015
Where: OMNI Boston
Boston, Massachusetts

Who Will Attend?

SYNERGY will be equally valuable to organizational leaders (decision-makers), and day-to-day practitioners (implementers) from the following:

TRIAL SPONSORS

  • Government Agencies (e.g. NIH, etc.,)
  • Big Pharmas
  • Mid-Size Pharmas
  • Biotech Companies
  • Med Devices Companies

INVESTIGATIVE SITES

  • For-Profit Hospitals
  • Non-Profit Hospitals
  • For-Profit Academic/Teaching Hospitals
  • Non-Profit Academic/Teaching Hospitals
  • Veterans Hospitals
  • Clinics/Multi-Physician & Others

SERVICE PROVIDERS/ 
CONSULTANCIES

  • CROs
  • IRBs
  • Technology Providers
  • Legal Services
  • Accounting/Business Svcs.
  • Patient Recruitment Svcs.
  • Lab Services
  • CR Job Placement Services
  • Financial Services

PATIENT GROUPS

  • Advocacy Organizations
  • Disease-Focused Patient Networks
  • Research Volunteers and Participant

GOVERNMENT AGENCIES

  • Regulatory Agencies
  • Funding Agencies
  • Oversight Agencies
  • Policy Makers
  • Lawmakers

WHAT ARE THE TAKE-AWAYS?

The Roman orator Cicero said that there are only two ways one can learn: (1) from one’s own mistakes, and (2) from the mistakes of others. The latter, he said, is less painful and more profitable. And communications research demonstrates that an element of revelation ensures better learning, and that the engagement model is more effective than a simple “tell” model since there will be not only an abundance of applicable solutions to “take home” and apply, but an appreciation for innovative systems thinking.

In any complex enterprise, people, processes and technology must interact and inevitably impact each other. A successful systems approach recognizes and optimizes these interactions to achieve high-performance outcomes that cannot otherwise be achieved—the synergy of the whole being greater than the sum of its parts. Using the stories of key leaders, this conference will examine the mistakes being made and opportunities being missed throughout the clinical research ecosystem, and share lessons learned, while developing strategies for improvement and integration. SYNERGY will thus arm attendees from sponsors, CROs, sites, IRBs and others with the skills to not only avoid making similar mistakes but to participate in development of systems solutions.

SYNERGY is dedicated to exploring the challenges, opportunities and benefits of creating innovative, comprehensive systems solutions — and doing it through collaboration across the entire clinical research endeavor. Attendees will experience synergy through a "hands-on" approach - working together with different stakeholders to address issues they all have, but have never gotten together to solve.

SYNERGY will engage clinical research stakeholders in a dialogue about systems thinking, about how it applies to clinical research processes so that together the participants can contribute to designing a next-generation clinical research system – a system built by all stakeholders reflecting the interests of all stakeholders — and can bring the tools and lessons home to their own institutions, business and organizations. The most effective way to shape the future is to build it and through SYNERGY, attendees will be helping to do so.

This first edition of SYNERGY will focus on three key challenges facing the clinical research enterprise:

1. Protocol/Trial Design
2. Patient Engagement 
3. Innovative Technologies

By equipping attendees to apply systems thinking, and the right tools, in each of these three discrete areas, your work in each area will become more integrated, efficient and streamlined.

The goal of SYNERGY – indeed the goal of ACRES itself – is to demonstrate how to create an integrated, interoperable ecosystem for clinical research in which every part of the research process will be able to enhance quality and safety, streamline operations, reduce costs, maximize resources and in the end, improve the quality of life for all. These three key challenges are some of the critical components of such a system.

 

Wednesday, September 30th, 2015

Advocacy Coalition Meeting by Massachusetts BioTech Council - 10:00 AM
Massachusetts Biotech Council 300 Technology Square, 8th Floor
Cambridge, MA 02139
USA
508 400 6209 [map]
Price: by Invitation

Advocacy Coalition Meeting

Fellow advocates kick-off a roundtable discussion to learn about Patients for Prescription Access, a coalition of like-minded patient advocate groups and individuals who are committed to making access to affordable medications a reality for Massachusetts’s residents regardless of their medical condition. 

Legislation has been introduced that would put a limit to the out of pocket expense for medication for residents.  If enacted, SB 541 would cap the cost of a 30-day prescription at $100. 

Your support is needed to help to help get this legislation passed into law. For details visit http://patientsforprescriptionaccess.com

Tuesday, September 22nd, 2015

Patient Reported Outcomes e-Clinical Outcome Assessment - 08:00
Hotel Tivolit Lisboa Portgual, Avenida da Liberdade, 185
Lisbon
Portgual
+351.213.198.900 [map]
Price: By invitation

Overview

Do you want to learn more about eCOA, and meet others who are leading and working in this exciting industry?

Then you should attend the PRO & eCOA Congress.

This is the only European event dedicated to providing case studies and pragmatic information on the clinical science, regulatory and innovative technologies used to collect patient data for clinical studies. Study leaders present their best practices, and caveats. Small group workshops discuss eSource, Safety Monitoring, and Biosensor integrations. You’ll see which technologies are in beta testing at the Innovation Lab (Boston).

At the end of two days, you will have met and engaged with Europe’s leading eCOA community; and garnered new tools and methodologies to effectively implement eCOA initiatives.

 

At the Congress, You Will Learn How to:

  • Effectively implement an ePRO Strategy within your organization
  • Become an internal leader in PRO and eCOA; and help teams expedite study set-up times and arrive at a go/no-go decision faster
  • Migrate standardized instruments to an electronic implementation


Key Congress Topics

  • The Science behind Why Rater Training is Critical to Clinical Trials
  • Global Regulations for Collecting electronic source data (eSource)
  • How BYOD is used today; and where it will be in 2016
  • Innovative data streams for eCOA: biosensors, wearables, Internet of Things

Who Should Attend

  • Clinical Operations
  • Data Management
  • Regulatory Affairs
  • Outsourcing
  • eClinical Technologies
  • Health Outcomes

Wednesday, September 16th, 2015

World Courier Biomedical Seminar - Jack is speaking - 08:00
The Palladium
Cologne, German Federal State of North Rhine-Westphalia
Germany [map]
Price: Invitation only

What is the World Courier Biomedical Seminar?

The World Courier Biomedical Seminar is the global conference where pharmaceutical, research and regulatory leaders receive insight on the dynamic industry — and the impact on global specialty transport. You'll collaborate with industry thought leaders to surface new and innovative ways to solve business challenges.

You'll capture industry knowledge from the most trusted sources for insights and best practices throughout the product journey — knowledge you can use to make better business decisions. You'll connect with peers and explore new ways to move medicine forward.

General Information Q: When and where is the World Courier Biomedical Seminar? This year’s event will take place 17-18 September 2015, at The Palladium in Cologne, Germany. The event will start with a launch dinner on the evening of 17 September for delegates staying overnight or attending locally, followed by a full day of presentations and panel discussions on Friday, 18 September.

Q: What can I expect? What is the value of this event? The World Courier Biomedical Seminar is the global conference where pharmaceutical, research and regulatory leaders receive insight on the dynamic industry — and the impact on global specialty transport. It is where you’ll: ▪ Collaborate with industry thought leaders to surface new and innovative ways to solve business challenges ▪ Gain comprehensive education from a trusted source for industry insight and best practices throughout the product journey — from lab to market ▪ Capture knowledge that you can use to improve your day-to-day business decisions

Q: What details do I need to know about the event schedule? The World Courier Biomedical Seminar starts with a launch dinner on the evening of Thursday, 17 September for delegates staying overnight or attending locally, followed by a full day of presentations and panel discussions Friday, 18 September. To view the full agenda, visit WCBiomedicalSeminar.com

Q: Who should attend? Attendees include biopharma companies, clinical research organizations (CROs), research institutes, clinical packaging companies, universities, hospitals, laboratories, regulatory bodies, trade associations and biotech companies.

Q: Are customers/associates’ families invited? If your family wishes to attend, please liaise directly with the hotel for your accommodation requirements. Any family member or guest who is not registered for the event will be unable to attend the Thursday night dinner. Registration and Cost

Q: What does it cost to attend the World Courier Biomedical Seminar? The registration fee for the World Courier Biomedical Seminar is just €295. The fee includes attendance at the dinner event on 17 September, a full day of educational sessions on 18 September and lunch on the 18th. Attendees are responsible for their own travel and accommodations.

Q: How do I register? Registration for the World Courier Biomedical Seminar is available through the website at WCBiomedicalSeminar.com/registration.php

Q: How do I pay? Upon registering for the event at http://wcbiomedicalseminar.com/registration.php, you will be invoiced by your local World Courier office. Invoices are payable upon receipt.

 

Tuesday, September 15th, 2015

Congressional Briefing Rayburn House of Rep. Office Building - 09:00AM
2318 Mill Road, Suite 800
Alexandria, VA 22314
USA [map]
Price: Invitation only

ASCO is holding a Congressional Briefing on Tuesday, September 15th to introduce Hill Staff to CancerLinQ and help identify what we need from Congress in order to make it work.

House of Representative Office Building, B-354 Rayburn Building at 9:00AM, Jack is speaking, along with Robin Zon, MD Michiana Hematology Oncology and Clifford Hudis, MD Memorial Sloan Ketterin Cancer Center.

To view the live streaming webcast on Tuesday Sept 13th at 9:00AM ET please click webcast. 

or go to www.asco.org/bigdatawebcast

 

 

 

Monday, September 14th, 2015

American Society of Clinical Oncology (ASCO) CancerLinQ Advisory Committee Meeting, Washington DC
American Society of Clinical Oncology (ASCO) CancerLinQ Advisory Committee Meeting, Washington DC - 1:00PM
2318 Mill Road, Suite 800
Alesandria, VA 22314
USA
571-483-1641 [map]
Price: By Invitation only

In January, ASCO announced that it will collaborate with leading technology company SAP to develop CancerLinQ™, the Society’s groundbreaking health information technology platform. CancerLinQ will harness big data from millions of de-identified patient records to deliver high-quality, personalized care to people with cancer and cancer survivors.

“In teaming with SAP, we found an ideal company with state-of-the-art technology, a commitment to invest major new resources, and a clear dedication to our patient-care mission,” 2014-2015 ASCO President Peter Paul Yu, MD, FACP, FASCO, said. “With our cancer expertise complemented by SAP’s software and technical insights, CancerLinQ is in a position to make a huge leap toward becoming the platform of choice for oncologists.”

CancerLinQ is one of the only major cancer data initiatives developed and led by physicians with the primary purpose of improving patient care. The Society is in a unique position to cut across specific business or regional interests and develop an interoperable system with the potential to benefit every patient with cancer.

“CancerLinQ will help improve cancer care by delivering the latest information to doctors no matter where they practice so that patients can receive high-quality, state-of-the-art care, regardless of where they live,” 2013-2014 ASCO President Clifford A. Hudis, MD, FACP, said. “With CancerLinQ, we can also learn from the care given to the 97% of adult patients who do not currently participate in clinical trials.”

When complete, CancerLinQ is expected to unlock real-world patient care data from millions of electronic health records and more securely process and analyze data to provide immediate high-quality feedback and clinical decision support to providers. Doctors will receive personalized insights on a previously unattainable scope and help patients gain benefits by having access to high-quality care based on the most up-to-date insights and findings.

This meeting is an ongoing review by the team of Patient Advocates that serve on the Patient Advisory Committee as part of ASCO's CancerLinQ project.

First Version of CancerLinQ Scheduled for Release in Late 2015

ASCO and SAP plan to deliver the first version of CancerLinQ in late 2015 with patient records from 15 vanguard oncology practices. Twelve practices have signed on to this effort, and four more practices will soon join, meaning approximately 500,000 patients will be represented in the first version of CancerLinQ. Insights gathered from the data are expected to help lay the groundwork for developing the full system, in which oncology practices across the United States can participate. 

Thursday, September 10th, 2015

Day 3 World CDx Boston 2015 Companion Diagnostics - 08:00AM
Hilton Boston at Logan Airport
Boston, MA 02128
USA
+44 (0)20 3141 8778 Jason Green [map]
Price: Please see website

Accelerating Targeted Drug Development to Market With High Value Companion Diagnostics

Helping pharma and biotech accelerate their future drug development with a fully defined and robust CDx strategy – World CDx Boston delivers end to end roadmap for pharma and biotech to successfully understand the true heterogeneity of disease, validate translational and predictive biomarkers and implement a robust CDx strategy to increase the efficacy and value of their drug candidates.

The 6th Annual World CDx Boston Summit continues to guide drug, diagnostic and technology developers all the way from early clinical development and translational biomarker validation to market launch of drug-CDx combinations. The World CDx Community will once again assemble to align drug-CDx co-development, showcase the most ground-breaking clinical trial results and refine personalized healthcare for targeted patient populations.

 

THE CENTRAL PILLAR TO FORGING THE SUSTAINABLE PATH TOWARDS PRECISION MEDICINE

For the 6th time, the World CDx community will be coming together in Boston to showcase the very latest advancements in companion diagnostics and tailored therapies that are improving and refining personalized healthcare.

With collaborations rife and the field rapidly coming of age, World CDx Boston 2015 will guide drug, diagnostic, and technology developers all the way from target identification to launch of drug-CDx combinations. Harnessing the latest clinical trial results and technological advancements, World CDx will be bringing togetherthose who have defined the field, as well as the brightest innovators to accelerate your personalized healthcare products to market.

Through a multitude of interactive learning formats and networking opportunities, meet with and benchmark against those who are harnessing the deeper and broader understanding of disease heterogeneity to further stratify complex patient populations.

Leave inspired with new ideas, knowledge, and connections to improve and rapidly progress your drug-CDx pipeline.

Wednesday, September 9th, 2015

PhRMA Research and Hope Awards with Tom Brokaw - 6:00PM
Andrew W. Mellon Auditorium
Washington, DC 20240
USA [map]
Price: By Invitation only

PhRMA Research & Hope Awards 2015

From Hope to Cures  #RH15

Celebrate the progress and promise of Oncology Research and Care

Featuring a keynote address by Tom Brokaw, Legendary Newsman, NBC News and NY Times Bestseller

Dinner and Awards Presentation.

PhRMA, along with its distinguished co-hosts, is pleased to honor individuals and organizations with the 2015 Research & Hope Awards, which will take place on September 9th in Washington DC. This year’s program will celebrate the progress and promise of Oncology Research & Care. Awards will be presented in the following categories:

- Academic Research

- Biopharmaceutical Industry Research

- Excellence in Advocacy & Activism

- Community Champion

- Visibility & Progress

The Research & Hope Awards illustrate how biopharmaceutical researchers and others in the innovation ecosystem work together to not only bring new medical advances to patients, but thwart deadly diseases through increased awareness, public health efforts, and increased collaboration.

 

PhRMA is joined by the following 2015 Research and Hope Co-Hosts:

Tuesday, September 8th, 2015

World CDx Boston 2015 Companion Diagnostics - 08:00AM
Hilton Boston at Logan Airport
Boston, MA 02128
USA
+44 (0)20 3141 8778 Jason Green [map]
Price: Please see website

Accelerating Targeted Drug Development to Market With High Value Companion Diagnostics

Helping pharma and biotech accelerate their future drug development with a fully defined and robust CDx strategy – World CDx Boston delivers end to end roadmap for pharma and biotech to successfully understand the true heterogeneity of disease, validate translational and predictive biomarkers and implement a robust CDx strategy to increase the efficacy and value of their drug candidates.

The 6th Annual World CDx Boston Summit continues to guide drug, diagnostic and technology developers all the way from early clinical development and translational biomarker validation to market launch of drug-CDx combinations. The World CDx Community will once again assemble to align drug-CDx co-development, showcase the most ground-breaking clinical trial results and refine personalized healthcare for targeted patient populations.

 

THE CENTRAL PILLAR TO FORGING THE SUSTAINABLE PATH TOWARDS PRECISION MEDICINE

For the 6th time, the World CDx community will be coming together in Boston to showcase the very latest advancements in companion diagnostics and tailored therapies that are improving and refining personalized healthcare.

With collaborations rife and the field rapidly coming of age, World CDx Boston 2015 will guide drug, diagnostic, and technology developers all the way from target identification to launch of drug-CDx combinations. Harnessing the latest clinical trial results and technological advancements, World CDx will be bringing togetherthose who have defined the field, as well as the brightest innovators to accelerate your personalized healthcare products to market.

Through a multitude of interactive learning formats and networking opportunities, meet with and benchmark against those who are harnessing the deeper and broader understanding of disease heterogeneity to further stratify complex patient populations.

Leave inspired with new ideas, knowledge, and connections to improve and rapidly progress your drug-CDx pipeline.

Sunday, August 16th, 2015

5th Annual ESCAPE Program by BagIt! at Miraval - 08:00
Miraval
Tuscon, AZ 85739
USA
800.825.4000 [map]
Price: By invitation only

The conference will focus on current critical questions of the day for the engaged, active advocate:

Collaboration

How to develop and nurture collaborations with other organizations and the private sector to enhance programs for cancer patients and survivors as well as funding opportunities.

Research and Policy Advocacy

Learn how to become involved in cancer research review.

Policy decisions are looming on the horizon that will affect people with cancer.  Interactive sessions include training on how to become a voice for cancer patients/survivors on state and federal policy issues. Community advocates represent many and opportunities to participate and respond abound.

Wellness

Learn techniques for combating compassion fatigue and burnout in advocacy work.

Wednesday, July 29th, 2015

AACR American Association for Cancer Research Webcast Local Advocacy for Medical Research
615 Chestnut St., 17th Floor
Philadelphia, PA 19106
USA
866 423 3965 [map]
Price: No charge

The Importance of Local Advocacy for Medical Research
​​

Advocacy often conjures images of traveling to Washington, DC and meeting with members of Congress and their staff on Capitol Hill. But there are plenty of ways to be active at the local level as well. Building on the momentum of the March 12 webinar, the AACR Office of Science Policy and Government Affairs will host its second advocacy webinar on Wednesday, July 29. Learn about the importance of advocacy activities during the August Congressional recess and hear how through local district meetings,​ town halls, and other activities, you can become an advocate for medical research at the local level.​ Download the ​presentation slides (PDF).

 

Panelists:

Leah Cook, MS, PhD
Postdoctoral Fellow, Moffitt Cancer Center

Jack Whelan
Research Advocate, Principal, Event Speaker, Jack-Whelan LLC

Mary Lee Watts, MPH, RD
Director, Government Relations, AACR Office of Science Policy and Government Affairs​

Becoming an Advocate for Medical Research

No one understands the constraints of decreased federal funding as well as researchers themselves. Many cancer researchers, particularly early career investigators, understand the importance of advocating for science and funding, yet the demands of starting and running a lab often mean that advocacy activities get left behind. How do you get started in advocacy, and how do you craft your message into one that will resonate with Congress? This webinar will help provide you with answers to those questions and more.​

Thursday, July 23rd, 2015

4th Annual Strengthening Patient Advocacy Relations Jack is a Keynote speaker - 08:00AM
Sheraton Philadelphia Universal City
Phiadelphia, PA 19104
USA
312.602.9683 [map]
Price: Pre-Register

4th Annual Strengthening Patient Advocacy Relations Conference

Advancing the Role of Patient Advocacy through Improved Collaboration with Advocacy Organizations, Strategically Measuring & Benchmarking Advocacy Initiatives to Increase Support While Empowering the Patient Community
July 23-24, 2015 | Philadelphia, PA

Twitter LinkedIn
ABOUT THE CONFERENCE

There is no question the paradigm has shifted in the healthcare industry with a progressive focus on patient centricity as health outcomes and quality of care become a heightened factor in pursuit of successful and effective healthcare. At the very center of this phenomenon is patient advocacy, evolving into an increasingly vital role within pharmaceutical and biotech companies. From an influential force formulating change in state and national legislation to a champion revolutionizing care and support for patients and care-givers, patient advocacy is the heart beat of the patient centric healthcare shift. It is essential advocacy executives stay abreast of impending legislation, remain current on trends and best practices within the industry and continue to innovative in thought processes to advance the patient advocacy role.

Throughout the conference, distinguished industry leaders and attendees will uncover the future of advocacy through progressive case studies complimented by interactive scenario-based workshops. Bringing together leading advocacy organizations and industry advocacy executives, attendees will have the unique opportunity to explore leading strategies surrounding cutting-edge topics for debate from gaining support of advocacy initiatives internally to embarking on global patient advocacy. Timely topics of discussion will delve deep into challenges ranging from career goals and the importance of evidenced based advocacy to evolving communication and uncovering key strategies in tackling international advocacy. Case study driven presentations, high level keynote sessions as well as roundtable panel discussions complemented by multiple networking opportunities will foster a sense of collaboration, inspiring progress and giving patient advocacy professionals the tools needed to maximize their impact on the industry as well as within the patient community

Wednesday, June 24th, 2015

Precision Medicine 2015: Patient Driven - 08:30AM
Harvard Medical School, Joesph B. Martin Conference Center
Boston, MA 02115
USA [map]
Price: No Charge

Join us at the Joseph Martin Conference Center at HMS in Boston on June 24th and 25th for the inaugural conference on Precision Medicine.

This 1½ day meeting will include expert panels on how we are going to pay for precision medicine, on the ethical and regulatory challengesdelivering precision medicine to the point of care, and several inspiring examples of patient-driven successes.

Keynote Speakers include:

 View the Agenda

Tuesday, June 16th, 2015

DIA 2015 Drug Information Association, Annual Meeting Patient Advocate Fellowship, Jack participating - 07:30 AM
Walter E. Washington Convention Center, 801 Mount Vernon Place Northwest
Washington, DC 20001
USA
888.257.6457 [map]
Price: $1350.

The DIA Annual Meeting, the largest multidisciplinary event that brings together a global network of life sciences professionals to foster innovation that will lead to the development of safe and effective medical products and therapies to patients. - See more at: http://www.diahome.org/en-US/Flagship-Meetings/DIA-Annual-Meeting/Meeting-Program.aspx#sthash.RHG7frES.dpuf

More info to follow.  Stay tuned.

 

Monday, June 15th, 2015

Oncology Market Access & Pricing 2015, Boston MA, Jack is a keynote speaker - 07:30
DoubleTree Suites by Hilton, 400 Soldiers Field Road
Boston, MA 02141
USA
201 204 1688 [map]
Price: TBD

Mid June 2015, Boston MA

Soon launching Oncology MARKET ACCESS AND PRICING 2015, the executive summit for decision makers from pharma, payors, specialty pharmacies, provider networks, GPOs and community oncology groups. 

Running in its 6th year, the conferences is regarded by many as the most targeted and high-level gathering on commercialization and market access strategies for oncology products in the US. 

A true forum of stakeholders interaction, the event provides an exceptional opportunity to foster strategic relationships and leverage best-in-class insights on how to innovative customer segmentation, targeting and contracting strategies. Pharma attendees join key stakeholders from the managed care market to secure access, adherence and product uptake in the shifting site-of-care environment. 

What’s in Store for Oncology Market Access 2015

  • Direct Consultations with the leading Players in Cancer Care – all in one room: Establish your organization as a strategic voice in the oncology utilization debate and recognize how to best communicate value for product positioning and sustainable market access
  • Payer Focus Groups - Get first hand perspectives on the latest reimbursement dynamics and discuss alternate payment models with decision makers from Aetna, Cigna, United, Well Point, Priority Health, Blue Cross and others.
  • Rise of Specialty Distribution – Collaborate with specialty pharmacies, maximize supply chain effectiveness through targeted distribution partnerships and deep-dive into industry-leading patient hub services.
  • Community Stakeholders – Hear directly from providers in the community how payor reimbursement is influencing treatment decisions and co-create patient assistance and adherence programs. Receive data from the Association of Community Cancer Centers and learn from the leaders of Dana Faber, Connecticut Center for Primary Care, Orange Health and others.
  • Policy Changes and Government Insights: Understand how plans on the exchanges are affecting oncology reimbursement, hear from CMS about shifts in Medicare benefits and identify the impact of new guidances on drug affordability and access.
  • Pre- and Post-launch Commercial Excellence: Gain actionable insights from leading industry peers on how to adjust forecasting, access, sales force and channel distribution strategies.

We surveyed the market and conducted additional qualitative interviews with 45+ executives. That has given us a range of “hot” topics the industry wants to discuss and learn more about. Get more info here

Friday, May 29th, 2015

ASCO American Society of Clinical Oncology, Annual Meeting, Chicago IL - 08:00 AM
McCormick Place Convention Center
Chicago, IL 60636
United States [map]
Price: By Invitation

About the Meeting

Attendees of the 2015 Annual Meeting will find cutting-edge scientific presentations and comprehensive educational content.

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting—"Illumination and Innovation." Prospective attendees can familiarize themselves with some basic information, including

 

More information to follow.  In planning stage.

Thursday, May 14th, 2015

NIH's NCTN Alliance for Clinical Trials in Oncology - 08:00AM
http://www.allianceforclinicaltrialsinoncology.org/main/
Chicago, IL 60636
USA [map]
Price: Invitation

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY 2015 SPRING GROUP MEETING CONVENES IN CHICAGO MAY 13-16

The Alliance for the Clinical Trials in Oncology will convene its 2015 Spring Group Meeting in Chicago, IL, May 13-16. Scientists, clinical research professionals, patient advocates and others interested in the latest developments in cancer research are expected to attend the four-day meeting at the Loews Chicago O’Hare Hotel. Meeting attendees will select from nearly 70 disease, modality, administrative and special sessions to attend led by distinguished oncology researchers and clinical trials specialists from across the country.

This meeting will showcase novel and innovative cancer control, prevention, and treatment trials that are conducted by investigators through a multidisciplinary academic and community research network, which is part of the NCI National Clinical Trials Network and Community Oncology Research Program. Meeting Highlights. Plenary Session | Friday, May 15 | 10 am-12 pm Monica M. Bertagnolli, MD, Group Chair of the Alliance, will provide opening remarks and an introduction of the speakers for this session. Peter J. O’Dwyer, MD, Director of the Developmental Therapeutics Program at the Abramson Cancer Center, will then discuss the NCI MATCH trial — an umbrella protocol for multiple, single-arm phase II trials that will recruit patients with all types of cancer whose tumors no longer respond to standard therapy, and then select a targeted drug based on the specific genetic abnormalities of the patient’s tumor. Electra D. Paskett, PhD, Director of the Alliance Cancer Control Program (CCP), will present awards for two new initiatives from the CCP that will facilitate ongoing training and assist young investigators in establishing competitive research profiles early in their careers. John C. Byrd, MD, D. Warren Brown Chair of Leukemia Research at Ohio State University Wexner Medical Center, is the 2015 Charles G. Moertel Lecture Award recipient. He will present a lecture on therapeutic agents active in chronic lymphocytic leukemia and related leukemia and lymphoma. Clifford Y. Ko, MD, Director of the Division of Research and Optimal Patient Care at the American College of Surgeons (ACS) and the Robert and Kelly Day Chair of Surgical Outcomes and Professor in the Department of Surgery at the University of California at Los Angeles, will discuss his research in studying quality of care, quality of life and outcomes in cancer surgery with a lecture titled, “Surgical Quality Management and Outcomes in Oncologic Care.”

Sunday, April 26th, 2015

ASCO's CancerLinQ Patient Advisory Committee - Invitation only
2318 Mill Road, Suite 800
Alexandria, VA 22314
USA
703 650 5345 [map]

For more information about 

ASCO's CancerLinq, check www.cancerlinq.com

ASCO, see www.ASCO.org

ASCO's CancerNet see www.cancer.net

ASCO's Conquer Cancer Foundation see www.conquercancerfoundation.org

 

Friday, April 24th, 2015

MCT - Congress Going Mobile with Clinical Trials, Jack giving a key note - 08:00 AM
Edinburgh International Conference Centre (EICC)
Edinburgh, Scotland EH3 8EE
United Kingdom
+44(0)7866 782165 [map]

A two day conference-led event, focusing on the impact, challenges and opportunities being presented through the adoption of mobile technology in clinical trials.

Following the inaugural 2014 event, the 2015 event will focus less on the theory and more on the practicalities of adopting mobile technology. From all angles – patient right through to sponsor – this programme challenges norms and offers ideas as to how the mobile industry will increase its speed of integration within the Clinical Trials process.

The two day congress, which will take place at the Edinburgh International Conference Centre (EICC), 24th-25th March 2015, will focus on the practicalities of adopting mobile technology in clinical trials. Looking at the field from all perspectives, from patient right through to sponsor, the programme is set to challenge norms and offer ideas as to how the mobile industry can increase its speed of integration within the clinical trials space.

Sponsored by Medidata, the congress brings together a community of providers, sponsors, academics, investigators and regulators, all with a shared goal of fostering innovation and collaboration that will take the industry forward in the adoption of mobile technology. Providing a global platform to raise the level of discussion in this fast-moving field, the congress will deliver a dynamic and energetic programme of speaker sessions, Q&As and panel discussions, including, among others:

– The Real Business of Clinical Trials: A frank discussion amongst representatives from some of the biggest names in the industry about their business outlook and the forecasted influence of mobile technology. Oliver Stokes from Chiltern will be joined by peers from PPD, Quintiles and Clintec.

– Device Design: Matt Kibby from BBK Worldwide will team-up with experts from Ericsson, Vodafone and Apple to discuss how intelligent design can provide transformational benefits in compliance, productivity and accuracy in clinical trials.

– Barriers to Adoption: A panel discussion amongst some the industry’s leading experts, including Eli Lilly, Novartis, Merck and Janssen, will look at the challenges that big pharma is currently faced with and drivers in speeding up long-term adoption of mobile.

– Cautionary Tales of Data Mountains: Marc Buyse from IDDI & CluePoints will discuss the importance of ensuring data quality in clinical trials that use mobile technology, delivering new thinking in how successful monitoring strategies can be approached.

– Effective Regulator Relations: Pfizer’s Craig Lipset will offer a thought-provoking session on how the industry can best work with regulators to ensure successful development programmes.

– Realities of On-site Adoption: A group of highly-experienced data professionals from Bayer, the NHS and ICON will deliver a 360 degree perspective on managing data mountains.

“The 2015 MCT-Congress programme has been designed to deliver the highest quality speakers and leading-edge industry discussion, promoting understanding and collaboration that will help shape the direction of mobile in clinical trials”, commented Liz Logan, Head of the MCT-Congress. “The event provides a unique and unbiased space to meet new people from around the world, spark genuine debate, share knowledge, network and build relationships that change the future of clinical development.”

Wednesday, April 22nd, 2015

PCT Partnerships in Clinical Trials, Boston MA, Jack is a keynote speaker - 08:00AM
Boston Convention and Exhibition Center, 415 Summer St.
Boston, MA 02210
USA
888-670-8200 [map]
Price: $2295.

Building value through partnerships, innovation, and education

IIR's Partnerships in Clinical Trials event is North America's largest conference serving the 
global clinical trials, operations and outsourcing community.

Delegates from all parts of the clinical trial value chain come to Partnerships in Clinical Trials to quickly identify, engage and enter into strategic relationships that drive their clinical trials successfully forward as well as take part in the 60+ sessions and workshops geared to focus on several topic areas of interest including but not limited to risk-based monitoring, strategic sourcing, emerging market, patient adherence, and more. This year's Partnerships in Clinical Trials event will again draw upwards of 1,300 industry attendees for four days of high level networking, idea exchange, and innovation.

In addition to productive partnering, Partnerships in Clinical Trials offers high-level workshops, case studies, and a lively Marketplace, debuting new content formats, improving the overall experience for all conference goers. The keynotes offers executive level panelists who openly share their insight and opinion on many important industry issues. Combined, these elements create an insightful and productive event that will have you coming back year after year. 

In 2014, partnering was introduced at Partnerships in Clinical Trials, powered by EBD Group's partneringONE®, the industry's most advanced networking system, which enables participants to efficiently mine a large pool of potential partners, and identify and pre-arrange private one-to-one meetings with literally dozens of company targets.

Partnerships in Clinical Trials is organized by IIR USA, one of the most recognized and trusted providers of trade conferences and expositions; seminars; training events; and specialized business information and networking experiences in America.

 

Friday, April 17th, 2015

AACR American Association for Cancer Research, Philadelphia PA - 08:00 AM
Philadelphia Convention Center
Philadelphia, PA 19107
United States [map]
Price: By Invitation

17th Annual Scientist↔Survivor Program at the Annual Meeting
April 18-22, 2015
Philadelphia, Pa.

The AACR annual meeting is internationally recognized for the quality of its outstanding program, which highlights compelling science and the latest advances in all areas of cancer research. TheAACR Annual Meeting 2015 focused on the many ways that basic, clinical and translational research is leading to improved understanding of cancer and to the development of new technologies and treatments aimed at the prevention, early detection, treatment, and cure of the disease.

About the 2015 Scientist↔Survivor Program at the Annual Meeting

Survivor and patient advocates who participate in the Scientist↔Survivor Program at the annual meeting:

  • Attend special lectures about cancer research that are tailored to a lay audience;
  • Discuss relevant and timely cancer topics during small group meetings, roundtable discussions and one-on-one meetings with scientific mentors;
  • Explore the scientific sessions of the annual meeting on their own or with scientific mentors or other advocates;
  • Communicate to scientists the key issues, questions and concerns of the survivor and patient advocacy communities;
  • Promote their organizations' missions by participating in their own poster sessions; and
  • Network with scientists and fellow advocates from local, national, and international cancer organizations.

Tuesday, April 7th, 2015

13th Annual eyeforpharma Philadelphia 2015 summit, Jack is a keynote speaker - 07:30 AM
Hyatt Regency at Penn's Landing, 201 South Columbus Blvd.
Philadelphia, PA 19106
USA
215 928 1234 [map]
Price: $2299.

April 7-8th, 2015, Hyatt Regency Philadelphia at Penn’s Landing • #efpPhilly

Collaborate to succeed in customer-driven healthcare

The summit will feature three interconnected tracks designed to provide a comprehensive learning experience with a broad range of perspectives that can help you adjust your 2015-2016 strategy and become a sustainable customer- centric organization.

  • Restructure your commercial strategy to position yourself as a front runner in the fee-for-value healthcare eco-system
  • Improve sales & marketing effectiveness by building global capabilities and nimble local strategies to better understand and engage with customers
  • Create evidence-driven partnerships with stakeholders to build trust and redefine value from your customers’ perspective
  • Establish innovative value-added services that enhance outcomes and position pharma as a holistic partner in healthcare

Learn how to cater to your customers' unmet needs, redefine your value proposition, engage and empower patients and propel commercial excellence!

Each talk on this agenda is designed to offer you insights and solutions to your core challenges. If you would like to join in the discussion as a presenter or suggest a new topic for panel discussion or session, please contact Antanina Kapchonava or Evena Liao.

Wednesday, April 1st, 2015

HXR Health Experience Refactored, Boston MA, Jack speaking - 08:00 AM
TBD
Boston, MA 02210
USA [map]
Price: TBA

HxRefactored brings together the developers and designers driving a better health experience. Alongside our partner, Mad*Pow, we are thrilled to offer an immersive and educational experience for both the front-end and back-end of health IT. Join us in Boston, MA this year for HxRefactored 2015!

HxRefactored 2014 was a great success! The a revolutionary design and technology conference gathered over 650 designers, developers and leaders in health for two days of thought provoking talks, workshops and discussions on improving the quality of the health experience. Click here to view HxR 2014 videos. Stay tuned for more details about HxR 2015 on April 1-2 in Boston!

 

Wednesday, March 25th, 2015

MCT - Congress Going Mobile with Clinical Trials, Jack giving a keynote - 08:00 AM
Edinburgh International Conference Centre (EICC)
Edinburgh, Scotland EH3 8EE
United Kingdom
+44(0)7866 782165 [map]

MCT-Congress, a two-day event dedicated to the business of mobile technology in the clinical trial space, has unveiled its eagerly anticipated conference programme for 2015. The two day congress, which will take place at the Edinburgh International Conference Centre (EICC), 24th-25th March 2015, will focus on the practicalities of adopting mobile technology in clinical trials. Looking at the field from all perspectives, from patient right through to sponsor, the programme is set to challenge norms and offer ideas as to how the mobile industry can increase its speed of integration within the clinical trials space.

Sponsored by Medidata, the congress brings together a community of providers, sponsors, academics, investigators and regulators, all with a shared goal of fostering innovation and collaboration that will take the industry forward in the adoption of mobile technology. Providing a global platform to raise the level of discussion in this fast-moving field, the congress will deliver a dynamic and energetic programme of speaker sessions, Q&As and panel discussions, including, among others:

– The Real Business of Clinical Trials: A frank discussion amongst representatives from some of the biggest names in the industry about their business outlook and the forecasted influence of mobile technology. Oliver Stokes from Chiltern will be joined by peers from PPD, Quintiles and Clintec.

– Device Design: Matt Kibby from BBK Worldwide will team-up with experts from Ericsson, Vodafone and Apple to discuss how intelligent design can provide transformational benefits in compliance, productivity and accuracy in clinical trials.

– Barriers to Adoption: A panel discussion amongst some the industry’s leading experts, including Eli Lilly, Novartis, Merck and Janssen, will look at the challenges that big pharma is currently faced with and drivers in speeding up long-term adoption of mobile.

– Cautionary Tales of Data Mountains: Marc Buyse from IDDI & CluePoints will discuss the importance of ensuring data quality in clinical trials that use mobile technology, delivering new thinking in how successful monitoring strategies can be approached.

– Effective Regulator Relations: Pfizer’s Craig Lipset will offer a thought-provoking session on how the industry can best work with regulators to ensure successful development programmes.

– Realities of On-site Adoption: A group of highly-experienced data professionals from Bayer, the NHS and ICON will deliver a 360 degree perspective on managing data mountains.

“The 2015 MCT-Congress programme has been designed to deliver the highest quality speakers and leading-edge industry discussion, promoting understanding and collaboration that will help shape the direction of mobile in clinical trials”, commented Liz Logan, Head of the MCT-Congress. “The event provides a unique and unbiased space to meet new people from around the world, spark genuine debate, share knowledge, network and build relationships that change the future of clinical development.”

Monday, March 23rd, 2015

3th Annual eyeforpharma, Barcelona Spain, Jack is speaking - 08:00 AM
CCIB - Centre de Convencions Internacional de Barcelona
Barcelona, Catalonia 08019
Spain
blair@eyeforpharma.com [map]
Price: $2495

eyeforpharma Barcelona 2015 will set the vision for your 2020 plans. As your customer takes charge this meeting will enable you take the steps you need to become their partner of choice. The conference will aim to demonstrate real innovation and patient centric solutions by following these four principles

  • Do it Right: Create a future-proof model which truly represents and reflects customer desires. Fill it with strong ethics, standards, cross-functional communication and a real sense of the value you provide
  • The Era of Empowerment: Incentivise your newly-trained sales force to engage key influencers, create ambassadors and drive a step-change in results – right the way through to patient outcomes. See who from Pfizer, GSK and MSD will be speaking on this
  • A Bulletproof Core: Build the ultimate set of processes and systems to guarantee your core activities remain in permanently good health. Create KPI dashboards which encompass all channels to reflect the patient-oriented evolution of your company
  • Get Engaged: Listen, map and understand your customer to plot the decisive value proposition and become your customer’s natural partner of choice. Deliver education and services which build trust and parity with physicians and patients. Novartis, LEO Pharma and UCB reveal their approach

Monday, March 2nd, 2015

16th Annual Patient Assistance & Access Program, Baltimore, MD - 4:00PM Pre-conference Day 1
Hyatt Regency
Baltimore, MD
USA
339 298 2123 [map]
Price: 2399.00

Ensure Prescription Drug Coverage, Financial Support and Access to Care for Uninsured and Underinsured Patients

MARCH 2-4, 2015 | HYATT REGENCY | BALTIMORE, MD

As health reform continues to sweep in major changes to our nation’s healthcare system, patient assistance and access programs are rapidly evolving to assess and meet new needs.

For the past 15 years, CBI has been pleased to provide the must-attend forum for executives engaged in pharmaceutical patient assistance and access programs. Now, as millions of uninsured Americans gain some form of insurance coverage, manufacturer-sponsored PAPs face unprecedented challenges as they rise up to evolve the PAP model to best address changing needs in the market.

This annual meeting convenes hundreds of executives from the pharmaceutical industry and from patient foundations and clinics for the most robust and renowned forum on this critical issue.

Exchange, network and learn. Choose from focused Tracks and Workshops and engage in smaller, interactive breakout sessions.

Hear Expert Insights On:

  • Exchange adjustments and renewals
  • State Medicaid expansion
  • Legislative and regulatory challenges to patient access
  • New waves of patients and evolving assistance models
  • Access challenges for specialty medicines
  • The OIG’s Special Advisory Bulletin on co-pay assistance
  • Benefit verification and prior authorization
  • ICD-10 conversion and implications for patient access
  • Evolving PAP technology, including hub and ePrescribing services
  • Patient access offerings for biosimilars

PAP Compassion Spotlight:

CBI showcases organizations that are working to strengthen the resources that serve those in the community who are medically underserved. The goal of the Compassion for Patients Spotlight Series is to communicate the importance of these organizations and the great works they accomplish for those who cannot help themselves. If you would like to nominate your organization for the compassion spotlight, please contact Amanda Batstone at 339-298-2123 or amanda.batstone@cbinet.com.

Monday, February 23rd, 2015

Rare Disease Week on Capitol Hill, Washington DC, Jack presenting - 5:00 PM Reception
Carnegie Institute for Science, 1530 P Street
Washington, DC 20001
USA
202 803 6047 [map]
Price: By invitation

RDLA

Rare Disease Legislative Advocates (RDLA) is a collaborative organization designed to support the advocacy of all rare disease groups.

Our goal is to empower the patient to become an advocate!

By growing the patient advocacy community & working collectively we can amplify our many voices to ensure rare disease patients are heard in State & Federal Government.

RDLA provides:

  • DC Office with workstation & meeting space for organizations to use when working in DC
  • Consulting on legislative and grassroots strategies
  • Online advocacy tools to contact Members of Congress
  • Assistance with coalition building and support for legislation
  • Coordination of Lobby Days & Congressional Caucus Briefings
  • Conference calls/meetings to learn about legislation
  • Clearinghouse of all legislation that affects rare disease patients

RDLA is for  rare disease organizations or individuals who are or who want to be legislative advocates.

RDLA is open to all members of the rare disease community with an interest in sharing ideas and advocating for the introduction or enactment of legislation. RDLA was created as a clearinghouse of ideas designed to bring together rare disease organizations active on the Hill to share information around common causes.  It does not promote any specific policy, but provides support to all rare disease organizations seeking introduction/enactment of legislation. RDLA meetings and the website are an educational resource and a platform for individual organizations to promote their legislation.

RDLA is coordinated by Andy Russell, Associate Director of Advocacy & Government Relations,  Julia Jenkins, Executive Director of the EveryLife Foundation for Rare Diseases and Jennifer Bernstein, Vice President at Horizon Government Affiars.

- See more at: http://rareadvocates.org/about/#sthash.iaYTe7Kc.dpuf

Tuesday, February 3rd, 2015

Expanded Access Programs, Philadelphia, PA - 7:30 AM
Sonesta Hotel
Philadelphia, PA 19103
USA
800 766 3782 [map]
Price: $2199.

9:30  PATIENT ADDRESS:

Patient Perspective on Clinical Trials, Research and Expanded Access Programs

Jack Whelan

Author, Lecturer, Research Advocate
Cancer Warrior & Survivor

CBI’s Expanded Access Programs is a tailored, two-day meeting for those considering or currently working on the design and execution of a variety of access management programs, including but not limited to: Expanded Access Programs, Early Access Programs, Compassionate Use Programs, Named Patient Programs and Managed Access Programs. Share best practices and lessons learned around providing investigational, pre-launch or end-of-lifecycle drugs to patients for treatment purposes

Recent legislation, introduced just before the New Year, stands to dramatically reform the requirements of pharmaceutical and biotech manufacturers to offer compassionate use and expanded access programs. For companies whose drug is granted “Breakthrough,” “Fast Track” or “Qualified Infectious Disease Product”designation, it is critical that they understand the sweeping implications and to prepare now! Never has this meeting been more timely or critical.

The CURE Act is in the U.S. House of Representatives and intends to require that these drugs have a publicly available corporate expanded access policy for the compassionate use of the drug. This includes, but not limited to, designated point person, robust procedures, specific criteria for enrollment and policies for denials. Expect too the formation of an “Expanded Access Task Force” and upcoming formalization of the FDA’s May 2013 guidance, as the focus on Expanded Access Programs is mounting with the CURE Act.

Wednesday, November 5th, 2014

13th Annual Partnerships in Clinical Trials Congress- Barcelona Spain -Connecting and Collaborating on Continuous Innovaction - 08:00 AM
CCIB - Centre de Convencions Internacional de Barcelona
Barcelona
Spain [map]
Price: Registration required

13th Annual Partnerships in Clinical Trials Congress
Bringing together demand and solutions to drive innovation and strengthen partnerships

Background...
Partnerships in Clinical Trials looks at the outsourcing relationship between pharma and biotech sponsors and providers in clinical trials. Since 2001, we have brought together creators, innovators, storytellers and rising stars to provoke change and demand solutions to the challenge of advancing clinical trial collaborations.

This year...

Partnerships 2014 will deliver fresh and inspirational stories, speakers, solutions and resolutions.

Questions we'll answer…
• What will be the effect of transparency and compliance requirements?
• How will technologies be used and implemented?
• If regulators expect RBM despite implementation concerns – what can
  industry do?
• How will social media influence the future clinical trials?

Featured topics…
• Embracing new technology and disruptive innovation
• Examining the impact of new compliance regulations on people, process
  and spend
• TransCelerate a year on: What does this practically mean for pharma
  companies?
• Advancing your patient recruitment
• Private equity in outsourcing
• Successful partnering in risk based monitoring

 

New formats: Pain-points panel, interactive hubs, candid interviews; dramatization of a patient’s perspective. Plus, as ever we'll bring you a significant number of case studies, panels and joint presentations

New speakers: Looking outside the traditional stakeholders of pharma, CROs and providers: 2014 will have even more emphasis on patient, site, investigator and ARO

New topics:
•    Transparency: Greater visibility, data standards, identifying trends, data privacy and anti-corruption – including a futurists view
•    Disruptive technologies: How they're being used and how it’s being taken forward
•    More emphasis on patient-perspectives
•    Increased emphasis on the impact of social media

Important industry updates:
•    TransCelerate’s plans for 2014
•    Is disruptive innovation working?
•    Private equity in outsourcing: impact on CRO and client
•    Advances in patient recruitment
•    Risk-based monitoring and compliance issues
•    Social media and its increasing role

Even more investment in social events and networking

Partnerships Bar - Join us at the Partnerships Bar and relax and unwind at the end of a long day

iCafe - Stay connected throughout PCT - Visit the iCafe in the Exhibition Hall to recharge your laptop or phone in a secure unit

Tuesday, October 28th, 2014

ASCO CancerLinQ -Jack serves on Advisory Committee & Data Governance Oversight Committee
ASCO CancerLinQ Advisory Committee & Data Governance Oversight Committee - 07:30AM
2318 Mill Road
Alexandria, VA 22314
Unites States [map]
Price: Invitation only

Jack is honored to serve on this important ASCO CancerLinQ Advisory Committee, our next scheduled meeting is October 28, 2014 

Monday, October 27th, 2014

Aware for All Boston - 5:00 PM
Northeastern University, Curry Student Center
Boston, MA 02210
Unites States [map]
Price: No Charge

AWARE for All Boston, MA

Researcher panel answers questions

AWARE for All is an educational program that is free and open to the public for the purpose of providing education to help people make informed decisions about clinical research participation.

Join us in Boston on the evening of Monday, October 27 for a fun, informative night to:

  • Receive free health information and screenings from a variety of organizations and centers
  • Learn about participating in clinical research and ask questions
  • Connect with local research professionals and patients through a panel discussion

Dinner will be provided and the event will conclude with a ceremony to honor clinical research volunteers, as well as a raffle with prizes and giveaways!

National Sponsor: MS_RT_4CWomen share information on breast cancer

Collaborators:

Dana Farber Cancer Institute, Joslin Diabetes Center, Brigham & Women’s, Cambridge Hospital, Harvard School of Public Health, Harvard Medical School, Harvard School of Dental Medicine, Northeastern University, Fenway Health/ Fenway Institute

Event Venue:

Curry Student Center, Northeastern University

Event Time:

5:00pm - 8:00pm

Event Date:

Monday, October 27, 2014

Event Location:

346 Huntington Avenue, Boston, MA, United States

 

AWARE for All

 AWARE for All is a free program that aims to educate and empower the public in making informed decisions about clinical research participation. This event includes free health screenings and food, informational exhibits that feature community organizations and research centers, local physician and patient speakers, and a reception to honor clinical research participants. The AWARE events are sponsored nationally by EMD Serono and regionally by local organizations and research centers. Please email awareforall@ciscrp.org if you are interested in supporting our AWARE for All Educational Events as a regional or local sponsor.

Our lives are impacted by clinical research every day. Each medication you take was proven safe and made available with the help of clinical trials and the individuals who participated. This process and those who get involved are crucial to the advancement of medicine. 

AWARE for All Take-Aways:

  • Learn what clinical trials are and how they work
  • Learn why society needs clinical research
  • Understand the safety, benefits and risks of clinical research
  • Meet local area doctors and patients
  • Learn important questions to ask your doctor or healthcare provider so that you can make informed decisions regarding your participation

Since its inception, AWARE for All has amassed an impressive track record of engagement in cities including Baltimore, Boston, Dallas, Indianapolis, and Philadelphia. The program is also prominent in the research Triangle – Raleigh, Durham and Chapel Hill, N.C.

Part of what makes AWARE unique and effective is that CISCRP engages 30 to 50 community partners in each host city. Major universities and research hospitals, community health agencies, patient advocacy groups, and grassroots entities such as churches, community centers and even neighborhood hair salons work with CISCRP to promote the program and educate the community.

According to evaluations of the programs conducted to date, the AWARE model is demonstrating its impact. More than half (53%) of AWARE attendees who never participated in a clinical study prior to the program rated their knowledge of the clinical research process as poor or fair.

After attending the AWARE program, 93% rated their knowledge of the clinical research process as good or excellent. Another significant indicator of AWARE’s efficacy is that three-quarters of attendees said they are more likely to participate in a clinical trial following an AWARE program.

The National Cancer Institute (NCI), partnered with CISCRP to plan and implement a local clinical research awareness day, providing consultation and support in program evaluation by reviewing current goals and methods. NCI’s Office of Market Research and Evaluation determined that the current questions being used to test clinical trial knowledge were sound.

Why are AWARE for All events important?

Surveys have shown that 94% of the public recognizes that participation in clinical research is very important to advance medical science, however,

  • 74% say they have no ‘real’ knowledge of the clinical research process
  • 98% do not know where and how to identify and evaluate appropriate clinical studies for patients diagnosed with cancer and other chronic diseases.

There is a need for general education about the clinical research process including the risks, benefits and the rights of participants. Patients typically learn about the risks and benefits for the first time when asked to sign an informed consent document, which is required of all participants before beginning a study. This is not an ideal time for such education because the person or loved one may be under great stress due to illness. In fact, a recent survey showed that

  • 35% of people who signed consent forms said they did not understand what they signed and another
  • 10% claimed never to have read the document at all.

The purpose of AWARE for All is to address this lack of fundamental knowledge.

Through AWARE for All, CISCRP and our organizational partners help build greater awareness and understanding of the clinical research process and the important role participation plays in advancing medical science.

If you have questions regarding our AWARE for All program, please contact CISCRP at 617-725-2750 or email us.

Friday, October 24th, 2014

Ashfield Healthcare Event, Wonder what the Pharmaceutical industry will be like 2020
Wonder what the Pharmaceutical industry will be like in 2020 - 08:00 AM
Boston, MA
United States [map]

More details to follow.  Place holder.  

Tuesday, October 21st, 2014

NORD Rare Diseases and Orphan Products Summit - Jack speaking "Patient Voice in Research, Clinical Trials and Legislative Advocacy"
NORD Rare Diseases and Orphan Products Breakthrough Summit - Alexandria, VA - 08:00AM
Hilton Alexandria Mark Center, 5000 Seminary Road
Alexandria, VA 22311
Unites States
800 445 8667 [map]
Price: Registration required

NORD’s Rare Diseases and Orphan Products Breakthrough Summit is the largest and most meaningful multistakeholder event of its kind - Powered by over 30 years of passion and serving the patients and families affected by rare diseases with new channels of answers, advocacy, advancements in research and access to life-transforming treatments.  The 2014 Breakthrough Summit is concentrated with innovative content and convenes the top leaders from the FDA, NIH, Industry, Patient Groups, Payers and Research Institutions to address the progress of rare disease diagnosis, genomics, drug development, patient engagement, product approvals, FDA oversight and market accessibility to orphan products.

Expecting an unprecedented turnout, the NORD 2014 Breakthrough Summit is crafted with multiple workshops and focused tracks of content to ensure high quality learning, networking and accessibility to thought leaders in the rare disease community.

  • Network, learn and benchmark from hundreds of industry counterparts, patient advocacy stakeholders, investors and FDA leadership to better align their thinking on complex issues
  • Gain insight into the strategic models for commercializing an orphan product
  • Learn strategies to stay ahead of the curve on the newest R&D advancements in rare diagnostics and treatment regimens

 

Jack Whelan is speaking on October 22 at lunch from 12:30PM - 1:30PM and again at 1:30PM

Topic:  Patient Voice in Research Advocacy, Clinical Trials Advocacy and Legislative Advocacy.

Tuesday, October 14th, 2014

New Mexico Cancer Care Alliance 8th Annual HERO - Jack is Helping to Enhance Research in Oncology
8th Annual HERO Helping to Enhance Research in Oncology - 5:00PM
Albuquerque Marriott Pyramid North
Albuquerque, NM 87109
United States
505 272 7799 [map]
Price: Registration required

 

Featured Speaker Jack Whelan will bring laughter and tears about his story participating in six Clinical Trials for his rare incurable blood cancer.  

Registration and Photos:  5:00PM - 6:00PM

Program:  6:00PM - 7:30PM

For more information please click.

Monday, October 6th, 2014

Innovation Days, Pharma, Biotech & Medtech Event 2014 - Paris France Jack speaking Patient Empowerment
Innovation Days 2014 The Leading Partnering Meeting in Open Innovation for Life Sciences - 08:00 AM
Cite International Universitaire de Paris 17, Boulevard Jourdan
Paris, FR 75014
France
33 (0) 1 41 12 27 71 [map]
Price: Registration required

Conferences – Exhibition Hall – One-on-one partnering meetings – Networking

Innovation Days brings together public and private actors of the life sciences to maximize business opportunities during two days of high level conferences and one-on-one partnering meetings.

Pre-screened one-on-one partnering meetings

Find the most suitable business partners amongst innovative life science companies, top European clusters and pharma executives. Thanks to our partnering platform you can plan your meetings and promote your company and delegates.

 More info

Conferences, workshops and panel discussions

  • Two days of presentation tackling the issues of Open Innovation models for entrepreneurs, investors and partners.
  • Digital Forum : A specific focus on the challenges of digital health
  • The Innovation Prize awarding ceremony

 More info

Best of Innovation Presentations

An afternoon dedicated to innovative companies in the field of life sciences featuring the best candidates from the Innovation Prize and selected companies. The companies will be challenged by a jury of experts and the public.

 More info

Innovation Gallery - Exhibitions

Meet and discuss with technology transfer officers, service providers and international delegates in the Exhibition hall. Discover the posters from the most innovative projects of the Innovation Prize in the Innovation gallery.

 

Tuesday, September 23rd, 2014

Jimmy Fund - Special Events- Appreciation Night with Red Sox - Jack Speaking
Jimmy Fund Special Events Volunteer Appreciation Night with Boston Red Sox - 5:30 PM
Fenway Park
Boston, MA 02210
United States
6178205145 [map]
Price: By special invitation only - Red Sox Game follows

Jack is the guest speaker along with Red Sox Hall of Fame winner and well-known radio broadcaster Joe Castiglione.

Joe's the real star!  Jack is honored to share his story and commentary about Advocacy for Dana Farber Cancer Institute.

 

Tuesday, September 23rd, 2014

World CDx Companion Diagnostics Boston 2014, Forging the Path to Precision Medicine - 07:30AM
Le Meridien Cambridge 20 Sidney Street
Cambrigde, MA 02139
USA [map]
Price: Registration required

Forging the Path to Precision Medicine

World CDx Boston 2014 is the 5th annual summit which will provide the springboard for your companion diagnostic strategy to reach the next level of success. By bringing together the industry’s leaders and those pushing the boundaries with companion diagnostics, World CDx Boston 2014 will be discussing and tackling the biggest opportunities and challenges in the precision medicine space.

World CDx Boston 2014 will enable you to maximize your understanding of disease heterogeneity, revolutionize validation of clinically relevant biomarkers with incorporation into clinical trial design,and master the co-development and commercialization of drug-CDx combinations.

This summit will deliver a multitude of interactive formats, such as one-on-one keynote interviews, live virtual Twitter debates, breakout roundtables, panel discussions and much more.

This dynamic platform will allow you to leverage ground-breaking advances with companion diagnostics and provide you with extensive opportunities to network with the fields leaders and those who feel confined by the same challenges as you. World CDx Boston 2014 will provide you with the blueprint to maximize your drug-companion diagnostic research.

A dedicated 3 day conference, World CDx Boston 2014 delivers pioneering case studies and discussions to ensure you learn how to:

  • Construct and develop complete biomarker strategies dealing with incorporation of biomarkers into clinical trial design, huge data sets, patient stratification and more 
  • Maximize the power of Next Generation Sequencing in the pre-clinical and clinical phases of development 
  • Amplify your drug-companion diagnostic research inside and outside of oncology to supercharge your entire portfolio
  • Navigate the regulatory and commercialization landscapes to accelerate speed to market
  • Coordinate Rx-CDx development to ensure practical alignment and ensure that launch is efficient
  • Realize the potential of cell free DNA, liquid biopsies and circulating cancer biomarkers to unearth novel approaches to drug-CDx development

Saturday, September 20th, 2014

AACR Hematologic Malignancies - 08:00 AM
Sheraton Philadelphia Downtown
Philadelphia, PA
United States [map]
Price: $2195.

Conference Chairperson
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Mass.

Conference Co-Chairpersons
Scott A. Armstrong, Memorial Sloan Kettering Cancer Center, New York, N.Y.
Riccardo Dalla-Favera, Columbia University Institute for Cancer Genetics, New York, N.Y.

The AACR is proud to announce a new Special Conference focused on the blood-based cancers and associated disorders categorized as hematologic malignancies and will include presentations pertaining to leukemia, lymphoma, myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms. This conference will span the spectrum of relevant cancer science and medicine, from basic science discoveries to their translation in the clinic, and will cover those scientific areas that cut across all blood cancers such as genomics, epigenetics, cell death pathways, and the tumor microenvironment, as well as translational and clinical topics such as targetable signaling pathways, drug development, immunotherapy, other treatment modalities, and early clinical trials.

This conference offers a unique opportunity for a lively discussion, in a small setting, of the challenges in the field among basic, translational, and clinical researchers and for potential collaborations among national and international investigators in the field. The chairpersons and members of the Scientific Program Committee for this Special Conference are world-renowned experts in the diverse areas of the field. Under their leadership, the meeting will provide an outstanding forum for the presentation of today’s most exciting developments in the research and treatment of hematologic malignancies. In addition, the major goals of this AACR conference are to highlight the common aspects of both hematologic malignancies and solid tumors and to foster new knowledge and creative ideas about how to treat and cure these diseases.

Scientific Program Committee

  • Julian Adams, Infinity Pharmaceuticals Inc., Cambridge, Mass.
  • John C. Byrd, Ohio State University Comprehensive Cancer Center, Columbus, Ohio
  • Faith Davies, Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom
  • Richard B. Gaynor, Eli Lilly and Company, Indianapolis, Ind.
  • Randy D. Gascoyne, BC Cancer Agency, Vancouver, BC, Canada
  • Douglas R. Green, St. Jude Children’s Research Hospital, Memphis, Tenn.
  • William N. Hait, Janssen Research & Development, Raritan, N.J.
  • Carl H. June, University of Pennsylvania, Philadelphia, Pa.
  • Michelle M. LeBeau, University of Chicago, Chicago, Ill.
  • Jonathan D. Licht, Northwestern University, Chicago, Ill.
  • Crystal L. Mackall, National Cancer Institute, Bethesda, Md.
  • Tak W. Mak, Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, Ont., Canada
  • Elaine R. Mardis, Washington School of Medicine, St. Louis, Mo.
  • Ari M. Melnick, Weill Cornell Medical College, New York, N.Y.
  • Charles G. Mullighan, St. Jude Children’s Research Hospital, Memphis, Tenn.
  • Kevin M. Shannon, University of California, San Francisco, Calif.
  • Phillip A. Sharp, MIT Koch Institute for Integrative Cancer Research, Cambridge, Mass.

Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available

The AACR would like to thank the following organizations for their generous support of this conference.*

Lead Supporter:
Bristol-Myers Squibb 

Supporters:
Janssen Research & Development LLC 
The Leukemia & Lymphoma Society 

Supporter - Plenary Session 3: Genomics
Penn Medicine

Supporter - Concurrent Session 3: Lymphoma
Lymphoma Research Foundation

Professional Education Grants: 
AbbVie, Celgene, Incyte, Pfizer, Seattle Genetics

*as of August 25, 2014

Wednesday, September 17th, 2014

AACR Rally for Medical Research Capitol Hill Day - 3:00PM Wednesday, 7:30AM Thursday
Hyatt Regency, kick-off then Capitol Hill
Washington, DC
United States [map]
Price: By Invitation only

 

VIDEO: Survivor-Research Advocate Jack Whelan speaks about the mission of AACR to prevent and cure all cancers.  Click for Video.

On September 18, 2014, the medical research advocacy community will meet with House and Senate offices in Washington, D.C., to urge Congress to invest in the National Institutes of Health (NIH) for the health and economic security of our nation. 

Wednesday, September 17, 2014

3:00pm - 4:30pm         CAPITOL HILL DAY TRAINING SESSION
Hyatt Regency Washington-Capitol Hill (Team Leaders are encouraged to attend.)

5:00pm - 7:00pm         RALLY FOR MEDICAL RESEARCH RECEPTION
Kennedy Caucus Room, Russell Senate Office Building, Room 325

Thursday, September 18, 2014

7:30am - 9:30am         CAPITOL HILL DAY KICK-OFF BREAKFAST
Hyatt Regency Washington-Capitol Hill, Ballroom A 

9:45am-5:00pm           RALLY FOR MEDICAL RESEARCH CAPITOL HILL DAY
Meetings with House and Senate offices 

 

Click for Promotional Flyer

Sunday, September 14th, 2014

Optimizing Clinical Research Performance - Sheraton Boston Hotel
Optimizing Clinical Research Performance - 09:00 AM
Sheraton Boston Hotel
Boston, MA 02210
United States [map]

CONFERENCE OVERVIEW:
In 2013, CenterWatch’s inaugural forum on Optimizing Clinical Research Performance, presented in association with iiBIG, became one of the industry’s must-attend conferences for its unique, trend-setting, strategic content and innovative solutions with topics based on original research and analysis featured in The CenterWatch Monthly and CWWeekly newsletters, two of the industry’s leading news publications.

September 15-16, 2014 in Boston, CenterWatch introduces its 2nd annual forum — presented in a new day-and-a-half format featuring more general sessions and strategically positioned break-out discussions — intended to foster compelling and actionable conversations among senior-level, clinical research professionals from pharma, CROs, investigative sites and niche service providers.

This revised forum will welcome more than 30 thought leaders and presenters at the forefront of driving change across the global clinical research landscape through novel collaboration and creative solutions. Sessions will focus on key emerging trends — chosen by the CenterWatch conference team and supported by informative data and implementable strategies — on topics such as the evolution of patient partnerships, recruitment and retention strategies, vital technology drivers, critical regulatory changes and more, to propel powerful and insightful dialogue that will extend well beyond the conference rooms and networking breaks.

Attendees will benefit from this well-organized, more efficient format featuring timely sessions and rewarding networking opportunities and receptions with the goal of laying the foundation for new partnerships that ultimately will drive the success of the industry.

Thursday, September 4th, 2014

eyeforpharma Patient-Centered Clinical Trials - 08:00AM
Hyatt Regency
Boston, MA 02210
United States
201-204-1688 [map]
VIDEO: Cancer Survivor Research Advocate Jack Whelan speaks on how pharma can become more patient centric - Click for Video.

 

Unleash the Potential of Patient-Focused Clinical Research

Revitalize Recruitment, Enrollment and Study Management

The role of the patient in healthcare has become ever more participatory. In 2014, patient centricity is no longer just viewed as a commercial opportunity. This is the only conference that addresses the latest trends and innovations in clinical trial management from a patient-centric perspective.

What you can expect

The conference will offer a unique mix of engaging sessions, debates and 1-1 networking with top pharma, patient groups, site representatives and industry thought leaders. While reimagining the entire patient journey from recruitment through to the post-trial debrief, delegates will learn and debate new approaches to:

  • Develop the patient-pharma relationship in clinical research
  • Maximize trial success through improvements in current workflows and trial operations
  • Draw on patient-initiated research and (e)PRO
  • Optimize the patient experience before the study even starts
  • Address trial-fatigue through new systems and innovations
  • Close ties with principal investigators and research sites
  • Re-think Informed Consent in the digital age
  • Leverage social media and digital technology for recruitment and engagement

And there’s more to cover.

With actual case studies and best practice examples, Top Tier Executives on the speaker faculty will present actionable solutions on how to implement the more efficient clinical trial: Closer to the patients, improved in design, data capture and management, truly integrated with the site, and fully leveraging online and mobile technologies.

It’s about putting patients at the heart of the trial – and what that practically means for study design, trial processes and clinical operations.

Sunday, August 17th, 2014

4th Cancer Advocacy Leadership Conference, Tucson AZ - Jack speaks on Patient Centered Clinical Trials
Encouraging and Sustaining Cancer Advocacy Programs and Efforts (ESCAPE) - 5-Day Conf.
Miraval Resorts Arizona
outside Tucson, AZ 85739
United States
520 575 9602 [map]
Price: By nomination, invitation and selection only

Jack Whelan a Research Analyst turned Research Advocate, a Waldenstrom's Macroglobulinemia blood cancer survivor is participating as Dinner Speaker:  Topic is Patient Centered Clinical Trials joined by Dr. Brian Hoffman, physician turned patient, a Chronic Lymphocytic Leukemia blood cancer survivor.  

Jack is also leading a panel of participant experts who will present Patient Advocacy Programs and represent the following advocacy groups/organizations:

  • FORCE: Facing Our Risk of Cancer Empowerment, Diane Rose, Director of Programs
  • Project Lead, National Breast Cancer Coalition, Jessica Jones
  • Department of Defense, Congressionally Directed Medical Research Programs, Brenda Bryant
  • Research Advocacy Network and Research Advocacy Institute, Elaine Newcomb
  • Drug Information Association, Patient Advocate Fellowship Program, Jack Whelan
  • American Association for Cancer Research (AACR) Scientist - Survivor Program, Jack Whelan
  • AACR Minorities in Cancer Research (MICR) Science of Cancer Healthcare Disparities, Jack Whelan

This is an exceptional event for qualified Advocates who deserve the benefits of a program designed specifically for advocates many of who are cancer survivors who require more balance between advocacy work and mindfulness.

ESCAPE 2014

Encouraging and Sustaining Cancer Advocacy Programs and Efforts

Cancer Advocacy Leadership Conference Sunday, August 17 – Thursday, August 21, 2014 Tucson, AZ

Discover a healthy balance in your own personal health and well-being & your community advocacy work and efforts! We believe that healthy programs need healthy leaders. In order for both individuals and programs to grow, flourish, and prosper they need to be nurtured. ESCAPE offers you the opportunity to do so. ESCAPE is unique. It will bring together advocates from around the country who are involved in cancer-related programs and projects to:

    • network with other community advocates, both novice and veteran;
    • share experiences and gain insight, tools, and skills for:Growth and sustainability of cancer advocacy efforts
    • Volunteers
    • Fundraising
    • Social media
    • Burnout and compassion fatigue prevention
    • Integration of mind, body and spirit for balanced living

The program agenda is balanced and will include plenary sessions, workshops, and informal networking groups.

 

Monday, August 11th, 2014

Rare Disease Legislative Advocacy in District Lobby Days- Jack meeting with Sen. Elizabeth Warren, Edward Markey, Rep Niki Tsongas
RDLA In-District Lobby Days, Jack Meets with Federal Lawmakers in Boston MA - 09:00 AM
JFK Federal Building 15 New Sudbury Street
Boston, MA 02203
United States
202 808 8858 [map]
Price: Invitation only

In August, Members of Congress will return home to their districts to connect with constituents.  This is the perfect opportunity for rare disease advocates to strengthen relationships with Members of Congress or build new relationships following up visits to Washington, DC. This is RDLA's 1st annual In-District Lobby Days!

Jack is meeting with United States' Senator Elizabeth Warren, Senator Edward Markey, Representative Niki Tsongas to discuss:

  • Rare Disease Congressional Caucus

  • H.R. 460 Patients Access to Treatment Act

  • H.R. 4384 America Heals

  • S.2115 America Cures 

 

Friday, August 8th, 2014

Best of ASCO 2014 Annual Meeting, Boston, Renaissance Boston Waterfront Hotel
Best of ASCO 2014 Annual Meeting - Boston - 07:00 AM Exhibits Open
Renaissance Boston Waterfront Hotel
Boston, MA 02210
United States [map]
Price: Registration required

The Best of ASCO Meetings will feature practice-changing science and educational highlights from the 2014 ASCO Annual Meeting and offer a personal and interactive setting to showcase your organization’s latest advances in oncology research and practice. The Meetings collectively bring together over 1300 members of the oncology community from a broad range of specialties, who work together to strengthen collaborative treatment approaches and to enhance patient care. 

The intimate exhibit area provides a level playing field for the select organizations that secure space. Food service is located with the exhibitors, providing ample opportunity for contact with attendees. 

Why attend a Best of ASCO Meeting?

“The Best of ASCO Meetings are great distillations of all the ASCO content. They condense 5 days of sprawling convention center activities into a tightly packaged, 2 days of clinical pearls that are centered on helping oncologists be up to the minute with treatments,” – Harold J. Burstein, MD, PhD, Dana-Farber Cancer Institute

“The ability of any oncology professional to have access to in-person presentations of the practice-changing results from the Annual Meeting is a true strength of the program.” – Jedd Wolchok, MD, PhD, Memorial Sloan-Kettering Cancer Center




Please note:  Exhibits for Friday, August 8 are sold out.

Application for Exhibit Space on Saturday, August 9

View the floor plan for Saturday exhibits.

 

Exhibit Schedule for Friday, August 8 exhibitors:

Move In: Thursday, August 7, 2014 - 4:00 PM - 6:00 PM

Exhibit Hours: Friday, August 8, 2014 - 7:00 AM - 3:00 PM

Move Out: Friday, August 8, 2014 - 3:00 PM - 4:00 PM

Wednesday, August 6th, 2014

Partnership in Clinical Trials 2015 Boston, Jack serves on Planning Advisory Board Meeting
Partnerships in Clinical Trials Boston 2015 Advisory Board Planning Meeting - 09:00 AM
Boston, MA
United States
646 895 7331 [map]
Price: Invitation only

Jack serves on IIRUSA's Partnerships in Clinical Trials, Boston 2015 Planning Advisory Board which is planning for an exciting conference in Boston on April 22-24, 2015.  Jack represents the e-Patient, the Patient's Voice at this well-managed conference.  For planning information, please contact Conference Producer at IIRUSA Marina Adamsky telephone: 646 895 7331 email: MAdamsky@iirusa.com

 

Thursday, July 31st, 2014

National Women's Survivor Convention - 08:00
Gaylord Opryland Resort 2800 Opryland Drive
Nashville, TN 37214
United States
615 719 0741 [map]
Price: Registration required

Date and location:July 31st through August 2nd, 2014

Gaylord Opryland Resortin Nashville, Tennessee

Who Should Attend:  All women, all cancers, all ages, all stages

Tagline: Transforming survivorship andhelp women re-enter their livesby supporting, educating, and connecting women whose lives have been touched by cancer.

Description:The National Women's Survivors Convention is a place for womensurvivors of cancer to come together over the issues surrounding survivorship.  All women, all cancers, all ages, and all stages are welcome.  The conventionis not just a conference; it exists to fill the emotional gap in treatment that most survivors experience.  The convention exists to answer the questionsthat burn in everysurvivor’s mind: “Am I normal?  What is the new normal?  How do I redefine normal?”

Purpose: Many people think that a survivor's ordeal is over once they've had their last treatment.  This couldn't be further from the truth; survivorship contains its own set of challenges, difficulties, and obstacles.  What's worse, many people are left without any sort of support system to try and piece their lives back together after their treatment is completed—lives that will never be “normal” again. 

While survivorship programs are becoming a requirement for certification in the near future for many treatment centers, there remains the need for a place where women survivors can come together and understand that yes, what they're going through is normal.  The convention does that, and gives them the tools they need to live rich, satisfying, happy lives.

History:  The convention was startedin 2013 by Karen Shayne and Judy Pearson after five years of intensive research and study.  Over 1,000 women attendedfrom 49 states and five countriesalong with over 100 cancer related organizations who exhibited at the convention.  Produced in connection with the Women Survivors Alliance, the convention also premiered the nation's first digital magazine for women survivors, The Plum

Tuesday, June 24th, 2014

Massachusetts State House, Jack is Team Leader with LLS advocating for Specialty Tiers resolution
Leukemia & Lymphoma Society Mission Day at Massachusetts State House - 09:00AM
Commonwealth of Massachusetts State House - 24 Beacon Street
Boston, MA 01233
United States [map]
Price: .00

LLS Advocates – Mission Day to advocate for improved access to care for patients living in Massachusetts. To date we have 40 visits scheduled with lawmakers and staff!

EVENT LOGISTICS

  • On Tuesday, June 24th we’ll start the day at the Omni Parker House, located at 60 School Street in Boston to plan for meetings with state senators and representatives. 
  • Registration will be open from 10-10:30am, holding a brief training session starting promptly at 10:30am. 

OUR POLICY ISSUE

  • During our training session, we’ll provide you a stack of “leave-behind” folders that have been pre-stuffed with materials. 
  • Training includes:

An overview of “specialty tiers,” the issue we’ll be discussing

Letter of support that we’ve invited our partner organizations to sign onto this week 

LEGISLATIVE VISITS

  • Pair with other advocates. 
  • Visit key legislators, including representatives/senatosr and/or members of important committees. 
  • Present patient and caregiver stories

 

Saturday, June 21st, 2014

Genentech Gives Back Volunteer Benefit Concert, Jack is 1 of 4 Survivors featured
Genentech Gives Back Concert AT&T Park - 09:00 AM
AT&T Stadium 24 Willie Mays Plaza
San Francisco, CA 94107
United States [map]
Price: By Invitation, employees, family and friends

Jack was fortunate to share the stage at AT&T Park in San Francisco with celebrities Usher, Foo Fighter and Colbie Caillat and the CEO's of Genentech Ian Clark, and parent company Roche CEO of Roche Group.  His story of hope and survival was presented in a short video to more than 20,000 attendees.  

"This year Genentech Gives Back Week kicked it up a notch, with thousands of employees online and in the community volunteering and fundraising for charity.

At Genentech we believe that innovation and a desire to do good can lead to the biggest breakthroughs. This idea is reflected in everything we do - from the medicines we create to the communities where we live and work.

Genentech Gives Back Week, is a company-wide initiative that raises money for charity and encourages employees to volunteer with local and national non-profits. Genentech is always working to make the world a better place, but Gives Back Week is an especially meaningful time of year. It gives employees a chance to reconnect with colleagues in the spirit of giving and helps us collectively make a real and positive change in our communities. 

Growing Year Over Year

This year the event blossomed in both size and scope. One of the most exciting new developments was the expansion of the event’s online component. Genentech now offers a virtual equivalent to all the in-person events so that employees across the country can participate as well. By doing so, the event saw increased participation and fundraising, including online auctions, donations, and meal shares. Employees working off-site and on campuses other than South San Francisco were even able to check-in online to have their donation counted toward the annual Children's Walk. 

See the event on Twitter  

Tuesday, June 17th, 2014

11th Annual - The Patients Summit 2014, London - 08:00 AM
Tower Bridge Hilton
London SE1 2BY
England
44-203-002-4300 [map]

Everybody in the industry is currently talking about what patient centricity really means and how to achieve it. At the Patient Summit 2014, our expert speakers will show you how to turn this buzzword into a reality to drive your business forward, through real understanding and engagement with patients. 

Differentiate your business with a strategy built around the patient experience

Patient Centricity: learn how to move beyond the buzzword with a realistic assessment of the industry and your company.

Put the patient at the centre through collaboration: the pharma company as a partner of the patient associations.

Ensure organisational cohesion and smooth relationshs between departments when shifting away from the physician and towards the patient.

Build trust in your business through continued patient centricity after the drug is on the market.

Understand the outcomes which are important to patients.

Implement a ‘Patient Centric Selling Approach’.

Understand the patient journey throughout and post treatment to ensure you're providing a positive patient experience.

Panel: Learn how customer insight can help your business and how to get it.

Panel: Use your knowledge of patient need to attract the attention of physicians and payers.

A superior service: do more for your patients with support programmes and additional services.

A better relationship with patients: recognise where patients see the gaps your company could fill.

Ensure all those involved in the patient journey are completely integrated and working together to implement a patient centric strategy and provide a fuller service.

Involve patients in clinical trials and ensure superior, personalised care and a closer relationship.

Panel: Work through HCPs: ensure your HCPs are properly informed and adequately translating the benefits of your product to the patients.

Support patients' choice and independence through home treatments.

Equip yourself to do more for patients: understand them, their families and those who care for them.

The Patient Voice: understand and work with the growth of the multi stakeholder coalition to represent patient views.

Engender a generation of healthy patients through the promotion of active engagement in healthcare.

Panel: ensure patient adherence through engagement.

Contact:

Sophie Akister
VP Patient Engagement
Global Event Director | eyeforpharma
Direct tel: +44 (0) 207 422 4322
Email: sakister@eyeforpharma.com

 

 

Sunday, June 15th, 2014

DIA 2014 50th Annual Meeting - 08:00 AM
San Diego Convention Center
San Diegp, CA
USA
215.442.6100 [map]
Price: $1574.00

The DIA 2014 50th Annual Meeting is the largest multidisciplinary event that brings together a community of life sciences professionals at all levels and across all disciplines involved in the discovery, development, and life cycle management of medical products all with a common goal to foster innovation that will lead to the development of safe and effective medical products and therapies to patients.

DIA 2014 50th Annual Meeting will:

  • Provide a global unbiased platform to raise the level of discussion to facilitate innovation that will change the future of health care
  • Provide comprehensive coverage of the full development and life cycle management of process for all health care products
  • Offer a holistic and integrated approach to the development life cycle management of regulated health care products

DIA 2014 50th Annual Meeting provides the best opportunity to meet with people from around the world, share your views and knowledge, network, and build new relationships.

Who Should Attend?

This meeting is designed for individuals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related medical products. The Annual Meeting is intended to strengthen professionals’ understanding of the value of cross-discipline integration and to foster innovation for better health outcomes.

Friday, June 13th, 2014

Third Annual Strengthening Patient Advocacy Relations Across the Life Sciences - 08:00 AM
Arlington, VA 22101
USA
312.602.9683 [map]
Price: $1995.00

In recent years, the idea of patient centricity has gained increased prominence within the healthcare industry, creating a call to action for life science companies to establish and cultivate a robust and adaptable patient advocacy function internally. Today, more often than not, patients are increasingly self-educated through the internet, social media outlets and local patient groups. Nevertheless, industry insight and education will prove invaluable and is an integral part of fully understanding a disease state as well as treatment options, and as such, patients will look to advocacy executives for additional support.

Central to this program will be vast knowledge share surrounding proactive patient immersion within clinical trial design, the identification of market access strategies in accordance with the implementation of the ACA as well as approaches in uncovering and partnering with the most optimal patient groups, especially among a inundated disease state. Other discussions will include shared success and failure stories on locating the best home for the patient advocacy function internally, as well as working with international patient groups. Attendees will gain unique insider perspective from patient advocate leaders regarding challenges and benefits of creating industry partnerships.

This exceptionally distinct annual conference will provide participants with extensive networking as well as in-depth learning through interactive sessions, panel discussions and case studies, complemented by multiple networking opportunities with industry peers and patient advocate speakers. Attendees will have the opportunity to learn strategies for overcoming key challenges involved in the patient advocacy relations role across the life sciences. Through fostering a sense of collaboration, this unparallel conference program will inspire innovation and help bring clarity to pharmaceutical and biotech patient advocacy relations professionals that wish to maximize their impact on the industry as well as within the patient community.

Jack Whelan is speaking about A Patient Perspective: Building Effective Industry Alliances with Advocate Leaders sharing his experiences as a six year cancer survivor, participant in many Clinical Trials, riding the road to Personalized Medicine still under construction, now making the transition from IT Research Analyst to Research Advocate and supporter of the Life Sciences industry by leadership in several national Life Sciences and Advocacy organizations. 

 

Sunday, June 1st, 2014

Health Data Consortium Event - Health DataPalozza - 08:00 AM
Marriott Wardman Park
Washington, DC 20008
USA
1-877-212-5752 [map]
Price: $695.00

What People Are Saying

"I have 3 words about Health Datapalooza. Don't miss it."
Marcia Kean, Chairman, Strategic Initiatives, Feinstein Kean Healthcare | An Ogilvy Company

"Health Datapalooza is an incredible gathering of tech innovators, clinicians, patient advocates, entrepreneurs, health care leaders, policymakers, and researchers. It's helping to fuel the creation of a rising tide of new tools and services that are making a real difference in people's lives."
Todd Park, US CTO

"If you are an entrepreneur looking for 'the next big thing', leveraging health data is it and the Health Datapalooza is the conference you won't want to miss!"
Sunnie Southern, Founder and CEO, Viable Synergy, LLC

Friday, May 30th, 2014

American Society of Clinical Oncology (ASCO) 50th Annual Meeting, Chicago, IL
ASCO 50th Annual Meeting Science & Society - 08:00 AM
McCormick Place
Chicago, IL 60636
USA
888-282-2552 [map]
Price: $2495.00

Attendees of the 2014 Annual Meeting will find cutting-edge scientific presentations and comprehensive educational content.

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Science and Society." Prospective attendees can familiarize themselves with some basic information, including:

Education Sessions
Education Sessions offer interdisciplinary or multidisciplinary explorations of focused areas of clinical oncology. ASCO's Cancer Education Committee determines topics and format for these sessions that will best serve the educational needs of Annual Meeting attendees. Particular care is taken to ensure that these sessions address issues including surgical, radiation, and geriatric oncology; symptom management; health services research; international perspectives; and pathology, as appropriate.

Clinical Problems in Oncology Sessions
Clinical Problems in Oncology Sessions combine the use of case-based panel discussion with interactive keypad technology for audience participation. These sessions are ticketed and require an additional registration fee.

Meet the Professor Sessions
Meet the Professor Sessions enable interactive discussion between attendees and recognized experts in a variety of subspecialty fields. The format is informal with an emphasis on a face-to-face exchange with the expert. These sessions are ticketed and require an additional registration fee.

Core Sessions Track
The Core Sessions track highlights the latest updates in science and clinical practice. Designed to help busy oncologists streamline their Annual Meeting experience, Core Sessions may include such topics as controversies in a particular disease site, personalized care, or new developments in the field. The Cancer Education Committee has designated one or more education sessions in each track as Core Sessions.

Special Sessions
Special Sessions include the presentation of Awards and Award Lectures as well as symposia recommended by other oncology-related organizations, the Cancer Education Committee, the Scientific Program Committee, and the ASCO Board of Directors as being of particular interest, importance, and relevance to Meeting attendees.

Plenary Session
The Plenary Session includes 15-minute didactic presentations highlighting abstracts of scientific research deemed to have the highest merit and greatest impact on oncology research and practice. Experts in the field will serve as Discussants to place research findings into perspective. The Plenary Session will take place on Sunday, June 1, 2014, 1:00 PM-4:00 PM.

Oral Abstract Sessions
Oral Abstract Sessions include didactic presentations of abstracts representing important clinical and translational research findings by topic category. Presenting authors may use PowerPoint slides to accompany their oral presentation. Experts in the field (Discussants) are chosen to provide comprehensive themed discussions of the findings from predetermined abstracts.

Clinical Science Symposia
Clinical Science Symposia provide a forum for science in oncology, combining didactic lectures on a specific topic with the presentation of abstracts. Experts in the field (Discussants) place studies in the appropriate context based on the strength of the evidence and critically discuss the conclusions in terms of their applicability to clinical practice.

Highlights of the Day Sessions
Highlights of the Day Sessions invite expert discussants to present key findings, put abstracts into clinical context, and provide an overview of the previous day's oral abstract sessions.

Poster Discussion Sessions
Posters Discussion Sessions highlight selected abstracts of clinical research in poster format. The posters are grouped by topic and are on display for a specified time, followed by a discussion session in which expert Discussants comment on the research findings.

General Poster Sessions
General Poster Sessions include selected abstracts of clinical research in poster format. The posters are grouped by topic and are on display for a specified time. The Annual Meeting will again include Trials in Progress poster presentations within each track, designed to facilitate awareness of open, ongoing clinical trials of any phase.

Thursday, May 15th, 2014

International Waldenstrom's Macrogloublinemia Foundation, Education Forum, Tampa, FL
International Waldenstrom's Macroglobulinemia Foundation Educational Forum and Conference - 08:00 AM
Renaissance International Plaza
Tampa, FL
USA
800 468 3571 [map]
Price: $275

The IWMF's annual Educational Forum is a unique opportunity for patients and caregivers to learn about our disease from specialists in Waldenstrom’s macroglobulinemia (WM) who are involved in many areas of clinical practice and research. Held in a different part of the United States every year, the “Ed Forum” offers something for everyone, no matter what your experience or level of knowledge.


Presentations aimed at the layperson address symptoms and complications of the disease, current treatment options, new therapies on the horizon, and recent research findings that may someday lead to a cure. Breakout sessions permit in-depth exploration of specialized topics and opportunities for patients and caregivers to share their experiences in a safe and supportive environment.

Waldenstrom's Macroglobulinemia is a lymphoplasmacytic lymphoma as defined by the Revised European American Lymphoma Classification (REAL) and the World Health Organization (WHO). The clinical features of this rare and indolent disease result from the presence of IgM paraprotein and infiltration of the bone marrow with lymphoplasmacytic cells. The clinical features are similar to those of multiple myeloma (MM) except that an enlarged spleen or liver is common in WM and uncommon in MM, while bone lesions and renal disease are common in MM and uncommon in WM.

The disease begins with a malignant change to the B-cell during its maturation so that it continues to reproduce more malignant B-cells. The result is an overproduction by the malignant B-cells of a protein called monoclonal immunoglobulin M antibody (IgM). WM is also characterized by a highly variable degree of bone marrow involvement. As a result of the cell changes and marrow involvement, normal functions of blood and lymph tissue are suppressed. WM is usually an indolent and chronic disease that is treatable. It is not yet curable.
 

 

Tuesday, May 6th, 2014

American Society of Clinical Oncology ASCO CLQ Advisory, Alexandria VA/Washington DC
CLQ Committee - 08:00
2318 Mill Road Suite 800
Alexandria, VA 22314
USA
571 483 1645 [map]
Price: By Invitation

Saturday, April 26th, 2014

Multiple Myeloma Research Foundation Race for Research, Boston, MA
Multiple Myeloma Research Foundation (MMRF) Race for Research - 07:00 Registration
Carson Beach
South Boston, MA 02210
USA
203 652 0208 [map]
Price: .00

Saturday, April 26, 2014 Boston, MA USA

MMRF Race for Research

This inspiring event unites multiple myeloma patients, family members, friends, health professioals and the local community.  Come walk, run, stroll with us to support MMRF's critical work and truly make and inpace in the fight against cancer.

Saturday, April 5th, 2014

AACR Annual Meeting, San Diego, CA - 08:00 AM
Convention Center, Marriott Marquis San Diego Marina
San Diego, CA 20001
USA [map]
Price: Members $849

The 105th Annual Meeting of the American Association for Cancer Research will be held April 5-9, 2014, in San Diego, California. As always, this AACR Annual Meeting will highlight the latest and most exciting discoveries in every area of cancer research, and it will provide a unique opportunity for investigators from all over the world to meet, network, and forge new scientific interactions. This year’s Annual Meeting theme, “Harnessing Breakthroughs • Targeting Cures,” reflects the great progress being made in cancer research as discoveries in the lab are translated into treatments in an increasingly targeted and precise manner. We will also continue to hold several sessions that will feature presentations of new data on cutting-edge clinical trials along with commentaries on the science behind the trials and the implications of these trials for improved patient care.

© 2012 AACR/Todd Buchanan.  AACR Annual Meeting 2012, McCormick Place West Chicago, IL - registration areaAn important new feature of the AACR Annual Meeting 2014 will be to include talks by rising stars in cancer research in several of the major sessions. Along with the hundreds of invited talks, we will feature over 6,000 proffered papers by researchers from all over the world. We want to thank the Program Committee Co-Chairpersons for their incredible expertise, dedication, and guidance in shaping an innovative program that will be both enjoyable and educational.

It is clear that recent progress against cancer will lead to even greater opportunities for the prevention, treatment, and cures for all types of cancer as we become more entrenched in the era of precision medicine. We are confident that attending the AACR Annual Meeting will give you renewed energy, inspiration, and focus in your work. Please register early and submit your abstract by the December 3, 2013, deadline. We look forward to seeing you in San Diego.

Sunday, March 30th, 2014

Partnerships in Clinical Trials - 08:00 AM
The Mirage Hotel
Las Vegas, NV 89109
USA [map]
Price: Special $700

Where Key Stakeholders Collaborate to Drive Clinical Trial Success

We’re thrilled to introduce the all-new Partnerships in Clinical Trials
2014—the one and only event where key stakeholders collaborate to drive
clinical trial success. Your success is our success—and we’re giving the
tools you asked for to ensure that you have a highly enjoyable, productive
and rewarding experience.

Top 5 reasons to attend this year’s Partnerships in Clinical Trials conference

1. Because the Advisory Board Said So.
The Partnerships 2014 Advisory Board is a prestigious group of industry leaders that has dedicated their
time and energy in helping us build the most relevant conference experience for you. Their seal of approval
is stamped on every piece of content they have recommended, inspired, and approved, ensuring that the
content delivers you real-world ideas you can actually implement. Meet the Advisory Board on page 8.

2. Everyone Who’s Anyone is Here.
For more than 23 years, Partnerships has been THE gathering place for senior-level decision makers in
clinical outsourcing, research and operations—and 2014 will be no exception. As the pharmaceutical
landscape has evolved, so have we. Partnerships is now the place where the ENTIRE clinical
value chain meets. Network with payers, academic organizations, patient organizations, sites, tech gurus
and more!

3. A Brand New Marketplace for Ideation , Technology , and Discovery .
Gone are the days of a traditional expo hall and instead in 2014 you’ll find a centralized hub for
networking, tech, ideation, and innovation. Go to pages 6-7 for details on the new Ideation Stations
and Innovation Theatre being added to provide you direct access to game changers.

4. Introduction of .
Known globally as the most advanced solution for helping attendees generate connections that matter,
partneringONE® now has a home at Partnerships 2014—and will not be found at any other clinical trial
event. This best-in-class tool will help you efficiently engage with potential partners and conduct more faceto-
face meetings here than in the rest of the year, saving countless hours and dollars while jumpstarting your
next big strategic partnership.

5. ROI That ’s Tangible For You and Your Team.
Every session will wrap with at least three key takeaways or action items for you to take back to your office
and implement with your team. We’ll aggregate and summarize these takeaways into a toolkit that will
become your handy go-to-reference, increasing the ROI of attending Partnerships 2014 every
time you reach for it!
With all these exciting additions to the program for 2014, we invite
you and your team to attend IIR’s Partnerships in Las Vegas!

Jack is speaking on the following:

Partnering with Patients: What Do You Need From Each Other?

The patients of today are smart, informed and actionable for their
own health decisions. When it comes to engagement in clinical
trials, are pharmaceutical executives getting it right or are we
leaving a huge amount of resources on the table? Patients and
pharmaceutical executives come together to have a candid
conversation on what they need from each other to push the clinical
trials industry forward

Friday, February 28th, 2014

National Institutes of Health NIH Rare Disease Day - 08:00 AM
National Institutes of Health 6701 Democracy Boulevard
Bethesda, MD 28092
USA
301 402 4336 [map]
Price: .00 Pre-registration required

The National Institutes of Health (NIH) celebrates the seventh annual Rare Disease Day with a day-long celebration and recognition of the various rare diseases research activities supported by the NIH Office of Rare Diseases Research, the NIH Clinical Center, other NIH Institutes and Centers; the Food and Drug Administration’s Office of Orphan Product Development; other Federal Government agencies; the National Organization for Rare Disorders; and the Genetic Alliance. Rare Disease Day at NIH will be held in the Masur Auditorium (Building 10) from 8:30 a.m. to 5:00 p.m. on Friday.

Rare Disease Day was established to raise awareness with the public about rare diseases, the challenges encountered by those affected, the importance of research to develop diagnostics and treatments, and the impact of these diseases on patients' lives. The focus of Rare Disease Day 2010 was 'Patients and Researchers, Partners for Life!' and is aligned with ORDR's philosophy that researchers need to work closely with patients and patient advocacy groups to maximize chances for success. This philosophy has been put into practice in our very successful Rare Diseases Clinical Research Network.

Jack Whelan is presenting a poster and making a presentation that encourages all cancer patients to explore new molecular targeting agents available in Clinical Trials as a potentially safer more effective treatment option rather than conventional chemotherapy. There are far too many myths and misconceptions about Clinical Trials.  We are entering the era of more precision, Personalized Medicine.  Time to think differently.

 

 

Tuesday, February 25th, 2014

Rare Disease Legislative Conference & Lobby Day, meet with Congressmen, Washington DC
Legislative Conference and Lobby Day - 08:00 AM
750 9th St. NW Suite 750
Washington, DC 20001
USA
202 803 6047 [map]
Price: Invitation only

Rare Disease Legislative Advocates (RDLA) is a collaborative organization designed to support the advocacy of all rare disease groups.

Our goal is to empower the individual to become an advocate!

By growing the patient advocacy community & working collectively we can amplify our many voices to ensure rare disease patients are heard in State & Federal Government.

RDLA provides:

  • DC Office with workstation & meeting space for organizations to use when working in DC
  • Consulting on legislative and grassroots strategies
  • Online advocacy tools to contact Members of Congress
  • Assistance with coalition building and support for legislation
  • Coordination of Lobby Days & Congressional Caucus Briefings
  • Conference calls/meetings to learn about legislation
  • Clearinghouse of all legislation that affects rare disease patients

RDLA is for  rare disease organizations or individuals who are or who want to be legislative advocates.

RDLA is open to all members of the rare disease community with an interest in sharing ideas and advocating for the introduction or enactment of legislation. RDLA was created as a clearinghouse of ideas designed to bring together rare disease organizations active on the Hill to share information around common causes.  It does not promote any specific policy, but provides support to all rare disease organizations seeking introduction/enactment of legislation. RDLA meetings and the website are an educational resource and a platform for individual organizations to promote their legislation.

Monday, February 10th, 2014

Thermo Fisher Scientific Companion Diagnostics Training Week
Jack attending and is Dinner Keynote Speaker
Cambridge, MA 02141
USA [map]
Price: Invitation only

Wednesday, January 29th, 2014

2014 MassBio Policy Leadership Breakfast - Boston, MA
2014 MassBio Policy Leadership Breakfast - Boston, MA - 07:30 Registration
Omni Parker House 60 School Street
Boston, MA 02210
USA
508.530.3000 [map]
Price: By Invitation

Welcome Address by Geoff MacKay, President and CEO, Organogenesis, Inc., Chairman, MassBio Board of Directors and Robert Coughlin, President and CEO, MassBio

 

Opening Remarks:   The Honorable Martin J. Walsh, Mayor, City of Boston  


Panel Discussion:  

The Value of Medical Innovation in an Era of Cost Containment 

  

Please join us for a lively and timely panel discussion on medical innovation and its relation to and impact on health care cost containment. Can the two co-exist? Will the focus on cost hinder patient access? Will the innovative therapies and technologies developed here in Massachusetts actually drive down the cost of healthcare. We will hear from experts from the state and federal level on efforts to get a handle on the ever-rising cost of healthcare, as well as new approaches to ensure patients receive quality care and break though therapies. In addition, our panelists will include representatives from the life sciences industry, health care providers, payers, and patients.  

 

  • Robert J. Beall, Ph.D., President  & CEO, Cystic Fibrosis Foundation
  • David M. Cutler, Professor of Applied Economics, Department of Economics and Kennedy School of Government, Harvard University
  • Andrew Dreyfus, President & CEO, Blue Cross Blue Shield of Massachusetts
  • Geoff MacKay, President and CEO, Organogenesis and Chairman, MassBio
  • Elizabeth Nabel, MD, President, Brigham and Women's Health Care
  • Martha Bebinger,

Health Reporter, WBUR (Moderator)  

2014 MassBio Policy Leadership Award Presentation

Recognition of Nick Littlefield

Saturday, January 4th, 2014

Dana-Farber/Brigham and Womens Cancer Center Open House for Faulkner Hospital Patients
Dana Farber/Brigham and Womens Open House for Faulkner Hospital Patients and Families - 02:00 PM
459 Brookline Avenue
Boston, MA 02215
USA [map]
Price: Please pre-register

Jack is Master of Ceremonies

Presentation and remakrs from Craig Bunnell, MD, MPH, MBA, Chief Medical Officer, and
Anne Gross, PhD, RN, FAAN, Viceo President Adult Nursing and Clinical Serices.
RSVP Mark your calendar and tell us how many in your party by Friday, Dec. 20, to
shannon_watterson@dfci.harvard.edu or 617 582 8618617 582 8618

Friday, December 6th, 2013

American Association for Cancer Research, Science of Cancer Health Disparaties, Atlanta GA
Science of Cancer Health Disparaties AACR - 08:00 AM
Sheraton Atlanta Hotel
Atlanta, GA
USA
1-866-423-3965 [map]
Price: $1095

The AACR Cancer Health Disparities conferences are recognized as major gatherings that advance the understanding and, ultimately, help to eliminate the disparities in cancer that represent a major public health problem in our country. By promoting the exchange of novel ideas and information between a wide range of professionals from academia, industry, government, and the community, these conferences harness the potential and maximize the many opportunities for bringing research on health disparities from bench to bedside or community, and back again. The goals of these conferences have been to bring together scientists and other professionals working in a variety of disciplines to discuss the latest findings in the field and to stimulate the development of new research in cancer health disparities.

 

 

Thursday, December 5th, 2013

Drug Information Association (DIA) Patient Advocate Fellowship Alumni Program - Featuring Jack Whelan
Drug Information Association Patient Advocate Fellowship Alumni Program - 02:00 PM
Web conference
Boston, MA 02109
USA
completed [map]
Price: .00

Jack has participated in many clinical trials, essentially along the road under construction towards Personalized Medicine.  It has been a bumpy but promising road.  Much work remains but the task at hand is well understood and scientists are encouraged and optimistic about the promise of Personalized Medicine, the right medicine for the right patient at the right time.   

There are a variety of novel targeting agents currently in development and in Clinical Trials.  As Jack’s is a rare incurable blood cancer and the historical outcome for borrowing conventional chemotherapies from other blood cancers is not all that exciting, rather than becoming part of that history, Jack believes there’s sufficient evidence that one of the emerging targeting agents will help him achieve Progression Free Survival, perhaps a cure.   

Jack will present a fun informative, helpful, hopeful presentation (with some humor that has served him, his family and caregivers well) that summarized his treatment options and how this survivor is moving from his career and an IT Research Analyst to Research Advocate in connection with education and support services from DIA, AACR and ASCO patient advocacy programs.

Thursday, December 5th, 2013

Drug Information Association Patient Advocate Fellowship Alumni Program -Webex
Patient Advocate Fellowship Alumni Jack Whelan Cancer Today Magazine story - 2:00 PM ET
www.diahome.org
Boston, MA 01810
USA
866-668-0721 code: 460 661 4178 Meeting: 358 263 851 Password: JackWhelan [map]
Price: .00

 

Looking for a solution with his hematologist to treat/manage a rare, incurable blood cancer, Jack has participated in many clinical trials, essentially along the road under construction towards Personalized Medicine.  It has been a bumpy but promising road.  Much work remains but the task at hand is well understood and scientists are encouraged and optimistic about the promise of Personalized Medicine, the right medicine for the right patient at the right time.   

There are a variety of novel targeting agents currently in development and in Clinical Trials.  As Jack’s is a rare incurable blood cancer and the historical outcome for borrowing conventional chemotherapies from other blood cancers is not all that exciting, rather than becoming part of that history, Jack believes there’s sufficient evidence that one of the emerging targeting agents will help him achieve Progression Free Survival, perhaps a cure.   

Jack will present a fun informative, helpful, hopeful presentation (with some humor that has served him, his family and caregivers well) that summarized his treatment options and how this survivor is moving from his career and an IT Research Analyst to Research Advocate in connection with education and support services from DIA, AACR and RAN-ASCO patient advocacy programs.

Call: 1-866-668-0721
Enter code: 460 661 4178

Meeting Number: 358 263 851
Meeting Password: JackWhelan

Thursday, December 5th, 2013

2013 French-American Innovation Day at Harvard Medical School Boston
2013 French American Innovation Day - 07:30 AM
Harvard Medical School, Joe. B Martin Conference Center 77 Avenue Louis Pasteur
Boston, MA 02115
USA [map]
Price: Invitation only

The French American Innovation Day (FAID) is an annual French American seminar gathering scientists, industries and investors in state-of-the-art technologies. The aim of this event, organized by the Office of Science of the Embassy of France in U.S. is to:

  • point up the French and American high level researches and connection
  • pave the way for new collaborations between France and the USA
  • explore the latest researches

USA and France will analyse and enhance innovation in Life Sciences as an economic force for growth 

Bearing the title “Innovation in Life Sciences as a Driver for Growth” , the seminar breaks down into 2 days:

  • The first day with four thought-provoking roundtable sessions, each addressing relevant issues and sharing best practices in life sciences innovation and transatlantic partnerships ;
  • The second day will be dedicated to presentations of innovative American and French start up companies to the financial and biopharmaceutical communities for funding and collaboration; with the help of two accomplished scientific directors,
  • Dr. Christophe Benoist, Professor of Microbiology and Immunology at Harvard Medical School, Member of the French Académie des Sciences and the US National Academy of Sciences
  • Dr. Joshua Boger, founder of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and the Executive Chairman of Alkeus Pharmaceuticals

    The 2013 FAID is designed by and for the stakeholders in R&D, technology transfer, strategic alliances and funding/venturing in Life Sciences from both countries. 

Friday, November 22nd, 2013

2013 NCCN Patient Advocacy Summit, National Press Club, Washington DC
2013 NCCN Patient Advocacy Summit - 09:00AM
National Press Club
Washington, DC 20045
USA
202 662 7500 [map]
Price: By Invitation only

The National Comprehensive Cancer Network (NCCN) Patient Advocacy Summit: Health Care Reform in 2013 and Beyond will be held on Friday, November 22, 2013 at The National Press Club in Washington, D.C. from 9:30 AM until 3:05 PM. 

The 2013 NCCN Patient Advocacy summit will bring together oncology patient advocacy groups, patients, providers, payors, policy-makers, congressional staffers, industry, and employers to review and discuss the implementation of certain aspects of the Affordable Care Act and their effects on patients with cancer and their caregivers. Topics for review and discussion include the definition of essential health benefits and the impact on cancer patients, state health insurance exchanges, access to different types of insurance (Medicaid, employer-sponsored, exchanges), and new care models.

This policy summit will be opened by remarks from Tracie Cone, a cancer survivor and writer for the Associated Press, followed by a presentation from Susan Dentzer, Senior Policy Advisor to the Robert Wood Johnson Foundation. The program will be moderated by Dr. Clifford Goodman of the Lewin Group.Roundtable panelists will come from such organizations as America’s Health Insurance Plans, American Cancer Society Cancer Action Network, Enroll America, and Patient Advocate Foundation. With your participation, we can work towards our shared mission to improve oncology practice so that patients can live better lives.

Monday, November 18th, 2013

PhRMA Task Force Meeting - UMass Club, Boston MA - Jack is Luncheon Speaker
PhRMA Task Force Luncheon Meeting, UMass Club Boston - 11:30 AM
University of Massachusetts Club, Lowell Room, 225 Franklin Street
Boston, MA 02211
USA [map]
Price: By Invitation

Jack is luncheon speaker, describing his benefiting from participating in a variety of clinical trials of novel agents and his becoming a Research Advocate and Legislative Advocate for Patients, Caregivers, Family, Life Sciences and Healthcare.

 

 

Wednesday, November 13th, 2013

Leukemia & Lymphoma Society - Research Reception at the Boston College Club
The Leukemia & Lymphoma Society Research Update - Boston College Club - 6:30 PM
The Boston College Club - 100 Federal Street 36th Floor
Boston, MA 02109
USA [map]
Price: By Invitation

An update on the current state of activities to accelerate the cures of blood cancers from distinguished, internationally recognized researchers. 

Edwin Alyea, M.D.  Associate Director, Bone Marrow / Stem Cell Transplantation Program, Dana Farber / Brigham & Women's Cancer Center

Noopur Raje, M.D. Rita Keley Chair in Oncology, Massachusetts General Hospital, Director, Multiple Myeloma Program, MGH Associate Professor, Department of Medicine, Harvard Medical School, LLS Clinical Scholar

Wednesday, November 13th, 2013

WORLD CDX Boston 2013 - 08:00AM
Colonade Hotel, 120 Huntington Avenue
Boston, MA Boston
USA [map]
Price: $3995 with special options

The definitive meeting for powering theraputic and diagnostic collaboration is returning to Boston.  World CDx 2013 is back to deliver 50+ expert speakers from across the personalized medicine field in order to "fast-track your companion diagnostic programs".

World CDx puts the latest genomic technologies in the limelight.  We evaluated the applications and techniques of 'omics' to empower patient stratification and strengthen your biomarker strategies.

This year World CDx will help you improve the translation of your predictive biomarkers into the clinic with effective validation and explore the increasingly attractive alternatives to tissue biopsies.

As a patient with repeated need for bone marrow biopsies, I am in the ranks of thousands of blood cancer patients personally interested particularly in alternatives to tissue samples.

Jack Whelan 

Tuesday, November 12th, 2013

PhRMA and Chamber of Commerce News Conference, UMASS Medical Center, Worcester MA
Research in Your Backyard: Pharmaceutical Clinical Trials in Massachusetts - 11:00AM
University of Massachusetts Medical Center
Worcester, MA 01655
USA
508 856 8989 [map]
Price: .00
 

Worcester, MA (November 12, 2013) – Working with Massachusetts research institutions, including several facilities in Worcester, the nation’s biopharmaceutical research companies have conducted 4,710 clinical trials of new medicines in the state over the last 14 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Biopharmaceutical research companies have conducted nearly 500 clinical trials of new medicines in Worcester over the past 14 years, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Eighty-four of the more than 700 trials added throughout Massachusetts since 2012 have taken place in Worcester, the report found. Nearly 40 of the current Worcester trials target chronic diseases such as cancer, heart disease, stroke and diabetes.

"Clinical research in Central Massachusetts allows our researchers to be involved in the development of important new medicines for patients," said Tim Murray, president of the Worcester Regional Chamber of Commerce, in a statement. "Clinical trials have benefited such institutions as the UMass Medical School, Reliant Medical Group at Worcester Medical Center and Saint Vincent Hospital." 

The new report was released today by PhRMA and the Worcester Regional Chamber of Commerce at a news conference.  Conference speakers included former Massachusetts Lt. Gov. Tim Murray, the new president and CEO of the Worcester Regional Chamber of Commerce, Dr. Margaret Koziel, a senior clinical researcher at the University of Massachusetts Medical School, Jack Whelan, the survivor of a rare blood cancer, a Leukemia & Lymphoma Society volunteer and strong advocate of clinical trials and research, and PhRMA spokesman Jeff Trewhitt, co-author of the report.  

 

Tuesday, October 22nd, 2013

Testify at Massachusetts State House on State Guidelines on Biosimilars for substituting of switchable medicines for cancer patients.
Testify in support of Legislation on Biosimilars that protects patients and pharmaceutical - 1:00PM
State House 24 Beacon Street
Boston, MA 02133
USA
617 722 2000 [map]
Price: .00

Jack is testifying in support of House Bill H.3667 a policy change centered on the FDA approved biosimilar and interchangeable biologic products in the treatment of cancer patients.  Patient safety must come first.   Similar medication is not the same, it is only similar.  Similarities in biologics have a very wide range thus the implications of safety and effectiveness are very wide.  

 

 

Tuesday, October 22nd, 2013

Dana Farber Patient Family Advisory Council, held at Yawkey Center at DFCI, Boston MA
Patient Family Advisory Council Meeting - 5:30
450 Brookline Avenue
Boston, MA 02210
usa
877 442 3324 [map]
Price: .00

Regular meeting of the Dana Farber Cancer Institute Patient Family Advisory Council (PFAC) meeting.  This meeting is a joint session of Adult and Pediatric councils.  Some recent organizational restructuring took place at Dana-Farber to provide patients and families with improved access to resources.  One outcome was the formation of a new division entitled “Patient and Family Programs and Services (PFPS),”  information about which will be presented in detail at the October joint PFAC meeting.

Saturday, October 19th, 2013

Living with Blood Cancer: During Treatment and Beyond
Living with Blood Cancer: During Treatment and Beyond - Boston, MA - 12:00 Noon
Massachusetts General Hospital, O'Keefe Auditorium 55 Fruit Street
Boston, MA 02114
USA
508 810 1308 [map]
Price: no charge

AGENDA

12:00-1:00 pm          Networking lunch with other patients and families living with blood cancer

 1:00-2:15 pm           Updates in blood cancer treatment/clinical trials - MGH Cancer Center physicians

2:15-2:30 pm            Break

2:30-3:30 pm            Quality of life panel presentation - Panel of MGH experts

3:30- 4:00 pm          Sharing our experiences - Patient/Caregiver Panel

 

Registration is required for this program. Please register by calling Lynne Morin at 508-810-1308508-810-1308 or email lynne.morin@lls.org.

Wednesday, October 16th, 2013

Testify at Massachusetts State House on Healthcare insurance policy on Step Therapy and Specialty Tiers Legislation
Testify in support of Legislation S.477 and S.439 - 1:00PM
State House 24 Beacon Street
Boston, MA 02133
USA
617 722 2000 [map]
Price: .00

Jack is testifying along with Leukemia & Lymphoma Society and other leading Advocacy Groups speaking in favor of two important pieces of legislation that correct health insurance policy failures.   The first Step Therapy or "fail first" requires patients to try the lowest cost medication or prescription before being allowed to take the drug prescribed by his/her physician.  This is a foolish policy, aka "fail first" because it actually costs everyone more,   The individual price per pill doesn't reflect the true cost to all when you consider it may not be safer or more effective, the patient must get a new prescription when decline at the pharmacy, a waste of time for the patient, the physician and the pharmacist.  This bill costs the Commonwealth of Massachusetts and taxpayers nothing. 

The second bill is about fixing another serious inequity and unnecessary and unfair additional healthcare cost for patients that require certain Class IV drugs, typically expensive "pill form" chemotherapy or other druges for serious illness.  Presently, insurance companies can require patients to pay up toa 30% co-insurance (no the familial co-pay) but actually 30% of the cost of the medication which for many patients can be well over $1000 per month out of pocket.  After a lifetime of paying healthcare insurance premiums, it is not fair that insurance companies have instituted this shell game attempting to lower their costs, putting the burden squarely on patients who pay premiums for fair coverage. 

Jack is a strong voice speaking in support of legislation S.477 and S.439 that eliminate these inequities. 

Wednesday, October 16th, 2013

Optimizing Clinical Research Performance - Las Vegas, Jack is speaking, presenting the patient advocate perspective
Optimizing Clinical Research Performance - 09:00 AM
The Venetian
Las Vegas, NV 89109
usa
702 414 1100 [map]
Price: $1695.00

Building on the overwhelming success of its inaugural spring 2013 Conference in Boston, CenterWatch and iiBIG's faul 2013 forum in Las Vegas will continue to focus on innovative strategies and cutting-edge solutions to optimize clinical research performance and drive future success through novel collaboration and competitive differentiation. 

With more than 50 workshops, panel sessions and roundtable discussion, including 20+ NEW topics for the Fall Program, this conference brings together leaders from across the clinical research industry and offers hard-hitting, high quality, relevant presentations based in large part on the strategic, data-driven and substantive reports and market analyses from TheCenterWatch Monthly and CWWeekly publications.  

Three primary tracks include, Innovative Strategies, Operating Practices and Efficiences and Effective Oversight and Regulation.

Friday, September 27th, 2013

Lymphoma Research Foundation 18th Annual Educational Forum, New York
18th Annual Educational Forum on Lymphoma - 2:00 PM
New York Marriott at the Brooklyn Bridge
New York, NY 11201
USA
800 500 9976 [map]
Price: $100

The North American Educational Forum on Lymphoma is the most comprehensive lymphoma-specific educational conference in North America.  The two and a hlaf day annual program provides critical information on treatment options, patient support issues, clinical trials and the latest advances in lymphoma research to people with lymphoma and their caregivers.

Hear a variety of presentations and have your specific questions answered by our expert speaking faculty comprised of lymphoma specialists and patient support experts from around the world.  Be sure to check this comprehensive agenda. I highly recommend this one!   

Thursday, September 26th, 2013

Testify at Massachusetts State House - Step Therapy (Fail First) Legislation
Testify at MA State House in support of correcting Step Therapy policy from providers - 1:00 PM
Commonwealth of Massachusetts State House
Boston, MA 02108
USA [map]
Price: No charge

Patient advocacy lobby day on September 26th from 1:00-3:00 p.m.

LLS is spearheading a group of key partners from other organizations who are also interested in the Step Therapy and Specialty Tiers legislation passing. They range from The Multiple Sclerosis Society to the Pain Foundation, all groups who struggle with similar issues blood cancer patients face when it pertains to access to care. They will also be attending that day with their volunteers and it is our hope that together we can show our legislators how important these issues are to patients in Massachusetts living with chronic and rare diseases.  

We will be meeting together at 1:00 p.m. for an update on the legislation and to go over our “ask” for the day. We will then be breaking off into groups to have visits around the State House with key legislators.

Jack will give testimony about Step Therapy and Specialty Tiers negatively affects cancer patients with othjers with chronic illness.

Wednesday, September 25th, 2013

Atlas Venture Annual Meeting, Jack is speaking on cancer survivorship topics, new molecular agents, personalized medicine - 8:30AM
60 State Street
Boston, MA 02210
USA [map]
Price: Invitation only

Atlas Venture L.P. is a venture capital firm specializing in investments startups, seed, and early stage companies. It seeks to invest in the technology and life sciences sectors with a focus on personalized medicine, medical technologies, therapeutics, biopharmaceutical products, biology, drug discovery technologies, therapeutic platforms, innovative biomedical technologies, diagnostics, and medical devices. Within technology, the firm focuses on payments, SMB, consumer-facing innovation, emerging web service companies, next-generation media, gaming, and social technologies, enterprise and internet infrastructre, big data and mobile infrastructure, and internet related businesses.

Wednesday, September 25th, 2013

Clinical Collaboration Congress, Partnerships in Clinical Trials, Boston MA
Clinical Collaboration Congress - 08:00AM
Seaport Hotel, 200 Seaport Boulevard
Boston, Massachusetts 02210
USA
9782730480 [map]
Price: $2895.

Clinical Collaboration Congress - Where Pharma, CROs & Labs converge to Fast Track Clinical Research.

"The pharmaceutical industry has to be smarter about how it's doing business by getting more drugs to market while spending less.  This requires shifting the business models and partnering paradigms for the industry to be sustainable long term, while enabling the development of new improvements and solutions to today's clinical processes.  The organizers of the leading Partnerships in Clinical Trials events are proud to present the all-new Clinical Collaboration Congress (CCC), an interactive event experience for the clinical leaders to collaborate with peers on how to chance the way the industry does business.  Forward-thinking collaborative minds combine with interactive discussions that make you part of the learning experience for the highest level of engagement.

Collaboration is key.  CCC is the only event with a focus on cross-industry collaboration, consortia and new partnering paradigms to challenge the current clinical development model.

Location, location, location.  We're in biotech's backyard, so you'll travel less - or not at all, but get 3 days of content and networking.

Smaller is better.  Don't get lost in the crowd.  CCC brings you a dedicated track and pre-conference summit to address specific issues burdening small to mid-size pharmaceutical, biotech and medical device companies.

The only place to meet all of your Labs' vendors under one roof.  We're bringing back the Partnering with Labs track and the Logistics Task Force where stakeholders will tackle the biggest cost drivers and quality killers impacting clinical logistics.                                                                                                                                                                                                                                                                                                                                                       

Tuesday, August 27th, 2013

WEEI/NESN Jimmy Fund Radio-Television Telethon for Dana Farber Cancer Institute, Boston
WEEI/NESN Radio-Television Telethon with Boston Red Sox - 06:00AM
Fenway Park, Home of the Boston Red Sox
Boston, MA 02110
USA
1 800 52 JIMMY [map]
Price: .00

Call 877-738-1234 to make a donation or click here to make a gift.  

This is perhaps one of the most meaningful charities for me personally.  I hope to make this my third year volunteering working with the outstanding professionals at WEEI, NESN, The Boston Red Sox organization and Dana Farber Cancer Institute.  This is a two day, telethon which raises a considerable amount of money from across the country to help Dana Farber Cancer Institute in its continued quest for exceptional care, research and cure of a variety of cancers.  

For more details about this incredible fundraising effort, please click here, now.

Take a look at this great info, there is plenty of time to volunteer and get involved now.  You won't regret it.

Thanks,

Jack

Saturday, August 24th, 2013

IMF Philadelphia Patient & Family Seminar - 09:00 AM
Westin Philadelphia Hotel
Philadelphia, PA
USA
215 563 1600 [map]
Price: $85.00

Friday: Quality of Life Speakers, Mike Katz, Member of the IMF Board of Directors - Saturday General Session: Dr. Brian Durie, Cedars-Sinai CCC  August 23 - 24, 2013  Check in is 3 PM Check out is noon.  at the Westin Philadelphia Hotel.

Sunday, August 18th, 2013

ESCAPE Encouraging and Sustaining Cancer Advocacy Programs and Efforts, Tuscon AZ
ESCAPE - Cancer Advocacy Leadership Conference - 12:00
Cancer Advocacy Leadership Conference at Miraval
Tuscon, AZ 85739
USA
520 575 9602 [map]
Price: Priceless

ESCAPE 2013 is Encouraging and Sustaining Cancer Advocacy Programs and Efforts a very special by invitation only Cancer Advocacy Leadership Conference; this is the third annual conference managed by bagit4u.org which will be held on Sunday August 18 through Thursday August 22, 2013.

Tuesday, August 13th, 2013

Lymphoma Research Foundation - Ask the Doctor, Boston, MA
Updates on Lymphoma Treatment Options - 6:30 PM
Marriott Courtyard Boston Downtowm
Boston, Massachusetts 02115
USA
800 500 9976 [map]
Price: .00

This program is offered free-of-charge t all members of the lymphoma community, pre-registration is required.  Andrew M. Evans, D.O., M.Sc. Professor of Medicine, Chief of Hematology/Oncology at Tufts University School of Medicine has a fabulous program that presents a Lymphoma Overview, Treatment Options, Research Updates and Q&A Session.  Dinner will be provided for all registered attendees.  

Sunday, June 23rd, 2013

DIA 2013 Drug Information Association, Global Forum for Therapeutic Innovation, Boston MA
DIA 2013 Advancing Therapeutic Innovation and Regulatory Science - 08:00AM
Boston Exhibition and Convention Center
Boston, MA 02210
Uni
215 293 5817 [map]
Price: $1350 with special options

Key Topics include 22 Tracks and 250+ Offerings.

Learn practical solutions and participate in expert discussions on today's hottest topics: Big Data, Biosimilars/Follow-on Biologics, Data Standardization, Drug Shortages, Electronic Health Records, Electronic Medical Records, Ethical issues in Clinical Trials, Medical Devices, mHealth, Multi-regional Clinical Trials, New Models of Innovation, Orphan Drug Development, Patient/Caregiver Engagement, Patient Recruitment and Recruitment Strategies, Personalized Medicine, Tailored Therapies/Companion Diagnostics, Pricing and/or reimbursement, Quality by Design Strategies, Rare/Orphan diseases, Regulatory Strategy/Science, Risk Evaluation and mitigation strategy, Safety Regulations, Social Media, Special Populations, Strategic Planning, Unmet Medical Needs and More.....

Saturday, June 22nd, 2013

MMRF Clinical Insights in Multiple Myeloma patient symposia Boston, MA
Clinical Insights in Multiple Myeloma patient symposia, Boston, MA - 9:00
None yet
Boston, MA 02210
USA [map]
Price: .00

The MMRF provides educational programs for people with myeloma, family members and caregivers to learn about the latest disease and treatment information. These programs are developed in collaboration with top myeloma centers across the country.


Clinical Insights in Multiple Myeloma patient symposia

Patient education symposia and workshops that provide the latest information about multiple myeloma, current treatment options, clinical trials, and optimal disease management. The MMRF conducts these educational programs in collaboration with top myeloma cancer centers across the country.

Thursday, June 20th, 2013

Leukemia & Lymphoma Society 28th Annual Volunteer Appreciation Night, Boston MA
28th Annual Appreciation Night An Evening of Tribute to Volunteers - 06:00 PM
Renaissance Waterfront Hotel
Boston, MA 02210
USA
508 810 1305 [map]
Price: By Invitation

The Leukemia & Lymphoma Society Massachusetts Chapter will hold its 28th Annual Volunteer Appreciation Night at the Renaissance Waterfront Hotel in Boston on June 20th.  This is an opportunity for the chapter to recognize volunteers from this area and thank them for their valuable work on behalf of blood cancer patients and caregivers across the USA.   LLS is one of the most productive of advocacy organizations that attributes much of its success to the talents of a powerful volunteer force. 

Monday, June 17th, 2013

Institute of International Research Oncology Management Summit, Chicago IL Jack speaking on Quality Care
IIR's Ongology Management Summit - 09:00
The Wit Hotel
Chicago, IL 60636
USA
646 895 7337 [map]
Price: $1995.00

The Institute for International Research Oncology Management Summit held this year on June 17 and 18 in Chicago, IL brings together puiblic and private payer, providers and provider organizations, health systems, patient groups, pharmaceutical companies, employers, policy makers, PBMs and specialty pharmacy to strategize and exchange ideas about how to most effectively manage costs while improving quality and effectiveness of cancer care.

Jack is speaking from a patient perspective How Do You Evaluate and Measure Quality of Care in Oncology

Friday, May 31st, 2013

ASCO American Society of Clinical Oncology Focus on Research Scholar Program
2013 ASCO Annual Meeting Focus on Research Scholar Program - 09:00
McCormick Place
Chicago, IL 60636
USA
703 449 6418 [map]
Price: $2395.

Attendees at the ASCO Annual Meeting find cutting edge scientific presentation and comprehensive educational content. A great opportunity to network with medical professionals centered on oncology.  The Annual ASCO meeting brings together more than 25,000 oncology professionals from around the world representing a broad range of specialties making it an excellent venue for exploring the theme of this year's meeting - Building Bridges to Conquer Cancer. 

Jack is attending as a Research Advocate participating in the Research Advocacy Network managed ASCO Focus on Research Scholar Program.  

Thursday, May 23rd, 2013

Leukemia & Lymphoma Society Man and Woman of the Year
LLS Man & Woman of the Year - 7:00PM
The Taj
Boston, MA 02210
USA
508 810 1300 [map]
Price: $100 - $1000

The Massachusetts Chapter of the Leukemia & Lymphoma Society is conducting its annual Man and Woman of the Year event at The Taj, 15 Arlington Street Boston. 

Friday, May 17th, 2013

International Waldenstrom's Macroglobulinemia Foundation 2013 Ed Forum - 9:00
Westin San Diego Hotel
San Diego, CA 92101
USA
6178205145 [map]
Price: $295

IWMF's annual Educational Forum is a unique opportunity for patients and caregivers to learn about our disease from specialists in Waldenstrom’s macroglobulinemia (WM) who are involved in many areas of clinical practice and research. Held in a different part of the United States every year, the “Ed Forum” offers something for everyone, no matter what your experience or level of knowledge.


Presentations aimed at the layperson address symptoms and complications of the disease, current treatment options, new therapies on the horizon, and recent research findings that may someday lead to a cure. Breakout sessions permit in-depth exploration of specialized topics and opportunities for patients and caregivers to share their experiences in a safe and supportive environment.


Every Ed Forum is different, but “Early Bird” sessions typically begin on Friday morning and presentations continue through Saturday, culminating on Sunday morning with a popular “Ask the Doctor” session where patients can have their questions answered by a panel of experts.


Attending an Ed Forum in person is the best way to benefit from the program, but most sessions are videotaped and recorded on a set of DVDs for the benefit of those who cannot attend or those who simply want to reinforce their learning experience.  For information regarding DVD's, contact the IWMF Office at info@iwmf.com.

Monday, April 8th, 2013

Rally for Medical Research, Supporting NIH Funding, Washington DC
Rally for Medical Research - 11:00AM
Carnegie Library at 801 K Street
Washington, DC 20001
USA [map]
Price: no charge

Nearly 200 partnering organizations and thousands of people with millions more engaged in advocacy activities across the country will participate.  The Rally for Medical Research program is moderated by well-known TV personality Cokie Roberts featuring actress Maura Tierney, Members of Congress, patients and their families.

Jack is attending as a Cancer Warrior/Research Advocate. 

Saturday, April 6th, 2013

American Association for Cancer Research Annual Meeting 2013- - 8:00 AM
Walter E. Washington Convention Center
Washington, DC 20001
USA
215 440 9313 [map]
Price: Invitation and Membership only

Jack has been selected to participate in the Scientist - Survivor Program during the 2013 AACR annual meeting from April 6-9.

The American Association of Cancer Research annual meeting 2013 takes place Saturday, April 6 - Wednesday, April 10, 2013, at the Walter E. Washington Convention Center in Washington, D.C. It has been said around the world that the AACR Annual Meeting drives the cancer agenda.

This meeting brings together the best and latest findings in all major areas of cancer research. Through plenary sessions, symposia, forums, educational sessions, methods workshops, poster presentations, conversations with experts and networking, attendees walk away with a wealth of new information, more connections and renewed energy, inspiration and focus in their work.

Saturday, April 6th, 2013

AACR American Association for Cancer Research, Annual Meeting 2013, Washington
American Association for Cancer Research 2013 Annual Meeting - 08:00 AM
Walter E. Washington Convention Center
Washington, DC 20001
USA [map]
Price: Invitation only

This meeting brings together the best and latest findings in all major ares of cancer research.  Attendees come away with a wealth of new information concerning research, care and cure for a variety of cancers, more connections with people focused on cancer solutions and a general infusion of relevent information about what's happening in research labs and clinical research.

The American Association of Cancer Research annual meeting 2013 takes place Saturday, April 6 - Wednesday, April 10, 2013, at the Walter E. Washington Convention Center in Washington, D.C. It has been said around the world that the AACR Annual Meeting drives the cancer agenda.

This meeting brings together the best and latest findings in all major areas of cancer research. Through plenary sessions, symposia, forums, educational sessions, methods workshops, poster presentations, conversations with experts and networking, attendees walk away with a wealth of new information, more connections and renewed energy, inspiration and focus in their work.

Saturday, March 23rd, 2013

Massachusetts Lymphoma Workshop - 07:30 AM
Sheraton Needham Hotel 100 Cabot Street
Needham, MA 02494
USA
781 441 1110 [map]
Price: .00

Learn about your specific type of lymphoma, side effects of treatment, clinical trials and new therapies under development during comprehensive disease specific sessions.  Hear a variety of presentations and have your specific questions answered from an expert peaking faculty comprised of lymphoma specialists and experts.  Meet other people with your same type of lymphoma during breakfast, lunch and breakout sessions.  Hope to meet you here.  Jack

Thursday, March 21st, 2013

Enhancing Access to Clinical Trials - Ensuring Equal Access to Cancer Research - 3:30PM (ET)
http://www.enacct.org
On line Webinar from Bethesda, MD 20814
USA
301 893 7603 [map]

Part of ENAACT's Clinical Trials Training series.   Join me and ENACCT's Clinical Trial Training team, Bertie Ford, RN Genentech and Jacqueline Dieball, MPH, Dept. Organizational Effectiveness at the University of Michigan. I'm adding the e-Patient's perspective "Trials Participant Reflections". 

To reduce access barriers to cancer clinical trials, enhanced capacity of clinical research staff is needed to take into account a number of challenges they face to optimally and efficiently recruit patients to studies.  These challenges come from outside the oncology practice (how to work with community providers to enhance the flow of patient referrals, especially among ethnic and racial minorities) and within the practice (how to ensure patients are systematically screened for eligibility and offered trial participation with cultural sensitivity).  Despite these challenges, cultural competency training that specifically relates to the research setting is not widely available.

Objectives:

- Explain the rationale for patient-centered care in the Clinical Trial setting

- Describe ENACCT cultural competency training activities for oncology professionals

- Discuss training perspectives and outcomes.

Be sure to check this valuable seminar centered on Clinical Trials Access and Competency Training for Physician-Researchers and Research Staff.   A special welcome to my Clinical Trials research and care team.

Jack

 

Friday, January 11th, 2013

American Society of Hematology 2013 Highlights - Newton, MA - 07:30 Registration
Boston Marriott Newton Hotel 2345 Commonwealth Avenue
Newton, MA
USA [map]
Price: $75.00

Offered by Dana-Farber/Brigham and Women’s Cancer Center, the Leukemia and Lymphoma Society, and Harvard Medical School.


Course Overview

Within the last 4-5 years, significant advances in the management of blood cancers have been achieved.  The Annual Meeting of the American Society of Hematology held each December is the venue at which cutting-edge therapeutic advances are presented publicly for the first time.  This one-day CME is intended to share highlights from the meeting and provide attendees with an update on the recent advances in leukemia, lymphoma, multiple myeloma, myelodysplasia, myeloproliferative disorders, coagulation disorders, and stem cell transplantation.

Through lectures and Q&A, attendees will gain an enhanced understanding of emerging treatments available for blood cancers and blood disorders and how these new therapies can be integrated into daily practice.  The course is designed for medical oncologists, hematologists, internists with recently diagnosed patients, nurse practitioners, oncology nurses, and other interested clinicians. 

Learning Objectives

At the conclusion of this course, attendees will be able to:
• highlight the recent medical advances presented at the 2013 Annual Meeting of the American Society of Hematology (ASH), which will help physicians achieve better patient outcomes;
• recognize appropriate management and treatment options for hematologic malignancies and utilize these approaches in routine clinical practice.

ACGME COMPETENCIES:  This course has been designed to enhance one or more of the following Accreditation Council of Graduate Medical Education competencies:  Patient care  Medical knowledge  Practice-based learning and improvement.

About the Center for Hematologic Oncology at Dana-Farber/ Brigham and Women’s Cancer Center

We offer advanced, specialized care for patients with all types of hematologic malignancies, including leukemia and similar bone marrow disorders, lymphoma, multiple myeloma, Waldenstrom’s macroglobulinemia, and other related blood disorders. 

Dana-Farber/Brigham and Women’s Cancer Center is at the forefront of stem cell transplantation, performing more than 500 transplants each year. Our team of specialists are national leaders in basic and clinical research designed to bring cutting-edge, innovative therapies to patients with blood cancers.  The program is committed to working closely with referring oncologists to jointly devise clinical strategies to improve the care of our patients.


Agenda

7:30 am 
Registration and Continental Breakfast 

8:00 am 
Welcome and Introduction
Robert J. Soiffer, MD 

8:15 am 
Lymphoma
Ann S. LaCasce MD 

9:00 am 
Acute Lymphocytic Leukemia (ALL) and Chronic Myelogenous Leukemia (CML)
Daniel J. DeAngelo, MD, PhD 

9:30 am 
Chronic Lymphocytic Leukemia
Jennifer R. Brown, MD, PhD
 
10:00 am
Myeloproliferative Neoplasm (MPN) and Myelodysplastic Syndrome (MDS)
David P. Steensma, MD

10:30 am 
Break 

10:45 am 
Coagulation
Jean M. Connors, MD 

11:30 am 
Multiple Myeloma
Jacob Laubach, MD, MPP
 
12:15 pm
Lunch
 
1:15 pm 
Acute Myeloid Leukemia (AML) and Acute Promyelocytic Leukemia (APL)
Richard M. Stone, MD
 
1:45 pm
Stem Cell Transplantation
Corey S. Cutler, MD, MPH, FRCPC 

2:15 pm 
Closing Remarks 


Faculty

Robert J. Soiffer, MD
Course Director
Chief, Hematologic Malignancies
Co-Chief, Adult Bone Marrow/Stem Cell Transplantation Program
Dana-Farber/Brigham and Women’s Cancer Center;
Professor of Medicine
Harvard Medical School

Jennifer R. Brown, MD, PhD
Director, Chronic Lymphocytic Leukemia Center
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine
Harvard Medical School

Jean M. Connors, MD
Medical Director, Anticoagulation Management Service
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine
Harvard Medical School

Corey S. Cutler, MD, MPH, FRCPC
Medical Oncologist, Adult Bone Marrow/Stem Cell Transplantation Program
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine
Harvard Medical School

Daniel J. DeAngelo, MD, PhD
Medical Oncologist, Adult Leukemia Program
Dana-Farber/Brigham and Women’s Cancer Center;
Associate Professor of Medicine
Harvard Medical School

Ann S. LaCasce, MD
Medical Oncologist, Adult Lymphoma Program
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine
Harvard Medical School

Jacob Laubach, MD, MPP
Medical Oncologist, Jerome Lipper Multiple Myeloma Center
Dana-Farber/Brigham and Women’s Cancer Center;
Instructor in Medicine
Harvard Medical School

David P. Steensma, MD
Medical Oncologist, Adult Leukemia Program
Dana-Farber/Brigham and Women’s Cancer Center;
Associate Professor of Medicine
Harvard Medical School

Richard M. Stone, MD
Program Director, Adult Leukemia Program
Dana-Farber/Brigham and Women’s Cancer Center;
Professor of Medicine
Harvard Medical School

HMS Disclosure Policy

Harvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS’s policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity.  Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.


CME Credits

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credits

Up to 5.0 hours of Continuing Education Credit will be awarded for this lecture by The Leukemia & Lymphoma Society.  Nurses must provide their RN license number in order to receive credit. Provider approved by the California Board of Registered Nursing, Provider #: CEP5832.


Registration

Registration fee: $75.00 (non-refundable), includes: continental breakfast, lunch, course materials, and complimentary parking.

Wednesday, January 9th, 2013

LLS Team in Training Corp Breakfast @ KPMG in Boston, Jack speaking at this event
LLS Team in Training Corporate Breakfast - 8:30 AM
KPMG Two Financial Center 60 South Street
Boston, MA 02210
USA
508 810 1328 [map]
Price: .00

Jack will be speaking at this Leukemia & Lymphoma Society (LLS) corporate breakfast helping recruit runners and corporate sponsors for LLS' Team in Training events for 2013.  If you ever thought about running the Boston Marathon (you need to qualify to get a number), here's how to prepare.   You'll get professional training guidance in exchange for your awareness and fundraising for LLS.  Come hear about this fabulous program which has raised over $1.5 Billion and engaged more than 500,000 trainers, runners and participants.

Check in at the KMPG Security desk in the lobby at 60 State Street.  A light breakfast is included.

Hope to see you there.

Thursday, December 20th, 2012

Update on Lymphoma from 2012 American Society of Hematology Annual Meeting
Update on Lymphoma From the 2012 ASH Annual Meeting, webcast - 1:30 PM Eastern
CancerCare Webcast
Your home or office, MA 02210
USA
800 813 4673 [map]
Price: .00

Update on Lymphoma from the 2012 American Society of Hematology (ASH) Annual Meeting.  This is a webcast. Register at this url and get info emailed to you.  You can attend this one hour webcast from the comfort of your home or office.

Saturday, December 8th, 2012

American Society of Hematology (ASH) 54th Annual Meeting, Atlanta, GA
American Society of Hematology , 55th Annual Conference, Atlanta GA - 09:00
Georgia World Congress Center
Atlanta, GA
USA
888 273 5704 [map]
Price: $450

This is the primary conference and show focused on Hematology, the 55th Annual Conference.  This conference presents the best new scientific research in all areas of hematology. 

Friday, December 7th, 2012

Controversies in Multiple Myeloma: Current Debates in Optimal Care - 12:30
Georgia World Congress Center
Atlanta, GA 30313
USA
6178205145 [map]
Price: .00

CME-certified session on the latest in multiple myeloma research and care.  "Controversies in Multiple Myeloma: Current Debates in Optimal Care".  Welcome and Introduction, Overview of the Treatment, Defining High-risk Myeloma, Smoldering Myeloma: To Treat or Not to Treat, Optimal Therapies for Transplantation-Ineligible Patients, Debate: Minimal Residual Disease: A Treatment Goal or a Prognostic Marker,  Conclusion: Faculty Panel Commentary, Recommendations, Audience Questions.

Wednesday, November 28th, 2012

Personalized Medicine Conference, 8th Annual, Harvard Medical School - Boston, MA
Personalized Medicine Conference, 8th Annual, Boston MA - 08:00AM
Joseph Martin Conf Center, Harvard Medical School
Boston, MA 02115
USA
617 525 4489 [map]
Price: $450.00

This is the 8th Annual Personalized Medicine Conference, will be held at Harvard Medical School, Boston MA on November 28 and 28.  Widely considered the premier event in the field attracting over 600 national and international thought leaders.    

Tuesday, November 27th, 2012

Personalized Medicine Conference, 8th Annual, Boston MA - 6:00PM
Hotel Commonwealth, 500 Commonwealth Avenue
Boston, MA 02215
USA
202-589-1770 [map]

The Personalized Medicine Coalition cocktail reception will kick off the Harvard Medical School Personalized Medicine Conference on November 29th. A great people networking event.  

Tuesday, November 13th, 2012

Clinical Trials - Emerging Therapies, Be your own Advocate - 5:45 PM
9 Erie Drive
Natick, MA 01760
USA
508 810 1308 [map]
Price: .00

Check the flyer located for the Family Support Group event.      This important event sponsored by the Leukemia & Lymphoma Society includes a Light dinner.   Be sure to see all the details by click on the above link to download the .pdf announcement flyer.  

Friday, November 9th, 2012

2012 LRF North American Ed Forum on Lymphoma - 9:00
Manhattan Beach Marriott Hotel
Manhattan Beach, CA 90266
USA
310 546 7511 [map]
Price: $50.00

The North American Educational Forum on Lymphoma is the most comprehensive lymphoma-specific educational conference in North America. This annual 2 ½ day program provides critical information on treatment options, support issues, clinical trials and the latest advances in lymphoma research. 

Thursday, November 1st, 2012

Speak at LLS Family Support Group Presentation, Massachusetts Chapter of LLS, Natick MA
Jack Whelan, Guest Speaker -Surviving a rare incurable Blood Cancer - 6:00PM
9 Erie Drive Suite 101
Natick, MA 01760
USA
508 810 1300 [map]
Price: .00

Jack is a six year survivor of a rare blood cancer, sort of a hybrid of Non-Hodgkins Lymphoma and Multiple Myeloma sharing similar symptoms and treatment options.  Jack's presentation is fun, exciting and informative, helpful for newly diagnosed to long term survivors who are veterans of a variety of treatments.

Thursday, November 1st, 2012

Leading Edge Reform: Roles and Goals for Healthcare Advocates - 09:00 AM
Hyatt Regency Hotel
Boston, MA 02111
USA [map]
Price: from $25.00 - $445.00

This is the 4th Annual Conference of the National Association of Healthcare Advocacy Consultants.  Professional Presentations, Break out sessions, Exhibition, Networking and more.  Check out http://www.nahac.com

Tuesday, October 16th, 2012

Update on Lymphoma and Treatment Options - 6:00 PM
UMass Medical School, Hiatt Auditorium S1-608 55 Lake St. North
Worcester, MA 01655
USA
800 500 9976 [map]
Price: Pre-register .00

Update on Lymphoma Treatment Options.  Lymphoma Overview, Treatment Options, Research Updates, Question and Answer Session.    Featuring Andrew M. Evans, DO  MSc, Associate Professor of Medicine, Deputy Director for Clinical and Translational Research, Director Lymphoma Program.

Networking starts at 6;00 PM, Dinner is served at 6:30 PM.  

Wednesday, September 19th, 2012

Pfizer Personalized Medicine Workshop, Cambridge, MA
Personalized Medicine Workshop - 09:00 AM
Pfizer Cambridge North Site
Cambridge, MA 02149
USA [map]
Price: Invitation only

Pfizer Inc.: The world's largest research-based pharmaceutical company discovers, develops, manufactures and markets leading prescription products.  These medicine help to treat and prevent a range of conditions - from the most common to the most challenging- for people around the world.  

Overview of Workshop:  Welcome, Introduction to Personalized Medicine, Personalized Medicine Landscape, Patient Perspective, Media Opportunities, Access to Medicine, Challenges Faced by Patients and Providers, Health Insurance Exchange Development: Innovation in the States.

Sunday, August 26th, 2012

Patient Workshop WM & Multiple Myeloma - 10:00 AM
Hyatt Regency Newport
Newport, RI 02840
USA
401 851 1234 [map]
Price: $35.00

Thursday, August 23rd, 2012

7th Int'l Workshop on Waldenstroms & Multiple Myeloma Symposium - 3:00 PM Registration
Hyatt Regency Newport
Newport, RI 02840
USA
401 851 1234 [map]
Price: $895

Tuesday, August 21st, 2012

Jimmy Fund Telethon- WEEI/NESN - Red Sox Fundraising for DFCI, Fenway Park, Boston MA
Jimmy Fund Telethon- WEEI/NESN - Red Sox Fundraising for DFCI - 06:00 AM
Fenway Park
Boston, MA 02210
USA
6178205145 [map]
Price: .00

The 11th annual WEEI/NESN Jimmy Fund Radio-Telethon on August 21 and 22 will raise much needed funds to support adult and pediatic care and research at the Dana Farber Cancer Institute at Fenway Park in connection with the Boston Red Sox.  This is a 36 hour telethon broadcast on WEEI Sports Radio and NESN the New England Sports Network on TV.

Jack will be speaking, his second year on several radio and TV shows on behalf of Dana Farber Cancer Institute.  Making connections with Tom Caron, Jenny Dell, Jerry Remy, Don Orsillo, Joe Castiglione, Mikey Adams, Glenn Ordway, Michael Holley, and Jason Wolf.   A Special thanks to Lisa Scherber, Director of Patient and Family Programs at DFCI, an absolutely incredible gal, a key driving force along with many volunteers that make this a big win against Cancer..  

Tuesday, July 17th, 2012

Updates on Lymphoma and Treatment Options - 6:00 PM
Tufts Medical Center Stearns Auditorium 800 Washington St.
Boston, MA 02111
USA
800 500 9976 [map]
Price: .00

Tuesday, June 26th, 2012

Audience with Legislators from Commonwealth of MA - 10:00
24 Beacon Street
Boston, MA 02133
USA
617 722 2000 [map]
Price: .00

In conjunction with Leukemia Lymphoma Society, who is leading the charge on behalf of all blood cancer patients and caregivers, we will speak with representatives of the Massachusetts State Legislature on the Parity of Pill Form Chemotherapy Bill up for a vote this summer. 

Friday, June 1st, 2012

IWMF Educational Forum - 8:00 AM
Marriott Hotel at Philadephia Airport
Philadelphia, PA 19153
USA
941 927 4963 [map]
Price: $350

 The 2012 IWMF Educational Forum DVDs will be available in August